var title_f30_31_31216="Drain placement at surgery";
var content_f30_31_31216=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F81437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F81437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Drain placement at surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_31_31216=[""].join("\n");
var outline_f30_31_31216=null;
var title_f30_31_31217="MRSA susceptibility testing";
var content_f30_31_31217=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Detection of inducible clindamycin resistance in methicillin-resistant Staphylococcus aureus isolates using the D-test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 418px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel C shows an isolate susceptible to both erythromycin (E) and clindamycin (C). Panel B shows an isolate resistant to erythromycin, but fully susceptible to clindamycin, which illustrates the efflux mechanism of resistance to macrolides. In panel A, the isolate is resistant to erythromycin but has blunting of the zone of inhibition around the clindamycin disk adjacent to the erythromycin disk (D zone), which is the hallmark of the inducible MLSB resistance phenotype.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Edward O Mason Jr, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_31_31217=[""].join("\n");
var outline_f30_31_31217=null;
var title_f30_31_31218="Patient information: Newborn appearance (The Basics)";
var content_f30_31_31218=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/82980\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/20/7495\">",
"         Pregnancy terms",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/34/24099\">",
"          Normal newborn appearance",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?37/45/38609\">",
"         Patient information: Developmental dysplasia of the hip (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/28/34242\">",
"         Patient information: Down syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/20/23873\">",
"         Patient information: Hemangioma (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/23/23921\">",
"         Patient information: Hypospadias (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/13/12499\">",
"         Patient information: Labor and delivery (childbirth) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/41/29329\">",
"         Patient information: Torticollis in children (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?28/45/29394\">",
"         Patient information: Down syndrome (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Newborn appearance (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/newborn-appearance-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H14895539\">",
"      <span class=\"h1\">",
"       What does a healthy newborn look like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A healthy newborn baby might look strange at first. Before being born, a baby is surrounded by liquid in the uterus (",
"      <a class=\"graphic graphic_figure graphicRef82935 \" href=\"UTD.htm?7/20/7495\">",
"       figure 1",
"      </a>",
"      ). The baby is also in a curled-up position, because there&rsquo;s not much space to move around. Plus, babies who are born through the vagina have to squeeze through a small passage. All of these things can affect a newborn&rsquo;s appearance.",
"     </p>",
"     <p>",
"      The descriptions below should help you prepare for how your baby might look (",
"      <a class=\"graphic graphic_figure graphicRef82953 \" href=\"UTD.htm?23/34/24099\">",
"       figure 2",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Skin",
"        </strong>",
"        &ndash; Babies are born covered in a thick white substance, as well as fluid and blood from the mother&rsquo;s body. All of this washes off with the baby&rsquo;s first bath.",
"        <br/>",
"        <br/>",
"        A healthy newborn&rsquo;s skin is usually pink. But sometimes the skin can look slightly blue, especially in the hands, feet, and around the lips. That is normal.",
"        <br/>",
"        <br/>",
"        Your baby might have some bruises, red spots, or scratches on his or her skin after being born. This is nothing to worry about. Bruises and scratches can be caused by a device called a &ldquo;fetal probe&rdquo; that doctors use to monitor the baby during birth. Some newborns also have small acne-like spots or bumps on the skin; these will go away over time. You might notice that your newborn has one or more birthmarks, which might be permanent.",
"       </li>",
"       <li>",
"        <strong>",
"         Head",
"        </strong>",
"        &ndash; A newborn&rsquo;s head usually looks big compared to the rest of the body. The head might also look pointy or cone-shaped from being squeezed through the mother&rsquo;s vagina. The head should return to its normal shape within a few days. Newborns have several &ldquo;soft spots&rdquo; on their heads where the bones have not yet grown together.",
"        <br/>",
"        <br/>",
"        Some babies are born bald, while others have hair. Often, the hair that a baby is born with will fall out within a month or so and be replaced by new hair.",
"       </li>",
"       <li>",
"        <strong>",
"         Face",
"        </strong>",
"        &ndash; Your baby&rsquo;s face might look swollen or squished right after he or she is born. The mouth and nose will be filled with mucus, which a doctor or nurse will suction out. Both sides of the face should look symmetrical, or even.",
"        <br/>",
"        <br/>",
"        The whites of the eyes should be clear and white, although in premature babies, they might appear pale blue.",
"       </li>",
"       <li>",
"        <strong>",
"         Neck",
"        </strong>",
"        &ndash; The neck skin should be smooth and without lumps. Some babies are born with the neck twisted to one side, due to their position in the uterus. This is called &ldquo;wry neck&rdquo; or &ldquo;torticollis.&rdquo; There are ways to treat this and help straighten out the neck.",
"       </li>",
"       <li>",
"        <strong>",
"         Chest and belly",
"        </strong>",
"        &ndash; You might notice that your newborn has some swelling in the breast area. Sometimes the breasts might even leak a milky fluid. This is because of hormones from the mother&rsquo;s body. This swelling or leaking usually goes away within a few days or weeks.",
"        <br/>",
"        <br/>",
"        Your newborn&rsquo;s belly will probably be round and stick out a bit. After the umbilical cord is cut, a small stump will stay attached to your baby&rsquo;s belly button. Your baby&rsquo;s doctor or nurse will tell you how to care for it. The stump will fall off on its own within a week or two.",
"       </li>",
"       <li>",
"        <strong>",
"         Genitals",
"        </strong>",
"        &ndash; In both boys and girls, the genitals often look puffy or swollen after birth. If your baby is a girl, you might notice some discharge from the vagina. It is usually white in color but can sometimes be bloody. This is normal. It is caused by hormones in the mother&rsquo;s body, and will go away on its own.",
"        <br/>",
"        <br/>",
"        In newborn boys, the foreskin (the skin covering the tip of the penis) is usually tight and should not be pulled back. This skin will be removed surgically if you choose to have your baby circumcised.",
"       </li>",
"       <li>",
"        <span class=\"nowrap\">",
"         <strong>",
"          Arms/legs",
"         </strong>",
"        </span>",
"        &ndash; Your newborn might prefer to keep his or her arms and legs bent and close to the body, like they were when he or she was in the womb. The arms and legs should move equally on both sides of the body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14895571\">",
"      <span class=\"h1\">",
"       What will the doctor check for after my baby is born?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Soon after your baby is born, a doctor or nurse will:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Look at the baby&rsquo;s genitals to see whether the baby is a girl or a boy",
"       </li>",
"       <li>",
"        Look at the baby&rsquo;s skin to make sure it is a healthy color",
"       </li>",
"       <li>",
"        Check the body&rsquo;s position and movement",
"       </li>",
"       <li>",
"        Look over the baby&rsquo;s entire body to check that all the parts look normal",
"       </li>",
"       <li>",
"        Measure the baby&rsquo;s weight, length, and head size",
"       </li>",
"       <li>",
"        Make sure the baby&rsquo;s organs (including the heart and lungs) are working right",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14895586\">",
"      <span class=\"h1\">",
"       How can I tell if my baby has a problem?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can&rsquo;t always tell just by looking at a newborn whether he or she is healthy. No two babies look exactly the same. But your baby&rsquo;s doctor or nurse can check for certain things.",
"      <br/>",
"      <br/>",
"      The appearance, size, or position of some body parts can be symptoms of different health issues. Only a doctor or nurse can tell for sure whether your baby has a problem.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14895601\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/13/12499?source=see_link\">",
"       Patient information: Labor and delivery (childbirth) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/41/29329?source=see_link\">",
"       Patient information: Torticollis in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/28/34242?source=see_link\">",
"       Patient information: Down syndrome (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/45/38609?source=see_link\">",
"       Patient information: Developmental dysplasia of the hip (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/23/23921?source=see_link\">",
"       Patient information: Hypospadias (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/20/23873?source=see_link\">",
"       Patient information: Hemangioma (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/45/29394?source=see_link\">",
"       Patient information: Down syndrome (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?30/31/31218?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 82980 Version 5.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-199.231.185.123-7F5A86D682-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_31_31218=[""].join("\n");
var outline_f30_31_31218=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14895539\">",
"      What does a healthy newborn look like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14895571\">",
"      What will the doctor check for after my baby is born?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14895586\">",
"      How can I tell if my baby has a problem?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14895601\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/82980\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/20/7495\">",
"      Pregnancy terms",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/34/24099\">",
"       Normal newborn appearance",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/45/38609?source=related_link\">",
"      Patient information: Developmental dysplasia of the hip (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/45/29394?source=related_link\">",
"      Patient information: Down syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/28/34242?source=related_link\">",
"      Patient information: Down syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/20/23873?source=related_link\">",
"      Patient information: Hemangioma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/23/23921?source=related_link\">",
"      Patient information: Hypospadias (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/13/12499?source=related_link\">",
"      Patient information: Labor and delivery (childbirth) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/41/29329?source=related_link\">",
"      Patient information: Torticollis in children (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_31_31219="Succinylcholine (suxamethonium): Patient drug information";
var content_f30_31_31219=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Succinylcholine (suxamethonium): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     see \"Succinylcholine (suxamethonium): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"     see \"Succinylcholine (suxamethonium): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F223430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Anectine&reg;;",
"     </li>",
"     <li>",
"      Quelicin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F223431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Quelicin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700591",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may  rarely cause very bad side effects in children and teenagers. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to calm muscles during surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691273",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to calm muscles while on a breathing machine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702961",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to succinylcholine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703873",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you or a family member have had malignant hyperthermia. Signs of this health problem include a very high fever, a fast heartbeat, muscle stiffness, and trouble breathing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More eye pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698250",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11915 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-23D1513A50-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_31_31219=[""].join("\n");
var outline_f30_31_31219=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223430\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223431\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021990\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021992\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021991\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021995\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021996\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021998\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021994\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022000\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=related_link\">",
"      Succinylcholine (suxamethonium): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=related_link\">",
"      Succinylcholine (suxamethonium): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_31_31220="Apomorphine: Patient drug information";
var content_f30_31_31220=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Apomorphine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/14/21734?source=see_link\">",
"     see \"Apomorphine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F136184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Apokyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Parkinson's disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701539",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to apomorphine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfite allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low potassium levels or if you are taking a water pill, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697294",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low magnesium levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a stroke, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698275",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. You may need drugs to lower this side effect. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698316",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Runny nose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698397",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yawning.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698652",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Falling asleep during activities such as eating or talking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw syringe away after use. Do not use more than one time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696503",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If drug is stopped for more than 1 week, dose will need to be lowered.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10800 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-AFBC45AB80-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_31_31220=[""].join("\n");
var outline_f30_31_31220=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136184\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018530\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018532\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018531\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018536\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018537\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018539\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018534\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018535\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018540\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018541\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/14/21734?source=related_link\">",
"      Apomorphine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_31_31221="Fibronectin glomerulopathy";
var content_f30_31_31221=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fibronectin glomerulopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/31/31221/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/31/31221/contributors\">",
"     Simon Prince, DO",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/31/31221/contributors\">",
"     Brad H Rovin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/31/31221/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/31/31221/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/31/31221/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/31/31221/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/31/31221/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several glomerular disorders result from the deposition or accumulation of proteins within glomeruli that disrupt glomerular structure and function. One of these disorders is fibronectin glomerulopathy, which is a rare, familial glomerular disease caused by the deposition of fibronectin and other matrix-type proteins in glomeruli. Ultrastructurally, the deposits are electron-dense and usually homogenous to finely granular, occasionally showing fibrillar substructure.",
"   </p>",
"   <p>",
"    Fibronectin glomerulopathy will be reviewed here. Other glomerular disorders resulting from the deposition or accumulation of proteins within glomeruli, including amyloidosis, fibrillary glomerulonephritis, immunotactoid glomerulonephritis, and lipoprotein glomerulopathy, are presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/29/13784?source=see_link\">",
"     \"Renal amyloidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33064?source=see_link\">",
"     \"Glomerular diseases due to nonamyloid fibrillar deposits\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/27/1464?source=see_link\">",
"     \"Lipoprotein glomerulopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Biology of fibronectin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibronectin is a large dimeric glycoprotein consisting of two similar subunits (approximately 250 kD in weight). It functions as an adhesive glycoprotein, aiding in branching morphogenesis, cellular proliferation, wound healing, phagocytosis, platelet-platelet cohesion that is mediated in part by binding to the glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    receptor, and thrombus formation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31221/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fibronectin normally exists in a soluble or plasma form (which circulates in blood) and an insoluble or cellular form (which is seen in basement membranes and extracellular matrices).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fibronectin deposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although fibronectin is found in the normal glomerular mesangial matrix, enhanced fibronectin accumulation is variably observed in several different glomerulopathies, including diabetic nephropathy and lupus nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31221/abstract/4-11\">",
"     4-11",
"    </a>",
"    ]. The increase in fibronectin expression in these diseases is secondary to locally stimulated mesangial and epithelial cell production of the insoluble or cellular form.",
"   </p>",
"   <p>",
"    By comparison, fibronectin glomerulopathy is associated with accumulation of fibronectin that is mainly derived from the soluble plasma isoform. This was shown in a study in which the relative amounts of the two different isoforms of fibronectin were quantified by two antibodies, one of which detected both cellular and plasma fibronectins, and the other detected only the cellular form [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31221/abstract/12\">",
"     12",
"    </a>",
"    ]. Investigators examined 6 unrelated fibronectin glomerulopathy families and renal biopsy specimens from a total of 15 patients as well as 9 patients from 4 other previously reported families. Affected patients had predominant fibronectin deposits, with strong staining using the antibody against both the plasma and cellular forms, but weak staining using the antibody against the cellular form.",
"   </p>",
"   <p>",
"    Recurrent disease in renal allografts of patients who were transplanted for end-stage renal disease (ESRD) due to fibronectin glomerulopathy supports the hypothesis that renal accumulation of fibronectin is most likely due to an underlying abnormality in circulating plasma fibronectin:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrence was observed in a patient in whom a renal allograft biopsy performed 23 months after transplantation revealed the typical histologic features of fibronectin glomerulopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31221/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another patient had approximately 14 years of adequate renal function from a cadaveric kidney prior to biopsy-confirmed recurrent disease in the allograft [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31221/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is unclear why fibronectin is deposited in these cases. Theoretically, fibronectin may be complexed with other proteins. Immunoglobulins do not appear to be involved, as they are generally not seen by immunohistochemical analysis. Proteomic analysis of glomeruli removed from kidney biopsies of patients with fibronectin glomerulopathy by laser capture microscopy showed that, in addition to various isoforms of fibronectin, the deposits contained large amounts of the matrix proteins fibulin-1 and fibulin-5 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31221/abstract/15\">",
"     15",
"    </a>",
"    ]. This finding was unique to the deposits of fibronectin glomerulopathy. Fibulins were not expressed to a significant extent in normal glomeruli, Kimmelstiel-Wilson nodules of diabetic nephropathy, or in wire-loop lesions of lupus nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31221/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fibulins bind to fibronectin and regulate several functions of fibronectin, including those related to cell-shape, motility, and adhesion [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31221/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. It is possible that fibulin-fibronectin complexes disrupt normal, fibronectin-dependent mesangial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    podocyte motility, adhesion, and spreading, resulting in the characteristic clinical features. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analysis of family clusters indicates autosomal dominant transmission of the genetic defect in fibronectin glomerulopathy, with age-related penetrance [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31221/abstract/13\">",
"     13",
"    </a>",
"    ]. Linkage to the fibronectin gene was noted in an Italian pedigree, with 8 affected subjects, and missense mutations in this gene were then identified in 6 of 15 unrelated pedigrees (40 percent) with fibronectin glomerulopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31221/abstract/18\">",
"     18",
"    </a>",
"    ]. Although mutations in the fibronectin gene may be necessary for fibronectin glomerulopathy to develop, they are not sufficient since not all family members with the mutation develop clinical kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31221/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Functional studies of mutant fibronectin fragments revealed decreased binding to glomerular endothelial cells and podocytes and reduced ability to induce endothelial cell spreading and cytoskeletal reorganization compared to wild-type fragments. Prior studies in animal models suggested a possible role for the gene for uteroglobin, a protein that binds with high affinity to fibronectin [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31221/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. However, the uteroglobin gene was eventually excluded as causative for human disease [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31221/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibronectin glomerulopathy is rare. The disorder has a slight male predominance and was originally described only in Caucasians of European descent. Subsequently, an Asian family with this disease was reported [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31221/abstract/23\">",
"     23",
"    </a>",
"    ]. Cases in blacks or Hispanic patients have yet to be reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibronectin glomerulopathy is characterized clinically by varying degrees of proteinuria, which is typically first seen between the ages of 20 and 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31221/abstract/13\">",
"     13",
"    </a>",
"    ]. This is followed, over the next 15 to 20 years, by hypertension, microscopic hematuria, and, in most patients, slow progression to end-stage renal disease (ESRD). Complement levels are normal.",
"   </p>",
"   <p>",
"    In one of the largest studies, the clinical features of 23 affected patients were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31221/abstract/12\">",
"     12",
"    </a>",
"    ]. Eight of 16 in whom a 24-hour urine specimen was obtained at the time of diagnostic biopsy had more than 3 g of proteinuria. Microscopic hematuria and hypertension were observed in 12 and 10 patients, respectively. The mean plasma creatinine measured at the time of biopsy in 16 patients was 1.1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (97.2",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    Among the patients in whom follow-up was available, 4 patients had normal renal function, 6 patients had slowly progressive renal insufficiency, 5 were undergoing dialysis (range from time of biopsy was 2 to 13 years) and 4 had received a renal allograft.",
"   </p>",
"   <p>",
"    There also may be an association with hyperkalemic distal renal tubular acidosis (distal RTA) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31221/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGIC FINDINGS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first histologic examinations of fibronectin glomerulopathy described enlarged glomeruli with minimal hypercellularity and the presence of large deposits in the glomerular capillaries [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31221/abstract/14,24,25\">",
"     14,24,25",
"    </a>",
"    ]. In a patient with an appropriate clinical presentation, a family history of kidney disease, and histologic features as described in the ensuing sections, immunohistochemistry showing staining for fibronectin in the mesangium and along the capillary walls confirms the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Light microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Light microscopy shows glomerular enlargement and usually some evidence of minimal cellular proliferation, producing a lobular or clover-like appearance that may be confused with membranoproliferative glomerulonephritis (MPGN). The glomerular capillary walls may be thickened and the mesangium greatly expanded by acellular periodic acid-Schiff-positive (PAS-positive) homogeneous material that can result in severely narrowed capillary lumens. Staining with Congo red or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/57/3989?source=see_link\">",
"     methenamine",
"    </a>",
"    silver is consistently negative (",
"    <a class=\"graphic graphic_picture graphicRef86699 \" href=\"UTD.htm?19/47/20213\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There is no consistent specific tubulointerstitial compartment abnormality. However, interstitial fibrosis and tubular atrophy become more prominent over time, a common finding in progressive renal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Electron microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electron microscopy typically reveals large to massive non-descript electron-dense subendothelial and mesangial deposits. The deposits have been described as finely granular or fibrillar in some cases. If fibrillar, the fibrils are approximately 12 nm in width and 125 nm in length and are typically arranged in an irregular fashion. These fibrils are slightly wider than those seen in amyloid (8 to 10 nm). However, they are thinner than the fibrils in fibrillary glomerulonephritis (18 to 22 nm) and the microtubules of immunotactoid glomerulopathy (greater than 30 nm) (",
"    <a class=\"graphic graphic_picture graphicRef86700 \" href=\"UTD.htm?26/58/27554\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31221/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Immunofluorescence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoglobulin and complement component staining is absent or weak in fibronectin glomerulopathy. Immunohistochemistry examination showing staining for fibronectin in the mesangium and along the capillary walls confirms the diagnosis (",
"    <a class=\"graphic graphic_picture graphicRef88601 \" href=\"UTD.htm?2/45/2773\">",
"     picture 3",
"    </a>",
"    ). It is the plasma isoform of fibronectin that stains most intensely [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31221/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment for fibronectin glomerulopathy is uncertain. There are no data regarding the use of immunomodulating agents, plasmapheresis, or any other specific therapy aimed at the underlying disease.",
"   </p>",
"   <p>",
"    Currently, the most appropriate option is probably the use of nonspecific treatment methods intended to prolong adequate renal function. This includes strict control of the blood pressure and proteinuria, usually with the administration of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     End-stage renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the management of patients who develop end-stage renal disease (ESRD) due to fibronectin glomerulopathy is similar to that in other types of renal disease. These patients are good candidates for all forms of renal replacement therapy. Hemodialysis, peritoneal dialysis, and renal transplantation have all been used with good success. As previously mentioned, there have been case reports of disease recurrence in transplanted patients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31221/abstract/13\">",
"     13",
"    </a>",
"    ]. However, the true risk for recurrent disease in renal allograft is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1037702\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fibronectin glomerulopathy is a rare autosomal dominant inherited glomerular disease associated with the massive deposition of the glycoprotein, fibronectin. It is most likely caused by an underlying abnormality in circulating plasma fibronectin. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Fibronectin deposition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical characteristics include the onset of proteinuria between the ages of 20 and 40. This is followed by hypertension, microscopic hematuria, and slow progression to end-stage renal disease (ESRD) over the next 15 to 20 years. Complement levels are normal. There may be an association with hyperkalemic distal renal tubular acidosis (distal RTA). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis is made only by renal biopsy. No clinical or laboratory findings are characteristic. The diagnosis is suggested by the presence of large, finely granular electron-dense deposits. The diagnosis is confirmed by the demonstration of fibronectin staining by immunohistochemistry. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Histopathologic findings and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal treatment is uncertain. There are no data regarding the use of immunomodulating agents, plasmapheresis, or any other specific therapy. Nonspecific therapies that may prolong renal function include strict control of the blood pressure and the administration of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of patients who develop ESRD is similar to that in other types of renal disease. These patients are candidates for all forms of renal replacement therapy, including transplantation. There have been case reports of disease recurrence in transplanted patients. However, the true risk for recurrent disease in renal allograft is not well understood. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'End-stage renal disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12673153\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to thank Dr. Robert Mossey, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31221/abstract/1\">",
"      Sakai T, Larsen M, Yamada KM. Fibronectin requirement in branching morphogenesis. Nature 2003; 423:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31221/abstract/2\">",
"      Ni H, Yuen PS, Papalia JM, et al. Plasma fibronectin promotes thrombus growth and stability in injured arterioles. Proc Natl Acad Sci U S A 2003; 100:2415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31221/abstract/3\">",
"      Schena FP, Pertosa G. Fibronectin and the kidney. Nephron 1988; 48:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31221/abstract/4\">",
"      B&uuml;y&uuml;kbabani N, Droz D. Distribution of the extracellular matrix components in human glomerular lesions. J Pathol 1994; 172:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31221/abstract/5\">",
"      Altunkova I, Minkova V, Belovezhdov N. Role of fibronectin in immune glomerulonephritis. Nephron 1993; 63:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31221/abstract/6\">",
"      Lai KN, To WY, Leung JC, et al. Serologic study of immunoglobulin A-fibronectin aggregates in immunoglobulin A nephropathy. Am J Kidney Dis 1996; 27:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31221/abstract/7\">",
"      Shikata K, Makino H, Morioka S, et al. Distribution of extracellular matrix receptors in various forms of glomerulonephritis. Am J Kidney Dis 1995; 25:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31221/abstract/8\">",
"      Van Vliet A, Baelde HJ, Vleming LJ, et al. Distribution of fibronectin isoforms in human renal disease. J Pathol 2001; 193:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31221/abstract/9\">",
"      Zhao HL, Lai FM, Tong PC, et al. Clinicopathologic characteristics of nodular glomerulosclerosis in Chinese patients with type 2 diabetes. Am J Kidney Dis 2004; 44:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31221/abstract/10\">",
"      Ding L, Zhao M, Zou W, et al. Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study. Lupus 2004; 13:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31221/abstract/11\">",
"      Oomura A, Nakamura T, Arakawa M, et al. Alterations in the extracellular matrix components in human glomerular diseases. Virchows Arch A Pathol Anat Histopathol 1989; 415:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31221/abstract/12\">",
"      Str&oslash;m EH, Banfi G, Krapf R, et al. Glomerulopathy associated with predominant fibronectin deposits: a newly recognized hereditary disease. Kidney Int 1995; 48:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31221/abstract/13\">",
"      Gemperle O, Neuweiler J, Reutter FW, et al. Familial glomerulopathy with giant fibrillar (fibronectin-positive) deposits: 15-year follow-up in a large kindred. Am J Kidney Dis 1996; 28:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31221/abstract/14\">",
"      Tuttle SE, Sharma HM, Bay W, Hebert L. A unique familial lobular glomerulopathy. Arch Pathol Lab Med 1987; 111:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31221/abstract/15\">",
"      Satoskar AA, Shapiro JP, Bott CN, et al. Characterization of glomerular diseases using proteomic analysis of laser capture microdissected glomeruli. Mod Pathol 2012; 25:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31221/abstract/16\">",
"      Twal WO, Czirok A, Hegedus B, et al. Fibulin-1 suppression of fibronectin-regulated cell adhesion and motility. J Cell Sci 2001; 114:4587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31221/abstract/17\">",
"      Lomas AC, Mellody KT, Freeman LJ, et al. Fibulin-5 binds human smooth-muscle cells through alpha5beta1 and alpha4beta1 integrins, but does not support receptor activation. Biochem J 2007; 405:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31221/abstract/18\">",
"      Castelletti F, Donadelli R, Banterla F, et al. Mutations in FN1 cause glomerulopathy with fibronectin deposits. Proc Natl Acad Sci U S A 2008; 105:2538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31221/abstract/19\">",
"      Zhang Z, Kundu GC, Yuan CJ, et al. Severe fibronectin-deposit renal glomerular disease in mice lacking uteroglobin. Science 1997; 276:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31221/abstract/20\">",
"      Mukherjee AB, Kundu GC, Mandal AK, et al. Uteroglobin: physiological role in normal glomerular function uncovered by targeted disruption of the uteroglobin gene in mice. Am J Kidney Dis 1998; 32:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31221/abstract/21\">",
"      Vollmer M, Krapf R, Hildebrandt F. Exclusion of the uteroglobin gene as a candidate for fibronectin glomerulopathy (GFND). Nephrol Dial Transplant 1998; 13:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31221/abstract/22\">",
"      Hildebrandt F, Strahm B, Prochoroff A, et al. Glomerulopathy associated with predominant fibronectin deposits: exclusion of the genes for fibronectin, villin and desmin as causative genes. Am J Med Genet 1996; 63:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31221/abstract/23\">",
"      Sato H, Matsubara M, Marumo R, et al. Familial lobular glomerulopathy: first case report in Asia. Am J Kidney Dis 1998; 31:E3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31221/abstract/24\">",
"      B&uuml;rgin M, Hofmann E, Reutter FW, et al. Familial glomerulopathy with giant fibrillar deposits. Virchows Arch A Pathol Anat Histol 1980; 388:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31221/abstract/25\">",
"      Assmann KJ, Koene RA, Wetzels JF. Familial glomerulonephritis characterized by massive deposits of fibronectin. Am J Kidney Dis 1995; 25:781.",
"     </a>",
"    </li>",
"    <li>",
"     Sanders PW. Dysproteinemias and amyloidosis. In: Primer of Kidney Diseases, 2nd ed, Greenberg A, Cheung AK, Coffmann TM, et al (Eds), Academic Press, San Diego 1998. p.220.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3072 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.131.41.98-0FBBA5EC0B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_31_31221=[""].join("\n");
var outline_f30_31_31221=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1037702\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Biology of fibronectin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fibronectin deposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HISTOPATHOLOGIC FINDINGS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Light microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Electron microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Immunofluorescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      End-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1037702\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12673153\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3072\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3072|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/47/20213\" title=\"picture 1\">",
"      Light micrograph showing fibronectin glomerulopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/58/27554\" title=\"picture 2\">",
"      Electron micrograph showing fibronectin glomerulopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/45/2773\" title=\"picture 3\">",
"      Immunohistochemistry showing fibronectin staining in glomerulus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=related_link\">",
"      Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33064?source=related_link\">",
"      Glomerular diseases due to nonamyloid fibrillar deposits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/27/1464?source=related_link\">",
"      Lipoprotein glomerulopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=related_link\">",
"      Overview of the management of chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/29/13784?source=related_link\">",
"      Renal amyloidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_31_31222="Measurement of serum lipids and lipoproteins";
var content_f30_31_31222=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"19\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Measurement of serum lipids and lipoproteins",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/31/31222/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/31/31222/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/31/31222/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/31/31222/contributors\">",
"     Mason W Freeman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/31/31222/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/31/31222/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/31/31222/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 21, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipids, such as cholesterol and triglyceride, are insoluble in plasma. They are made soluble by attachment to circulating lipoproteins that transport lipids to various tissues for energy utilization, lipid deposition, steroid hormone production, and bile acid formation. The lipoprotein consists of esterified and unesterified cholesterol, triglycerides, and phospholipids, and protein. &nbsp;",
"   </p>",
"   <p>",
"    There are five major lipoproteins in blood: chylomicrons; very low density lipoprotein (VLDL); intermediate density lipoprotein (IDL); low density lipoprotein (LDL); and high density lipoprotein (HDL). Each of these classes of lipoproteins carries cholesterol and triglyceride to a varying degree, with LDL carrying the majority of cholesterol, and VLDL carrying the majority of triglyceride.",
"   </p>",
"   <p>",
"    In general, patient care issues related to screening, diagnosis, and treatment are based on the results of the measurement of serum lipids, which is generally accomplished by obtaining a lipid profile. On occasion, measurement of serum lipoproteins is necessary for one or more of these purposes. This topic will discuss the issues relevant to the measurement of serum lipids and lipoproteins. Other issues related to lipids and lipoproteins, such as their role in atherosclerosis, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=see_link\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24361010\">",
"    <span class=\"h1\">",
"     LIPID PROFILE AND COMPONENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A standard serum lipid profile measures the concentration of total and HDL-cholesterol (HDL-C) as well as the triglycerides. With these values, the LDL-cholesterol concentration can be estimated. (See",
"    <a class=\"local\" href=\"#H24360864\">",
"     'LDL-cholesterol'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24361770\">",
"    <span class=\"h2\">",
"     Total and HDL-C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum total and HDL-cholesterol are measured directly and can be obtained in fasting or nonfasting individuals; there are only small, clinically insignificant differences in these values between measurements in the fasting or non-fasting state [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31222/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The total cholesterol can vary by 4 to 11 percent within an individual due to multiple factors including stress, minor illness, and posture [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31222/abstract/2\">",
"     2",
"    </a>",
"    ]. Values may also vary between different laboratories, with data suggesting that a single measurement of serum cholesterol can vary as much as 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31222/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Thus, in an individual with a \"true\" serum cholesterol concentration of 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.2",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    the range of expected values is 172 to 228",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.5 to 5.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31222/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. These observations suggest that more than one measurement of total cholesterol should be obtained when treatment considerations demand a precise determination. Serum HDL-C may demonstrate even greater variability [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31222/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blood lipid levels also exhibit mild seasonal variation with a peak in total cholesterol level in the winter and a trough in the summer. One study found that the amplitude of seasonal variation of total cholesterol concentration was 3.9",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.10",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in men and 5.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.14",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in women [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31222/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3116442507\">",
"    <span class=\"h2\">",
"     Total cholesterol to HDL cholesterol ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ratio of total-cholesterol or LDL-cholesterol to HDL-cholesterol concentration has been used in many epidemiological studies to categorize populations into high risk and low risk subgroups. However, we do not recommend that the ratio be used to treat individual patients, as there is no randomized trial evidence to support such practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24360864\">",
"    <span class=\"h2\">",
"     LDL-cholesterol",
"    </span>",
"    &nbsp;&mdash;&nbsp;LDL-C reported in the lipid profile is generally calculated using the Friedewald formula, which states: LDL-cholesterol (LDL-C) &nbsp; = &nbsp; Total cholesterol &nbsp;- &nbsp;VLDL-cholesterol (VLDL-C) &nbsp;- &nbsp;HDL-C [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31222/abstract/7\">",
"     7",
"    </a>",
"    ]. Stated another way, and understanding that this is an approximation, the total cholesterol in plasma or serum is the sum of cholesterol found in each of the VLDL, HDL, and LDL lipoprotein particle types. The Friedewald formula is applied to lipid values measured in the fasted state. In a non-fasting patient, the contribution of post-prandial chylomicrons to the total lipoprotein pool makes the formula much less accurate.",
"   </p>",
"   <p>",
"    As mentioned above, total and HDL-C are measured directly (see",
"    <a class=\"local\" href=\"#H24361770\">",
"     'Total and HDL-C'",
"    </a>",
"    above). VLDL associated cholesterol is approximated by dividing the measured total triglyceride level by 5. With the measured total and HDL-C and triglyceride, an approximate LDL-C can be calculated. Calculators for determining LDL-C are available (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?21/1/21521?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?5/39/5746?source=see_link\">",
"     calculator 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are, however, several sources of error involved in the estimation of LDL-C using the Friedewald formula:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The formula is valid only if the total triglyceride concentration is less than 400",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.516",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      In patients with more pronounced hypertriglyceridemia, LDL-C levels must be measured directly (direct LDL), by ultracentrifugal single spin analysis or immunoprecipitation technique.",
"     </li>",
"     <li>",
"      The estimated LDL-C concentration is also influenced by the method error from each of the independent lipid measurements &mdash; total cholesterol, triglycerides, and HDL-cholesterol.",
"     </li>",
"     <li>",
"      The calculation of VLDL-C (from triglycerides) underestimates the cholesterol content of the atherogenic, intermediate density lipoprotein (IDL), and VLDL remnants. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=see_link\">",
"       \"Lipoprotein classification; metabolism; and role in atherosclerosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The estimated LDL-C concentration includes cholesterol contained in other lipoproteins, such as lipoprotein(a) and lipoprotein-X. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=see_link\">",
"       \"Lipoprotein(a) and cardiovascular disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18149?source=see_link\">",
"       \"Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Assays are available to directly measure the LDL-C concentration and should be considered in patients with a total triglyceride concentration &gt;400",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.516",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    However, even in patients with lower triglyceride values, some direct assays may give significantly different results than the estimated LDL-C, and all of the treatment guidelines for hypercholesterolemia were based upon the estimated value. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10613?source=see_link\">",
"     \"ATP III guidelines for treatment of high blood cholesterol\"",
"    </a>",
"    ). Furthermore, direct LDL measurement adds costs without apparent benefit in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31222/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, the estimated LDL remains the preferred means of assessing LDL-C unless the triglyceride concentration precludes this estimation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24363001\">",
"    <span class=\"h2\">",
"     Triglycerides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triglycerides are carried in chylomicron and VLDL particles. Triglyceride levels are influenced by recent food intake and should be measured in the fasting state when possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24362756\">",
"    <span class=\"h2\">",
"     Causes of inaccurate results",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the potential for variability between measurements (discussed above) of one or more component of the lipid profile, the following are two potential causes of inaccurate results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of a circulating monoclonal protein may lead to falsely low values of HDL",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      LDL cholesterol. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link&amp;anchor=H5#H5\">",
"       \"Recognition of monoclonal proteins\", section on 'Interference with laboratory tests'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The calculated LDL-C may be inaccurate in patients with a triglyceride levels above 400",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.516",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H24360864\">",
"       'LDL-cholesterol'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24362763\">",
"    <span class=\"h3\">",
"     After an ACS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the evidence is not robust, we believe that LDL- and HDL-cholesterol are relatively accurate when measured in the first 96 hours of hospitalization for an acute coronary syndrome (ACS).",
"   </p>",
"   <p>",
"    In initial small studies, clinically significant changes in components of the lipid profile (fall in LDL and HDL cholesterol and rise in triglycerides) were observed within hours after an acute myocardial infarction (and also surgical trauma or infection) and persisted for approximately two months (",
"    <a class=\"graphic graphic_figure graphicRef67633 \" href=\"UTD.htm?7/47/7933\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31222/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Possible causes of changes in serum lipids following an ACS include tissue injury, which can reduce serum concentrations of total cholesterol, HDL-cholesterol, LDL-cholesterol, and apolipoproteins B and A-I [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31222/abstract/11\">",
"     11",
"    </a>",
"    ]; hospitalization, which has been associated with significantly reduced levels of HDL-cholesterol compared with values determined in the outpatient setting [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31222/abstract/12\">",
"     12",
"    </a>",
"    ]; and stress-induced myocardial injury, which is associated with triglyceride elevation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31222/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the changes in lipid profile, the lipid profile has been thought to be most accurate in patients with an acute coronary syndrome (ACS) when obtained within hours of hospitalization or in the outpatient setting after at least one month has elapsed (",
"    <a class=\"graphic graphic_figure graphicRef67633 \" href=\"UTD.htm?7/47/7933\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31222/abstract/13\">",
"     13",
"    </a>",
"    ]. The 2007 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on non-ST elevation acute coronary syndromes recommended that a fasting lipid profile be obtained within the first 24 hours after admission [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31222/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the 2008 LUNAR trial, which had twice as many patients as all of the earlier studies combined, found that serum lipids remain relatively stable for the first 96 hours after an ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31222/abstract/15\">",
"     15",
"    </a>",
"    ]. The primary purpose of this randomized trial was to compare the relative efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    for LDL-cholesterol lowering in patients with an acute coronary syndrome. Serum lipids, including direct LDL-cholesterol, were measured in 507 patients on days one, two, and four after the event. The direct LDL-cholesterol levels fell slightly in the 24 hours after admission from 136.2 to 133.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.52 to 3.45",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and then rose somewhat to 141.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.67",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    over the next two days. Similar changes were noted for total cholesterol, while HDL-cholesterol changes were smaller and triglyceride levels remained unchanged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24362332\">",
"    <span class=\"h1\">",
"     LDL PARTICLE SIZE AND NUMBER",
"    </span>",
"    &nbsp;&mdash;&nbsp;LDL-cholesterol (LDL-C) does not accurately quantify LDL particles no matter how accurately the analytical techniques. This situation is most notable when the LDL particle size is small, since small LDL particles carry less cholesterol than large LDL particles. For the same amount of LDL-C, the patient with smaller LDL particles may require nearly 70 percent more LDL particles to carry the same amount of cholesterol as the patient with larger LDL particles [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31222/abstract/16\">",
"     16",
"    </a>",
"    ]. There are strong associations between LDL particles and cardiovascular disease, which provide a rationale for advanced lipoprotein testing for LDL subclasses and LDL particle numbers in cardiovascular risk assessment and treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31222/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, among patients with insulin resistance disorders (metabolic syndrome, type 2 diabetes), there is discordance between LDL-cholesterol and LDL particle",
"    <span class=\"nowrap\">",
"     concentration/apolipoprotein",
"    </span>",
"    B [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31222/abstract/18\">",
"     18",
"    </a>",
"    ]. This discordance results from LDL remodeling in insulin resistance, which results in a smaller, cholesterol depleted LDL particle. Thus, LDL cholesterol levels do not change with insulin resistance or with the number of metabolic risk factors, whereas the concentration of small LDL particles and total LDL particles increases progressively as the severity of insulin resistance increases and the number of metabolic risk factors increases. On statin therapy, nearly two-thirds of type 2 diabetes patients with LDL cholesterol levels less than 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    have excess LDL particles. In patients with type 2 diabetes and LDL cholesterol levels less than 70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    on statin therapy, 41 percent have excess numbers of LDL particles.",
"   </p>",
"   <p>",
"    A 2009 systematic review (of 24 studies) evaluated the association between cardiovascular outcomes and LDL subfractions or distribution (particle size; density) as well as total LDL particle number [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31222/abstract/19\">",
"     19",
"    </a>",
"    ]. Higher LDL particle number was consistently associated with increased cardiovascular risk, independent of lipid markers. LDL",
"    <span class=\"nowrap\">",
"     subfractions/size",
"    </span>",
"    did not add incremental risk prediction beyond that achieved with traditional risk factors.",
"   </p>",
"   <p>",
"    Lipoprotein particle sizes can be measured by special laboratories that use three different analytical techniques. These laboratory methods include nuclear magnetic resonance (NMR) spectroscopy (LipoScience, Inc.), gradient gel electrophoresis (GGE) (Berkeley HeartLab, Inc.), and analytical ultracentrifugation (Atherotech). Lipoprotein particle size is most often reported as an average size that takes into account the contribution of the small, intermediate, and large particles. Unlike the other methods, the NMR LipoProfile reports the total concentration or blood levels of the individual LDL subclasses and then derives the average LDL particle size [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31222/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In high cardiometabolic risk patients, such as those with diabetes, where the disconnect between LDL-C and LDL-P is greatest, the measurement of LDL-P may be of benefit for improved risk stratification and as a guide to",
"    <span class=\"nowrap\">",
"     titration/adjustment",
"    </span>",
"    of lipoprotein modifying therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31222/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24362266\">",
"    <span class=\"h1\">",
"     NON-HDL CHOLESTEROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-HDL cholesterol is defined as the difference between the total cholesterol and HDL cholesterol. Non-HDL cholesterol includes all cholesterol present in lipoprotein particles that is considered atherogenic, including LDL, lipoprotein(a), intermediate-density lipoprotein, and very-low-density lipoprotein. It has been suggested that the non-HDL cholesterol fraction may be a better tool for risk assessment than LDL cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31222/abstract/22\">",
"     22",
"    </a>",
"    ]. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10613?source=see_link&amp;anchor=H14#H14\">",
"     \"ATP III guidelines for treatment of high blood cholesterol\", section on 'Non-HDL-cholesterol'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24361278\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR MEASUREMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24361294\">",
"    <span class=\"h2\">",
"     Lipid profile",
"    </span>",
"    &nbsp;&mdash;&nbsp;A fasting lipid profile is recommended by many organizations when screening for lipid abnormalities and cardiovascular risk, and when monitoring therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33241?source=see_link&amp;anchor=H19#H19\">",
"     \"Screening guidelines for dyslipidemia\", section on 'Recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As decision making regarding either prevention or treatment of lipid abnormalities requires knowledge of all components of the lipid profile, we do not recommend routinely ordering individual components of the lipid profile. Thus, the lipid profile should be obtained, even if one component, such as LDL-C is of primary interest.",
"   </p>",
"   <p>",
"    Measuring LDL-C periodically can be helpful in determining whether a patient has met an LDL-C target or whether patients are adherent to treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\", section on 'Side effects and monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no reliable data on the optimal method of monitoring the effects of lipid-lowering therapy. ATP III recommends that the LDL-C be monitored every six weeks after the initiation of treatment until the LDL-C target is achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31222/abstract/23\">",
"     23",
"    </a>",
"    ]. Thereafter, measurement every six to 12 months is reasonable in patients adherent to lifestyle modifications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24362339\">",
"    <span class=\"h2\">",
"     Other measurements of LDL",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest measurement of LDL particle concentration, or the surrogate measure of apolipoprotein B, in individuals with insulin resistance disorders who have achieved their minimal acceptable LDL-cholesterol targets. In such patients this information may provide guidance as to treatment decisions, such as an increased dose of statins or combination lipid altering therapy with statin plus either niacin or fibrate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24361310\">",
"    <span class=\"h2\">",
"     Lipoproteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipoproteins particles, which carry cholesterol and triglycerides, are comprised in part of apolipoproteins. For instance, each LDL particle contains one molecule of apolipoprotein B (ApoB). Some have proposed that the measurement of lipoproteins or apolipoproteins may be useful in some patients. We agree with the 2010 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association guideline for assessment of cardiovascular risk in asymptomatic adults, which does not recommend the use of these tests for cardiovascular risk assessment in asymptomatic adults [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31222/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24363105\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The serum lipid profile measures total cholesterol and HDL-cholesterol (HDL-C), as well as the triglyceride level. With these values, the LDL-cholesterol (LDL-C) concentration can be estimated. (See",
"      <a class=\"local\" href=\"#H24361010\">",
"       'Lipid profile and components'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum total and HDL-cholesterol are measured directly and there are only small, clinically insignificant differences in these values when measured in the fasting or non-fasting state. Triglyceride levels may vary after a recent meal. Thus, we generally suggest that the lipid profile be measured in the fasting state. (See",
"      <a class=\"local\" href=\"#H24361770\">",
"       'Total and HDL-C'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24363001\">",
"       'Triglycerides'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LDL-C reported in the lipid profile is generally calculated from values for triglycerides, total cholesterol and HDL-C. (See",
"      <a class=\"local\" href=\"#H24360864\">",
"       'LDL-cholesterol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not recommend the routine measurement of LDL particle size or concentration (number), lipoprotein levels, or the use of &ldquo;ratios&rdquo;. (See",
"      <a class=\"local\" href=\"#H24362332\">",
"       'LDL particle size and number'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24361310\">",
"       'Lipoproteins'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3116442507\">",
"       'Total cholesterol to HDL cholesterol ratio'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31222/abstract/1\">",
"      Craig SR, Amin RV, Russell DW, Paradise NF. Blood cholesterol screening influence of fasting state on cholesterol results and management decisions. J Gen Intern Med 2000; 15:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31222/abstract/2\">",
"      Cooper GR, Myers GL, Smith SJ, Schlant RC. Blood lipid measurements. Variations and practical utility. JAMA 1992; 267:1652.",
"     </a>",
"    </li>",
"    <li>",
"     US Preventive Services Task Force. Guide to clinical preventive services, 2nd ed, Williams and Wilkins, Baltimore 1996. p.15.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31222/abstract/4\">",
"      Belsey R, Baer DM. Cardiac risk classification based on lipid screening. JAMA 1990; 263:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31222/abstract/5\">",
"      Bachorik PS, Cloey TA, Finney CA, et al. Lipoprotein-cholesterol analysis during screening: accuracy and reliability. Ann Intern Med 1991; 114:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31222/abstract/6\">",
"      Ockene IS, Chiriboga DE, Stanek EJ 3rd, et al. Seasonal variation in serum cholesterol levels: treatment implications and possible mechanisms. Arch Intern Med 2004; 164:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31222/abstract/7\">",
"      Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31222/abstract/8\">",
"      Faas FH, Earleywine A, Smith G, Simmons DL. How should low-density lipoprotein cholesterol concentration be determined? J Fam Pract 2002; 51:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31222/abstract/9\">",
"      Rosenson RS. Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol 1993; 22:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31222/abstract/10\">",
"      Rauoof MA, Iqbal K, Mir MM, Tramboo NA. Measurement of plasma lipids in patients admitted with acute myocardial infarction or unstable angina pectoris. Am J Cardiol 2001; 88:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31222/abstract/11\">",
"      Ettinger WH, Varma VK, Sorci-Thomas M, et al. Cytokines decrease apolipoprotein accumulation in medium from Hep G2 cells. Arterioscler Thromb 1994; 14:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31222/abstract/12\">",
"      Genest JJ, Corbett HM, McNamara JR, et al. Effect of hospitalization on high-density lipoprotein cholesterol in patients undergoing elective coronary angiography. Am J Cardiol 1988; 61:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31222/abstract/13\">",
"      Miller M. Lipid levels in the post-acute coronary syndrome setting: destabilizing another myth? J Am Coll Cardiol 2008; 51:1446.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson, JL, Adams, CD, Antman, EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College or Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:e1. Available at: www.acc.org/qualityandscience/clinical/statements.htm (accessed September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31222/abstract/15\">",
"      Pitt B, Loscalzo J, Ycas J, Raichlen JS. Lipid levels after acute coronary syndromes. J Am Coll Cardiol 2008; 51:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31222/abstract/16\">",
"      Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep 2004; 6:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31222/abstract/17\">",
"      Rosenson R, Lloyd-Jones D, Working group from the Adult Treatment Panel III of the National Cholesterol Educational Program. Critical appraisal of revised cholesterol guidelines for the very high-risk patient. Expert Rev Cardiovasc Ther 2005; 3:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31222/abstract/18\">",
"      Rosenson RS, Davidson MH, Pourfarzib R. Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis 2010; 213:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31222/abstract/19\">",
"      Ip S, Lichtenstein AH, Chung M, et al. Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes. Ann Intern Med 2009; 150:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31222/abstract/20\">",
"      Rosenson, RS. Clinical role of LDL and HDL subclasses and apolipoprotein measurement. ACC Curr J Rev 2004; 13:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31222/abstract/21\">",
"      Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008; 51:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31222/abstract/22\">",
"      Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001; 161:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31222/abstract/23\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31222/abstract/24\">",
"      Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010; 56:e50.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4556 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-199.231.185.123-BC6E475435-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_31_31222=[""].join("\n");
var outline_f30_31_31222=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24363105\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24361010\">",
"      LIPID PROFILE AND COMPONENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24361770\">",
"      Total and HDL-C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3116442507\">",
"      Total cholesterol to HDL cholesterol ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24360864\">",
"      LDL-cholesterol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24363001\">",
"      Triglycerides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24362756\">",
"      Causes of inaccurate results",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24362763\">",
"      - After an ACS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24362332\">",
"      LDL PARTICLE SIZE AND NUMBER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24362266\">",
"      NON-HDL CHOLESTEROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24361278\">",
"      INDICATIONS FOR MEASUREMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24361294\">",
"      Lipid profile",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24362339\">",
"      Other measurements of LDL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24361310\">",
"      Lipoproteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24363105\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4556\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4556|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/47/7933\" title=\"figure 1\">",
"      Short-term effects of MI on blood lipids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?21/1/21521?source=related_link\" title=\"calculator 1\">",
"      Calculator: Friedewald Equation for Low Density Lipoprotein (LDL-C)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?5/39/5746?source=related_link\" title=\"calculator 2\">",
"      Calculator: Friedewald Equation for Low Density Lipoprotein (LDL-C, SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10613?source=related_link\">",
"      ATP III guidelines for treatment of high blood cholesterol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18149?source=related_link\">",
"      Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=related_link\">",
"      Lipoprotein classification; metabolism; and role in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=related_link\">",
"      Lipoprotein(a) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=related_link\">",
"      Recognition of monoclonal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33241?source=related_link\">",
"      Screening guidelines for dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_31_31223="Pneumatosis intestinalis";
var content_f30_31_31223=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pneumatosis intestinalis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/31/31223/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/31/31223/contributors\">",
"     Eric Goldberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/31/31223/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/31/31223/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/31/31223/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/31/31223/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/31/31223/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/31/31223/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumatosis intestinalis (PI) refers to the presence of gas within the wall of the small or large intestine. Since its first description in 1783 by Du Vernoi, PI has appeared in the literature under many names, including pneumatosis cystoides intestinalis, intramural gas, pneumatosis coli, pseudolipomatosis, intestinal emphysema, bullous emphysema of the intestine, and lymphopneumatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. For the sake of simplicity and to avoid confusion, we will use the term \"pneumatosis intestinalis.\"",
"   </p>",
"   <p>",
"    The pathogenesis of PI is poorly understood, and is probably multifactorial. PI is not itself a disease, but rather a clinical sign. In some cases, PI is an incidental finding, whereas in others, it portends a life threatening intra-abdominal condition. As a result of the diverse array of clinical settings in which PI is encountered, its implications are often misinterpreted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of pneumatosis intestinalis (PI) is difficult to ascertain because most patients are asymptomatic and never come to clinical attention [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/2\">",
"     2",
"    </a>",
"    ]. PI can be seen in infants and adults. The majority of cases in infants are secondary to necrotizing enterocolitis, a disease associated with a high mortality rate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41591?source=see_link\">",
"     \"Clinical features and diagnosis of necrotizing enterocolitis in newborns\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PI in adults typically presents in the fifth to eighth decade and is idiopathic (15 percent) or secondary (85 percent) to a wide variety of gastrointestinal and non-gastrointestinal illnesses (",
"    <a class=\"graphic graphic_table graphicRef58197 \" href=\"UTD.htm?19/59/20413\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The course of PI is variable and determined largely by the underlying disorder. Mortality rates are high when PI is associated with diseases that lead to bowel necrosis or perforation. In contrast, the clinical course is generally benign when PI is idiopathic, such as when it occurs in association with obstructive pulmonary disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous hypotheses have been proposed to explain the pathogenesis of pneumatosis intestinalis (PI), including mechanical, bacterial, and biochemical causes. For any of these theories to gain acceptance, they must explain the association of PI with many different underlying conditions. Although the theories are distinctly different, they are not necessarily mutually exclusive. It is likely that multiple pathogenic mechanisms are involved in the formation of PI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mechanical theory",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the mechanical theory, gas dissects into the wall of the bowel from either the luminal surface through breaks in the mucosa or through the serosal surface by tracking along mesenteric blood vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/5\">",
"     5",
"    </a>",
"    ]. Once inside the bowel wall, gas may spread along the mesentery to distant sites [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanical theory has gained support for several reasons. First, PI can be reproduced experimentally by insufflating air into an excised colonic segment in which mucosal incisions have been made [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/7\">",
"     7",
"    </a>",
"    ]. Second, the mechanical theory accounts for the association of PI with conditions that disrupt mucosal integrity, such as necrotizing enterocolitis, intestinal ischemia, caustic ingestions, inflammatory bowel disease, and intestinal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/6\">",
"     6",
"    </a>",
"    ]. Third, the mechanical theory offers an explanation for the association of PI with obstructive pulmonary disease. In these patients, coughing may cause alveolar rupture and air may subsequently track along blood vessels into the mediastinum, through the diaphragm, and ultimately to the mesenteric root [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/8\">",
"     8",
"    </a>",
"    ]. Once air has gained access to the mesenteric root, it may course along small mesenteric blood vessels that ultimately penetrate through the bowel wall.",
"   </p>",
"   <p>",
"    The argument against the mechanical theory is that the direct tracking of air from the lungs into the bowel wall is the invariable absence of a \"gas trail\" from the mediastinum to the intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/9\">",
"     9",
"    </a>",
"    ]. Furthermore, some studies have found that the gas composition of the intramural cysts does not resemble alveolar air, but rather, the cysts contain a different mixture of hydrogen, nitrogen, and carbon dioxide [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Bacterial theory",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the bacterial theory, gas forming bacteria gain access to the submucosa through breaches in the mucosa. In support of this theory, PI has been reproduced experimentally by injecting the gas forming bacillus Clostridium perfringens into the bowel wall of rats [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/12\">",
"     12",
"    </a>",
"    ]. Further supporting the bacterial theory is that PI may resolve following treatment with antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/13\">",
"     13",
"    </a>",
"    ]. Finally, elemental diets have been reported to improve PI presumably by removing substrate for the production of gas by bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/14\">",
"     14",
"    </a>",
"    ]. The argument against the bacterial theory is that the cysts are sterile and if they rupture, the resulting pneumoperitoneum often follows a benign course without development of peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Biochemical theory",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biochemical theory proposes that luminal bacteria produce excessive amounts of hydrogen gas through fermentation of carbohydrates and other foodstuffs. As the pressure of the gas within the intestinal lumen increases, gas may be forced directly through the mucosa and become trapped within the submucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/17\">",
"     17",
"    </a>",
"    ]. Indeed, the hydrogen content of cysts has been reported to be as high as 50 percent, and some patients with PI have much higher levels of breath hydrogen than controls [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/10,17,18\">",
"     10,17,18",
"    </a>",
"    ]. One study reported a patient with PI and small bowel bacterial overgrowth producing large amounts of hydrogen gas [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/19\">",
"     19",
"    </a>",
"    ]. Case reports have documented PI in patients taking alpha glucosidase inhibitors, which increase intestinal gas [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3078?source=see_link\">",
"     \"Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumatosis intestinalis (PI) can affect any portion of the gastrointestinal tract distal to the stomach. Intramural gas can also affect the stomach, but this condition is referred to as gastric pneumatosis rather than pneumatosis intestinalis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/24\">",
"     24",
"    </a>",
"    ]. In one large series, PI involved the small bowel, colon, and small bowel and colon together in 42, 36, and 22 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/25\">",
"     25",
"    </a>",
"    ]. The cysts may be confined to the mucosa, submucosa, or subserosa, or the cysts may involve all three layers. Subserosal cysts are more commonly seen in small intestinal pneumatosis, while submucosal cysts are more commonly seen in colonic pneumatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On gross appearance, submucosal cysts are polypoid with the overlying mucosa displaying a bluish hue. Subserosal cysts are characteristically found near the mesenteric border adjacent to blood vessels and appear as multiple, glistening, pale-bluish, gas-filled blebs [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/15,26\">",
"     15,26",
"    </a>",
"    ]. The cysts of PI are truly pseudocysts since they lack an epithelial lining. However, they may become surrounded by a rim of histiocytes, multinuclear giant cells, lymphocytes, neutrophils, eosinophils, granulomas, and fibrosis, especially after they collapse [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/17,27\">",
"     17,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with pneumatosis intestinalis (PI) are asymptomatic and probably never come to clinical attention [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients who do come to clinical attention can present in a variety of ways. There may be signs and symptoms related to either the presence of PI or to the underlying disorder associated with PI. PI may also be discovered incidentally during radiographic or endoscopic examinations, or at the time of surgery.",
"   </p>",
"   <p>",
"    Symptoms of PI depend upon the region of intestine affected (",
"    <a class=\"graphic graphic_table graphicRef60778 \" href=\"UTD.htm?1/31/1532\">",
"     table 2",
"    </a>",
"    ). In one review of 919 patients, the most common symptoms of small intestinal pneumatosis in order of decreasing frequency were vomiting, abdominal distention, weight loss, abdominal pain, and diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/25\">",
"     25",
"    </a>",
"    ]. The most common symptoms of colonic pneumatosis in order of decreasing frequency were diarrhea, hematochezia, abdominal pain, abdominal distention, and constipation. Other symptoms reported with PI include flatulence, loss of appetite, and tenesmus. The non-specific nature of many of the symptoms of PI may lead to an erroneous diagnosis of irritable bowel syndrome.",
"   </p>",
"   <p>",
"    Physical examination can be completely normal or may show non-specific findings such as abdominal distention. A mass can be palpated on abdominal or digital rectal examination in approximately 10 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/25,28\">",
"     25,28",
"    </a>",
"    ]. There are reports of PI simulating organomegaly, but this finding is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications of PI occur in approximately 3 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/26\">",
"     26",
"    </a>",
"    ]. They include small and large bowel obstruction, volvulus, intussusception, pneumoperitoneum, and hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumatosis intestinalis (PI) may be detected by a variety of different radiographic imaging modalities, including plain films, contrast studies, computed tomography (CT) scan, ultrasound, and magnetic resonance imaging (MRI).",
"   </p>",
"   <p>",
"    When PI is often first detected on plain film, a CT study should be the next test in order to confirm the diagnosis and to look for an underlying cause.",
"   </p>",
"   <p>",
"    The following describes the findings observed with the various imaging modalities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal x-ray &ndash; PI is often detected by plain films of the abdomen, which will be positive in approximately two-thirds of affected patients (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72081 \" href=\"UTD.htm?11/31/11774\">",
"       image 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/15,25\">",
"       15,25",
"      </a>",
"      ]. Intramural gas can be linear, curvilinear, or circular in appearance. Linear pneumatosis is an ominous sign suggesting impending bowel perforation in PI accompanying bowel necrosis. However, linear pneumatosis may also follow a benign course, especially when associated with bowel infection [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. Pneumoperitoneum results from the rupture of subserosal blebs.",
"     </li>",
"     <li>",
"      Contrast studies &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       Barium",
"      </a>",
"      contrast studies of the small or large intestine can confirm the diagnosis of PI by demonstrating filling defects within the intestinal lumen corresponding to protrusion of submucosal, gas filled cysts. However, we prefer CT with oral and intravenous contrast to barium contrast studies for confirmation of the diagnosis (see below).",
"     </li>",
"     <li>",
"      CT scans &ndash; CT scans are more sensitive than plain films and may suggest the underlying cause of the pneumatosis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef58309 \" href=\"UTD.htm?9/26/9640\">",
"       image 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/32\">",
"       32",
"      </a>",
"      ]. Characteristic findings of PI on CT scan include circumferential collections of air adjacent to the lumen of the bowel that run in parallel with the wall of the bowel, but without the air-contrast or air-fluid levels characteristically seen with intraluminal air [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/33\">",
"       33",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      One report described the use of target air-enema CT (TACT) to diagnose and follow the course of PI [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/32\">",
"       32",
"      </a>",
"      ]. TACT is a way to image submucosal lesions of the colon in which CT images are obtained after introducing air into a prepped colon.",
"      <br/>",
"      <br/>",
"      CT scans can also be utilized to predict benign from clinically worrisome pneumatosis intestinalis. In a review of 44 cases of PI in children, the following variables were predictive of clinically worrisome pneumatosis intestinalis: soft tissue thickening of the bowel wall, free peritoneal fluid, peri-intestinal soft tissue stranding, and extent of the pneumatosis [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/34\">",
"       34",
"      </a>",
"      ]. Factors not predictive of clinically worrisome pneumatosis intestinalis included the location of the pneumatosis, the presence of free peritoneal air, and linear versus cystic morphology.",
"      <br/>",
"      <br/>",
"      In the setting of intestinal ischemia, a CT finding of PI is worrisome, but does not always indicate transmural infarction of the bowel in patients with intestinal ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/35\">",
"       35",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44377?source=see_link&amp;anchor=H21#H21\">",
"       \"Acute mesenteric ischemia\", section on 'Radiographic studies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ultrasound &ndash; On ultrasound, PI may appear as high-amplitude gas echoes with acoustic shadowing [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      MRI &ndash; Gas within the wall of the bowel may also be diagnosed with MRI [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/37\">",
"       37",
"      </a>",
"      ]. We obtain MRIs in patients with contrast allergies or contraindications to CT scanning.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Sigmoidoscopy/colonoscopy",
"      </span>",
"      &ndash; PI may be discovered incidentally on screening sigmoidoscopy or colonoscopy. Submucosal cysts usually have a pale or bluish appearance and when biopsied, they may rapidly deflate with an audible hiss [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/9,38\">",
"       9,38",
"      </a>",
"      ]. These features help distinguish PI from other disorders causing mucosal-protuberances such as adenomas, malignancies, familial adenomatosis polyposis, and colitis cystica profunda [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The critical decision in the management of patients with pneumatosis intestinalis (PI) is whether to treat conservatively or proceed with emergent exploratory laparotomy (",
"    <a class=\"graphic graphic_algorithm graphicRef69083 \" href=\"UTD.htm?18/35/19006\">",
"     algorithm 1",
"    </a>",
"    ). This decision hinges upon the likelihood that there has been an intra-abdominal catastrophe, such as a bowel infarction, accounting for the PI. Surgery should usually proceed immediately in such patients. In contrast, conservative management is appropriate when PI is due to non-life-threatening causes, such as chronic obstructive pulmonary disease or uncomplicated Crohn's disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H386508330\">",
"    <span class=\"h2\">",
"     Intra-abdominal catastrophe",
"    </span>",
"    &nbsp;&mdash;&nbsp;PI can lead to mesenteric ischemia and subsequent bowel infarction. It may not always be readily apparent whether a severe, life-threatening abdominal insult has occurred at the time of initial clinical presentation.",
"   </p>",
"   <p>",
"    The presence of certain clinical features may help to predict the necessity of surgical exploration. In a prospective review of 27 patients who presented with PI during a one-year period, the following clinical features predicted the presence of bowel necrosis: a history and physical examination that suggested an acute abdominal process, arterial pH &lt;7.3, HCO3 &lt;20",
"    <span class=\"nowrap\">",
"     mmol/L,",
"    </span>",
"    an elevated lactate level, an elevated serum amylase level, or the presence of portal venous gas [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proposed criteria suggest that patients can be managed conservatively if they lack the above findings and have historical features suggesting a benign cause of PI. Similarly, pneumoperitoneum caused by PI may be managed conservatively if there are no clinical features suggesting an underlying acute abdominal emergency [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A clinical algorithm has been proposed as a tool to identify clinical subgroups in patients with PI and portal venous gas needing direct surgical intervention. Mechanical causes, acute mesenteric ischemia, and benign idiopathic causes could be distinguished using the algorithm with a sensitivity of 89 percent, specificity of 100 percent, and positive predictive value of 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/39\">",
"     39",
"    </a>",
"    ]. Testing of the algorithm was performed on a limited number of cases, and it remains to be determined if it will prove useful on a larger population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H386508323\">",
"    <span class=\"h2\">",
"     Symptomatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management should be based upon symptoms once an acute intra-abdominal emergency has been excluded (",
"    <a class=\"graphic graphic_table graphicRef60778 \" href=\"UTD.htm?1/31/1532\">",
"     table 2",
"    </a>",
"    ). There are a variety of treatment options for patients with symptomatic PI, including antibiotics, special diets, high-flow oxygen therapy, hyperbaric oxygen therapy, surgery, and endoscopic therapy. Unfortunately, the efficacy of these treatments has been demonstrated only in small case series and none have been directly compared. Furthermore, recurrence within 18 months has been described in 30 to 40 percent of patients after all types of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/2,13,40-43\">",
"     2,13,40-43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H399616\">",
"    <span class=\"h3\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with mild symptoms which persist after treatment of the underlying cause of PI, we suggest a combination of antibiotics and an elemental diet (See",
"    <a class=\"local\" href=\"#H399623\">",
"     'Elemental diet'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The possible association of PI with gas producing anaerobic bacteria provided the rationale for therapeutic trials with antibiotics. Numerous reports have documented the success of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    in treating symptomatic PI [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/13,43,44\">",
"     13,43,44",
"    </a>",
"    ]. Treatment should be continued until resolution of the PI has been documented [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/13,43\">",
"     13,43",
"    </a>",
"    ]. A typical course is metronidazole (500 mg PO three times daily) for up to three months. Retreatment with a prolonged course has been effective in patients who relapsed following discontinuation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/43\">",
"     43",
"    </a>",
"    ]. We inform patients of the potential adverse reactions associated with metronidazole such as nausea, vomiting, diarrhea, and neuropathy, and the need to avoid alcohol. For patients who cannot tolerate metronidazole, other antibiotics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    have been used successfully. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Bacterial theory'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H399623\">",
"    <span class=\"h3\">",
"     Elemental diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;PI may resolve on an elemental diet (such as the enteral formula Vivonex), presumably by alteration of the colonic microflora [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/14,45\">",
"     14,45",
"    </a>",
"    ]. The elemental diet should be continued for two weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34073?source=see_link\">",
"     \"Nutrition support in critically ill patients: Enteral nutrition\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H386508351\">",
"    <span class=\"h3\">",
"     Inhalation oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with moderate to severe symptoms, we suggest a combination of antibiotics, an elemental diet, and inhalation oxygen therapy.&nbsp;Inhalation oxygen therapy has been used to treat PI since 1973 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/2\">",
"     2",
"    </a>",
"    ]. The rationale for the use of oxygen therapy is twofold. First, oxygen is toxic to the anaerobic intestinal bacteria that contribute to gas cyst formation. Second, the contents of the gas cysts are primarily non-oxygen gases [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. High concentrations of delivered oxygen increase the partial pressure of oxygen in the venous blood, and decrease the partial pressure of non-oxygen gases, such as nitrogen, creating a diffusion gradient across the cystic wall favoring the exit of gas from the cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/9,19\">",
"     9,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Numerous reports have shown oxygen therapy to be beneficial in cases of symptomatic PI [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/40,46-50\">",
"     40,46-50",
"    </a>",
"    ]. However, the optimal amount and duration of oxygen therapy required for cyst deflation is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/2\">",
"     2",
"    </a>",
"    ]. A reasonable approach is to use an FiO2 of 55 to 75 percent to achieve a PO2 of 200 to 350 mmHg for 4 to 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/17\">",
"     17",
"    </a>",
"    ]. A concern with oxygen therapy is the potential for toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28407?source=see_link\">",
"     \"Oxygen toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hyperbaric oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperbaric oxygen therapy has also been successful in treating patients with PI and may help to avoid the pulmonary toxicity and central nervous system toxicity that may be associated with prolonged high flow oxygen use [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/51\">",
"     51",
"    </a>",
"    ]. The protocol for using hyperbaric oxygen therapy is to administer 2.5 atmospheres for 2.5 hours on two or three consecutive days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery should be considered for patients with PI who remain symptomatic despite medical therapy or who develop complications from PI such as bowel obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/52\">",
"     52",
"    </a>",
"    ]. Although surgery can be effective, worsening of PI after surgery has also been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Endoscopic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop obstructive symptoms from PI may not be candidates for surgery because of high perioperative risk. Successful relief of obstruction in such patients has been described using endoscopic puncture and sclerotherapy of the cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H386508426\">",
"    <span class=\"h2\">",
"     Asymptomatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific therapy is indicated other than treatment of the underlying cause of PI for patients who are asymptomatic or minimally symptomatic. Intramural gas cysts usually resolve spontaneously over time [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31223/abstract/17\">",
"     17",
"    </a>",
"    ]. One of the most important interventions for asymptomatic patients is education of the patient and their physicians to prevent unnecessary surgical interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pneumatosis intestinalis (PI) may be incidental or indicate the presence of a life-threatening abdominal catastrophe. This distinction is made through the interpretation of clinical information provided in the history, physical examination, laboratory and radiographic data. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Emergent surgical exploration is indicated for patients with a suspected acute abdominal event. For all other patients, observation or conservative measures are appropriate (",
"      <a class=\"graphic graphic_algorithm graphicRef69083 \" href=\"UTD.htm?18/35/19006\">",
"       algorithm 1",
"      </a>",
"      ). In addition, education of the physicians involved in the care of patients with benign causes of PI is of paramount importance since it may help prevent unnecessary surgery. (See",
"      <a class=\"local\" href=\"#H386508330\">",
"       'Intra-abdominal catastrophe'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with mild symptoms who can be managed as outpatients, we suggest a combination of antibiotics and an elemental diet (such as the enteral formula Vivonex) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The elemental diet should be continued for two weeks.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      has been most studied, although several antibiotics have been used and may be acceptable alternatives. Metronidazole (500 mg three times daily) should be continued until there is symptomatic and radiographic resolution of PI. This may require extended courses of up to three months. Follow-up imaging should be performed once symptoms have resolved or at three months to document resolution. (See",
"      <a class=\"local\" href=\"#H399616\">",
"       'Antibiotics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H399623\">",
"       'Elemental diet'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with moderate to severe symptoms who require hospitalization, we suggest a combination of antibiotics, an elemental diet, and inhalation oxygen therapy&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H399616\">",
"       'Antibiotics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H399623\">",
"       'Elemental diet'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H386508351\">",
"       'Inhalation oxygen'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/1\">",
"      Sachse RE, Burke GW 3rd, Jonas M, et al. Benign pneumatosis intestinalis with subcutaneous emphysema in a liver transplant recipient. Am J Gastroenterol 1990; 85:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/2\">",
"      Heng Y, Schuffler MD, Haggitt RC, Rohrmann CA. Pneumatosis intestinalis: a review. Am J Gastroenterol 1995; 90:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/3\">",
"      KOSS LG. Abdominal gas cysts (pneumatosis cystoides intestinorum hominis); an analysis with a report of a case and a critical review of the literature. AMA Arch Pathol 1952; 53:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/4\">",
"      Knechtle SJ, Davidoff AM, Rice RP. Pneumatosis intestinalis. Surgical management and clinical outcome. Ann Surg 1990; 212:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/5\">",
"      Pieterse AS, Leong AS, Rowland R. The mucosal changes and pathogenesis of pneumatosis cystoides intestinalis. Hum Pathol 1985; 16:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/6\">",
"      Pear BL. Pneumatosis intestinalis: a review. Radiology 1998; 207:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/7\">",
"      KAY-BUTLER JJ. Interstitial emphysema of the caecum. Gut 1962; 3:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/8\">",
"      KEYTING WS, MCCARVER RR, KOVARIK JL, DAYWITT AL. Pneumatosis intestinalis: a new concept. Radiology 1961; 76:733.",
"     </a>",
"    </li>",
"    <li>",
"     Davila AD, Willenbucher RF. Other diseases of the colon and rectum. In: Sleisenger &amp; Fordtran's Gastrointestinal and Liver Disease, 6th ed, Feldman M, Scharschmidt B, Sleisenger M (Eds), WB Saunders Company, Philadelphia 1998. p.1979.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/10\">",
"      Read NW, Al-Janabi MN, Cann PA. Is raised breath hydrogen related to the pathogenesis of pneumatosis coli? Gut 1984; 25:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/11\">",
"      Florin TH, Hills BA. Does counterperfusion supersaturation cause gas cysts in pneumatosis cystoides coli, and can breathing heliox reduce them? Lancet 1995; 345:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/12\">",
"      Yale CE, Balish E, Wu JP. The bacterial etiology of pneumatosis cystoides intestinalis. Arch Surg 1974; 109:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/13\">",
"      Ellis BW. Symptomatic treatment of primary pneumatosis coli with metronidazole. Br Med J 1980; 280:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/14\">",
"      van der Linden W, Marsell R. Pneumatosis cystoides coli associated with high H2 excretion. Treatment with an elemental diet. Scand J Gastroenterol 1979; 14:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/15\">",
"      Mehta SN, Friedman G, Fried GM, Mayrand S. Pneumatosis cystoides intestinalis: laparoscopic features. Am J Gastroenterol 1996; 91:2610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/16\">",
"      Hoover EL, Cole GD, Mitchell LS, et al. Avoiding laparotomy in nonsurgical pneumoperitoneum. Am J Surg 1992; 164:99.",
"     </a>",
"    </li>",
"    <li>",
"     Sartor, RB, Murphy, ME, Rydzak, E. Miscellaneous inflammatory and structural disorders of the colon. In: Textbook of Gastroenterology, 1877, Third Edition, Yamada, T, Alpers, D, Laine, L, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/18\">",
"      Christl SU, Gibson GR, Murgatroyd PR, et al. Impaired hydrogen metabolism in pneumatosis cystoides intestinalis. Gastroenterology 1993; 104:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/19\">",
"      Levitt MD, Olsson S. Pneumatosis cystoides intestinalis and high breath H2 excretion: insights into the role of H2 in this condition. Gastroenterology 1995; 108:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/20\">",
"      Hisamoto A, Mizushima T, Sato K, et al. Pneumatosis cystoides intestinalis after alpha-glucosidase inhibitor treatment in a patient with interstitial pneumonitis. Intern Med 2006; 45:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/21\">",
"      Hayakawa T, Yoneshima M, Abe T, Nomura G. Pneumatosis cystoides intestinalis after treatment with an alpha-glucosidase inhibitor. Diabetes Care 1999; 22:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/22\">",
"      Yanaru R, Hizawa K, Nakamura S, et al. Regression of pneumatosis cystoides intestinalis after discontinuing of alpha-glucosidase inhibitor administration. J Clin Gastroenterol 2002; 35:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/23\">",
"      Azami Y. Paralytic ileus accompanied by pneumatosis cystoides intestinalis after acarbose treatment in an elderly diabetic patient with a history of heavy intake of maltitol. Intern Med 2000; 39:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/24\">",
"      Cordum NR, Dixon A, Campbell DR. Gastroduodenal pneumatosis: endoscopic and histological findings. Am J Gastroenterol 1997; 92:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/25\">",
"      Jamart J. Pneumatosis cystoides intestinalis. A statistical study of 919 cases. Acta Hepatogastroenterol (Stuttg) 1979; 26:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/26\">",
"      Galandiuk S, Fazio VW. Pneumatosis cystoides intestinalis. A review of the literature. Dis Colon Rectum 1986; 29:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/27\">",
"      H&ouml;er J, Truong S, Virnich N, et al. Pneumatosis cystoides intestinalis: confirmation of diagnosis by endoscopic puncture a review of pathogenesis, associated disease and therapy and a new theory of cyst formation. Endoscopy 1998; 30:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/28\">",
"      Chaput U, Ducrott&eacute; P, Denis P, Nouveau J. Pneumatosis cystoides intestinalis: an unusual cause of distal constipation. Gastroenterol Clin Biol 2010; 34:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/29\">",
"      Tobias R, Coleman S, Helman CA. Pneumatosis coli simulating hepatomegaly. Am J Gastroenterol 1985; 80:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/30\">",
"      Gelman SF, Brandt LJ. Pneumatosis intestinalis and AIDS: a case report and review of the literature. Am J Gastroenterol 1998; 93:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/31\">",
"      Kreiss C, Forohar F, Smithline AE, Brandt LJ. Pneumatosis intestinalis complicating C. difficile pseudomembranous colitis. Am J Gastroenterol 1999; 94:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/32\">",
"      Ihara E, Harada N, Motomura S, Chijiiwa Y. A new approach to Pneumatosis cystoides intestinalis by target air-enema CT. Am J Gastroenterol 1998; 93:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/33\">",
"      John A, Dickey K, Fenwick J, et al. Pneumatosis intestinalis in patients with Crohn's disease. Dig Dis Sci 1992; 37:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/34\">",
"      Olson DE, Kim YW, Ying J, Donnelly LF. CT predictors for differentiating benign and clinically worrisome pneumatosis intestinalis in children beyond the neonatal period. Radiology 2009; 253:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/35\">",
"      Kernagis LY, Levine MS, Jacobs JE. Pneumatosis intestinalis in patients with ischemia: correlation of CT findings with viability of the bowel. AJR Am J Roentgenol 2003; 180:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/36\">",
"      Vernacchia FS, Jeffrey RB, Laing FC, Wing VW. Sonographic recognition of pneumatosis intestinalis. AJR Am J Roentgenol 1985; 145:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/37\">",
"      Rabushka LS, Kuhlman JE. Pneumatosis intestinalis. Appearance on MR examination. Clin Imaging 1994; 18:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/38\">",
"      Varano VJ, Bonanno CA. Colonoscopic findings in Pneumatosis cystoides intestinalis. Am J Gastroenterol 1973; 59:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/39\">",
"      Wayne E, Ough M, Wu A, et al. Management algorithm for pneumatosis intestinalis and portal venous gas: treatment and outcome of 88 consecutive cases. J Gastrointest Surg 2010; 14:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/40\">",
"      Holt S, Gilmour HM, Buist TA, et al. High flow oxygen therapy for pneumatosis coli. Gut 1979; 20:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/41\">",
"      Grieve DA, Unsworth IP. Pneumatosis cystoides intestinalis: an experience with hyperbaric oxygen treatment. Aust N Z J Surg 1991; 61:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/42\">",
"      van der Linden W. Letter: Reappearance of intestinal gas cysts after oxygen treatment. Lancet 1974; 2:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/43\">",
"      Tak PP, Van Duinen CM, Bun P, et al. Pneumatosis cystoides intestinalis in intestinal pseudoobstruction. Resolution after therapy with metronidazole. Dig Dis Sci 1992; 37:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/44\">",
"      Jauhonen P, Lehtola J, Karttunen T. Treatment of pneumatosis coli with metronidazole. Endoscopic follow-up of one case. Dis Colon Rectum 1987; 30:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/45\">",
"      Johnston BT, McFarland RJ. Elemental diet in the treatment of pneumatosis coli. Scand J Gastroenterol 1995; 30:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/46\">",
"      Miralb&eacute;s M, Hinojosa J, Alonso J, Berenguer J. Oxygen therapy in pneumatosis coli. What is the minimum oxygen requirement? Dis Colon Rectum 1983; 26:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/47\">",
"      Shemen LJ, Stern H, Sidlofsky S, Myers ED. Treatment of pneumatosis cystoides intestinalis with high FIO2: report of two cases. Dis Colon Rectum 1979; 22:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/48\">",
"      Wyatt AP. Prolonged symptomatic and radiological remission of colonic gas cysts after oxygen therapy. Br J Surg 1975; 62:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/49\">",
"      Forgacs P, Wright PH, Wyatt AP. Treatment of intestinal gas cysts by oxygen breathing. Lancet 1973; 1:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/50\">",
"      Simon NM, Nyman KE, Divertie MB, et al. Pneumatosis cystoides intestinalis. Treatment with oxygen via close-fitting mask. JAMA 1975; 231:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/51\">",
"      Masterson JS, Fratkin LB, Osler TR, Trapp WG. Treatment of pneumatosis cystoides intestinalis with hyperbaric oxygen. Ann Surg 1978; 187:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/52\">",
"      Greenstein AJ, Nguyen SQ, Berlin A, et al. Pneumatosis intestinalis in adults: management, surgical indications, and risk factors for mortality. J Gastrointest Surg 2007; 11:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31223/abstract/53\">",
"      Johansson K, Lindstr&ouml;m E. Treatment of obstructive pneumatosis coli with endoscopic sclerotherapy: report of a case. Dis Colon Rectum 1991; 34:94.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2596 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.66.252.144-FC8D04C3D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_31_31223=[""].join("\n");
var outline_f30_31_31223=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mechanical theory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Bacterial theory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Biochemical theory",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H386508330\">",
"      Intra-abdominal catastrophe",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H386508323\">",
"      Symptomatic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H399616\">",
"      - Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H399623\">",
"      - Elemental diet",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H386508351\">",
"      - Inhalation oxygen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hyperbaric oxygen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Endoscopic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H386508426\">",
"      Asymptomatic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2596\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2596|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?18/35/19006\" title=\"algorithm 1\">",
"      Rx pneumatosis intestinalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2596|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/31/11774\" title=\"diagnostic image 1\">",
"      Pneumatosis intestinalis plain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/26/9640\" title=\"diagnostic image 2\">",
"      CT scan pneumatosis coli",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2596|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/59/20413\" title=\"table 1\">",
"      Causes of pneumatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/31/1532\" title=\"table 2\">",
"      Pneumatosis symptoms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44377?source=related_link\">",
"      Acute mesenteric ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3078?source=related_link\">",
"      Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41591?source=related_link\">",
"      Clinical features and diagnosis of necrotizing enterocolitis in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34073?source=related_link\">",
"      Nutrition support in critically ill patients: Enteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28407?source=related_link\">",
"      Oxygen toxicity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_31_31224="Alprazolam: Drug information";
var content_f30_31_31224=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Alprazolam: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/29/7637?source=see_link\">",
"    see \"Alprazolam: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/35/7735?source=see_link\">",
"    see \"Alprazolam: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F132040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alprazolam Intensol&trade;;",
"     </li>",
"     <li>",
"      Niravam&trade;;",
"     </li>",
"     <li>",
"      Xanax XR&reg;;",
"     </li>",
"     <li>",
"      Xanax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F132041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Alpraz&reg;;",
"     </li>",
"     <li>",
"      Apo-Alpraz&reg; TS;",
"     </li>",
"     <li>",
"      Mylan-Alprazolam;",
"     </li>",
"     <li>",
"      NTP-Alprazolam;",
"     </li>",
"     <li>",
"      Nu-Alpraz;",
"     </li>",
"     <li>",
"      Teva-Alprazolam;",
"     </li>",
"     <li>",
"      Xanax TS&trade;;",
"     </li>",
"     <li>",
"      Xanax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F132085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Benzodiazepine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F132045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Treatment &gt;4 months should be re-evaluated to determine the patient's continued need for the drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anxiety:",
"     </b>",
"     Oral:",
"     <i>",
"      Immediate release:",
"     </i>",
"     Initial: 0.25-0.5 mg 3 times/day; titrate dose upward every 3-4 days; usual maximum: 4 mg/day. Patients requiring doses &gt;4 mg/day should be increased cautiously. Periodic reassessment and consideration of dosage reduction is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Panic disorder:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Immediate release:",
"     </i>",
"     Initial: 0.5 mg 3 times/day; dose may be increased every 3-4 days in increments &le;1 mg/day. Mean effective dosage: 5-6 mg/day; some patients may require much as 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Extended release:",
"     </i>",
"     0.5-1 mg once daily; may increase dose every 3-4 days in increments &le;1 mg/day (range: 3-6 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Switching from immediate release to extended release:",
"     </i>",
"     Patients may be switched to extended release tablets by taking the total daily dose of the immediate release tablets and giving it once daily using the extended release preparation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Preoperative anxiety (unlabeled use):",
"     </b>",
"     Oral: 0.5 mg 60-90 minutes before procedure (De Witte, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dose reduction:",
"     </b>",
"     Abrupt discontinuation should be avoided. Daily dose may be decreased by 0.5 mg every 3 days; however, some patients may require a slower reduction. If withdrawal symptoms occur, resume previous dose and discontinue on a less rapid schedule.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F132062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/35/7735?source=see_link\">",
"      see \"Alprazolam: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anxiety (unlabeled use):",
"     </b>",
"     Oral: Immediate release: Initial: 0.005 mg/kg/dose or 0.125 mg/dose 3 times/day; increase in increments of 0.125-0.25 mg, up to a maximum of 0.02 mg/kg/dose or 0.06 mg/kg/day (range of doses reported in one study: 0.375-3 mg/day) (Pfefferbaum, 1987). See \"Dose Reduction\" comment in adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Treatment &gt;4 months should be re-evaluated to determine the patient's continued need for the drug.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F132046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Elderly patients may be more sensitive to the effects of alprazolam including ataxia and oversedation. The elderly may also have impaired renal function leading to decreased clearance. Titrate gradually, if needed and tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Immediate release:",
"     </i>",
"     Initial 0.25 mg 2-3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Extended release:",
"     </i>",
"     Initial: 0.5 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2606647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; however, use caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F132047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Advanced liver disease:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Immediate release: 0.25 mg 2-3 times/day; titrate gradually if needed and tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended release: 0.5 mg once daily; titrate gradually if needed and tolerate",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F132014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [concentrate]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alprazolam Intensol&trade;: 1 mg/mL (30 mL) [dye free, ethanol free, sugar free; contains propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 0.25 mg, 0.5 mg, 1 mg, 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xanax&reg;: 0.25 mg, 0.5 mg, 1 mg, 2 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 0.5 mg, 1 mg, 2 mg, 3 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xanax XR&reg;: 0.5 mg, 1 mg, 2 mg, 3 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral: 0.25 mg, 0.5 mg, 1 mg, 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Niravam&trade;: 0.25 mg, 0.5 mg, 1 mg, 2 mg [scored; orange flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F131999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes oral solution",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F132087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F132018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Immediate release preparations: Can be administered sublingually if oral administration is not possible; absorption and onset of effect are comparable to oral administration (Scavone,1987; Scavone, 1992)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended release tablet: Should be taken once daily in the morning; do not crush, break, or chew.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Orally-disintegrating tablets: Using dry hands, place tablet on top of tongue and allow to disintegrate. If using one-half of tablet, immediately discard remaining half (may not remain stable). Administration with water is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F132017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of anxiety disorder (GAD); short-term relief of symptoms of anxiety; panic disorder, with or without agoraphobia; anxiety associated with depression",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F132081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anxiety in children",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F132095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ALPRAZolam may be confused with alprostadil, LORazepam, triazolam",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Xanax&reg; may be confused with Fanapt&reg;, Lanoxin&reg;, Tenex&reg;, Tylox&reg;, Xopenex&reg;, Zantac&reg;, ZyrTEC&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F132083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Abnormal coordination, cognitive disorder, depression, drowsiness, fatigue, irritability, lightheadedness, memory impairment, sedation, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Appetite increased/decreased, constipation, weight gain/loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Micturition difficulty",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp;  skeletal: Dysarthria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain, hypotension, palpitation, sinus tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Agitation, akathisia, ataxia, attention disturbance, confusion, depersonalization, derealization, disorientation, disinhibition, dizziness, dream abnormalities, fear, hallucination, headache, hypersomnia, hypoesthesia, insomnia, lethargy, malaise, mental impairment, nervousness, nightmares, restlessness, seizure, syncope, talkativeness, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Dermatitis, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea, libido increased, menstrual disorders, sexual dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, dyspepsia, nausea, salivation increased, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Incontinence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Bilirubin increased, jaundice, liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, dyskinesia, dystonia, muscle cramps, muscle twitching, myalgia, paresthesia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Allergic rhinitis, dyspnea, hyperventilation, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Amnesia, angioedema, bilirubin increased, diplopia, falls, homicidal ideation, galactorrhea, gynecomastia, hepatic failure, hepatitis, hyperprolactinemia, hypomania, jaundice, liver enzymes increased, mania, peripheral edema, sleep apnea syndrome, Stevens-Johnson syndrome, suicidal ideation, syncope, tinnitus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F132021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to alprazolam or any component of the formulation (cross-sensitivity with other benzodiazepines may exist); narrow-angle glaucoma; concurrent use with ketoconazole or itraconazole",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F132003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anterograde amnesia: Benzodiazepines have been associated with anterograde amnesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Paradoxical reactions: Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines, particularly in adolescent/pediatric or psychiatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use caution in patients with depression, particularly if suicidal risk may be present; episodes of mania or hypomania have occurred in depressed patients treated with alprazolam.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use (generally &gt;10 days).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment or predisposition to urate nephropathy; has weak uricosuric properties.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants/psychoactive medications: Use with caution in patients receiving other CNS depressants or psychoactive medication; effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use with caution in patients taking strong CYP3A4 inhibitors, moderate or strong CYP3A4 inducers and major CYP3A4 substrates (see Drug Interactions); consider alternative agents that avoid or lessen the potential for CYP-mediated interactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: In older adults, benzodiazepines increase the risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents.  Due to increased sensitivity in this age group, avoid use for treatment of insomnia, agitation, or delirium (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obese patients: Use with caution in obese patients; may have prolonged action when discontinued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breakthrough anxiety: At the end of dosing interval, breakthrough anxiety may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Rebound or withdrawal symptoms, including seizures, may occur following abrupt discontinuation or large decreases in dose (more common in patients receiving &gt;4 mg/day or prolonged treatment); the risk of seizures appears to be greatest 24-72 hours following discontinuation of therapy. Use caution when reducing dose or withdrawing therapy; decrease slowly (eg, &le;0.5 mg every 3 days) and monitor for withdrawal symptoms. Flumazenil may cause withdrawal in patients receiving long-term benzodiazepine therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F132079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F132008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Benzodiazepines (metabolized by oxidation). Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of ALPRAZolam. Management: In patients receiving boceprevir, consider lower alprazolam doses and monitor closely for symptoms of toxicity (including prolonged sedation and respiratory depression).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation). Specifically, the active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: May increase the serum concentration of ALPRAZolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of ALPRAZolam. Management: Concurrent use of alprazolam with indinavir is contraindicated.  All patients receiving such a combination should be monitored closely for excessive response to alprazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Lansoprazole; Pantoprazole; RABEprazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; PARoxetine; Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of ALPRAZolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F132035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cigarette: Smoking may decrease alprazolam concentrations up to 50%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase CNS depression. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Alprazolam serum concentration is unlikely to be increased by grapefruit juice because of alprazolam's high oral bioavailability. The C",
"     <sub>",
"      max",
"     </sub>",
"     of the extended release formulation is increased by 25% when a high-fat meal is given 2 hours before dosing. T",
"     <sub>",
"      max",
"     </sub>",
"     is decreased 33% when food is given immediately prior to dose and increased by 33% when food is given &ge;1 hour after dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease alprazolam levels. Valerian, kava kava, and gotu kola may increase CNS depression. Management: Avoid St John's wort. Avoid valerian, kava kava, and gotu kola.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F132009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F132025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Benzodiazepines have the potential to cause harm to the fetus. Alprazolam and its metabolites cross the human placenta. Teratogenic effects have been observed with some benzodiazepines; however, additional studies are needed. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and &ldquo;floppy infant syndrome&rdquo; (which also includes withdrawal symptoms) has been reported with some benzodiazepines.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F132050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F132026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In a study of eight postpartum women, peak concentrations of alprazolam were found in breast milk ~1 hour after the maternal dose and the half-life was ~14 hours. Samples were obtained over 36 hours following a single oral dose of alprazolam 0.5 mg. Metabolites were not detected in breast milk. In this study, the estimated exposure to the breast-feeding infant was ~3% of the weight-adjusted maternal dose. Drowsiness, lethargy, or weight loss in nursing infants have been observed in case reports following maternal use of some benzodiazepines.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9405830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Extended release tablet should be taken once daily in the morning.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F132024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (ALPRAZolam Intensol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (30 mL): $81.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (ALPRAZolam ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (60): $128.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (60): $160.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (60): $212.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (60): $319.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Xanax XR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (60): $240.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (60): $299.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (60): $396.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (60): $595.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (ALPRAZolam Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg (100): $151.73",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (100): $189.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $252.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $428.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (Niravam Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg (100): $406.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $675.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $1148.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (ALPRAZolam Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg (100): $69.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (100): $91.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $115.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $196.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Xanax Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg (100): $197.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (100): $245.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $327.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $556.93",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F132011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory and cardiovascular status",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F132027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aceprax (PY, UY);",
"     </li>",
"     <li>",
"      Actazolam (ID);",
"     </li>",
"     <li>",
"      Alcelam (TH);",
"     </li>",
"     <li>",
"      Alnax (TH);",
"     </li>",
"     <li>",
"      Alpaz (PE);",
"     </li>",
"     <li>",
"      Alplax (AR);",
"     </li>",
"     <li>",
"      Alpralid (IL);",
"     </li>",
"     <li>",
"      Alpraline (MY);",
"     </li>",
"     <li>",
"      Alpranax (KP, MY);",
"     </li>",
"     <li>",
"      Alprax (AU, HK, IN, TH);",
"     </li>",
"     <li>",
"      Alpraz (LU);",
"     </li>",
"     <li>",
"      Alprocontin (IN);",
"     </li>",
"     <li>",
"      Alprox (HU, IL);",
"     </li>",
"     <li>",
"      Altrox (PH);",
"     </li>",
"     <li>",
"      Alviz (ID);",
"     </li>",
"     <li>",
"      Alzam (MX, ZA);",
"     </li>",
"     <li>",
"      Alzax (KP);",
"     </li>",
"     <li>",
"      Alzolam (IN, SG);",
"     </li>",
"     <li>",
"      Anpress (TH);",
"     </li>",
"     <li>",
"      Ansiolit (EC);",
"     </li>",
"     <li>",
"      Apo-Alpraz (SG);",
"     </li>",
"     <li>",
"      Apraz (BR);",
"     </li>",
"     <li>",
"      Aprazo (TW);",
"     </li>",
"     <li>",
"      Asolan (MY);",
"     </li>",
"     <li>",
"      Axal (PH);",
"     </li>",
"     <li>",
"      Azor (ZA);",
"     </li>",
"     <li>",
"      Cassadan (DE);",
"     </li>",
"     <li>",
"      Constan (JP);",
"     </li>",
"     <li>",
"      Dixin (CO);",
"     </li>",
"     <li>",
"      Farmapram (MX);",
"     </li>",
"     <li>",
"      Feprax (ID);",
"     </li>",
"     <li>",
"      Frontal (BR);",
"     </li>",
"     <li>",
"      Frontin (HU);",
"     </li>",
"     <li>",
"      Helex (HR);",
"     </li>",
"     <li>",
"      Irizz. (MX);",
"     </li>",
"     <li>",
"      Kalma (AU);",
"     </li>",
"     <li>",
"      Kinax (TW);",
"     </li>",
"     <li>",
"      Marzolam (TH);",
"     </li>",
"     <li>",
"      Neupax (MX);",
"     </li>",
"     <li>",
"      Pacyl (IN);",
"     </li>",
"     <li>",
"      Pharnax (TH);",
"     </li>",
"     <li>",
"      Prazol (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Prazovex (MY);",
"     </li>",
"     <li>",
"      Prinox (AR);",
"     </li>",
"     <li>",
"      Solanax (JP);",
"     </li>",
"     <li>",
"      Soxietas (ID);",
"     </li>",
"     <li>",
"      Tafil (DE, DK, MX, VE);",
"     </li>",
"     <li>",
"      Tafil D (MU);",
"     </li>",
"     <li>",
"      Tazun (MX);",
"     </li>",
"     <li>",
"      Trankimazin Retard (ES);",
"     </li>",
"     <li>",
"      Tranquinal (BR, CR, DO, EC, GT, HN, NI, PA, PY, SV, UY);",
"     </li>",
"     <li>",
"      Tricalma (CN);",
"     </li>",
"     <li>",
"      Valeans (IT);",
"     </li>",
"     <li>",
"      Xanacine (TH);",
"     </li>",
"     <li>",
"      Xanagis (IL);",
"     </li>",
"     <li>",
"      Xanax (AE, AR, AU, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CO, CY, CZ, DE, EC, EE, EG, ET, FR, GB, GH, GM, GN, GR, GY, HK, HR, HU, IE, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, NZ, OM, PE, PK, PL, PT, QA, RU, SA, SC, SD, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Xanax SR (BG, SG);",
"     </li>",
"     <li>",
"      Xanax XR (IL, TH, TW);",
"     </li>",
"     <li>",
"      Xanor (AT, FI, NO, PH, SE, ZA);",
"     </li>",
"     <li>",
"      Xanor XR (PH);",
"     </li>",
"     <li>",
"      Zacetin (KP);",
"     </li>",
"     <li>",
"      Zanapam (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Zolam (IN);",
"     </li>",
"     <li>",
"      Zolarem (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Zolastin (ID);",
"     </li>",
"     <li>",
"      Zoldac (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Zopax (ZA);",
"     </li>",
"     <li>",
"      Zotran (CN);",
"     </li>",
"     <li>",
"      Zypraz (ID);",
"     </li>",
"     <li>",
"      Zyren (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F132002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the central nervous system, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F132020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Immediate release and extended release formulations: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Immediate release: 5.1 &plusmn; 1.7 hours; Extended release: 11.3 &plusmn; 4.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Extended release: Slower relative to immediate release formulation resulting in a concentration that is maintained 5-11 hours after dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.9-1.2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 80%; primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4; forms two active metabolites (4-hydroxyalprazolam and &alpha;-hydroxyalprazolam)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 11.2 hours (Immediate release range: 6.3-26.9 hours; Extended release range: 10.7-15.8 hours); Orally-disintegrating tablet range: 7.9-19.2 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elderly: 16.3 hours (range: 9-26.9 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alcoholic liver disease: 19.7 hours (range: 5.8-65.3 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Obesity: 21.8 hours (range: 9.9-40.4 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Race: Asians: Increased by ~25% (as compared to Caucasians)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: ~9 hours (Glue, 2006); decreased by 1 hour when administered at bedtime (as compared to morning administration); decreased by 33% when administered with a high-fat meal; increased by 33% when administered &ge;1 hour after a high-fat meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orally-disintegrating tablet: 1.5-2 hours; occurs ~15 minutes earlier when administered with water; decreased by 2 hours when administered with a high-fat meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as unchanged drug and metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/31/31224/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/31/31224/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bergman U, Rosa FW, Baum C, et al, \"Effects of Exposure to Benzodiazepine During Fetal Life,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 1992, 340(8821):694-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/31/31224/abstract-text/1355799/pubmed\" id=\"1355799\" target=\"_blank\">",
"        1355799",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bernstein GA, Garfinkel BD, and Borchardt CM, &ldquo;Comparative Studies of Pharmacotherapy for School Refusal,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1990, 29(5):773-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/31/31224/abstract-text/2228932/pubmed\" id=\"2228932\" target=\"_blank\">",
"        2228932",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      De Witte JL, Alegret C, Sessler DI, et al, &ldquo;Preoperative Alprazolam Reduces Anxiety in Ambulatory Surgery Patients: A Comparison With Oral Midazolam,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2002, 95(6):1601-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/31/31224/abstract-text/12456424/pubmed\" id=\"12456424\" target=\"_blank\">",
"        12456424",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glue P, Fang A, Gandelman K, et al, &ldquo;Pharmacokinetics of an Extended Release Formulation of Alprazolam (Xanax XR) in Healthy Normal Adolescent and Adult Volunteers,&rdquo;",
"      <i>",
"       Am J Ther",
"      </i>",
"      , 2006, 13(5):418-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/31/31224/abstract-text/16988537/pubmed\" id=\"16988537\" target=\"_blank\">",
"        16988537",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Iqbal MM, Sobhan T, Ryals T, et al, \"Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant,\"",
"      <i>",
"       Psychiatr Serv",
"      </i>",
"      , 2002, 53(1):39-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/31/31224/abstract-text/11773648/pubmed\" id=\"11773648\" target=\"_blank\">",
"        11773648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/31/31224/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moulin CH, Rolachon A, Cohard M, et al, &ldquo;Fulminant Hepatitis Secondary to Alprazolam,&rdquo;",
"      <i>",
"       Therapie",
"      </i>",
"      , 1994, 49(4):362-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/31/31224/abstract-text/7878609/pubmed\" id=\"7878609\" target=\"_blank\">",
"        7878609",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mumford GK, Evans SM, Fleishaker JC, et al, &ldquo;Alprazolam Absorption Kinetics Affects Abuse Liability,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57(3):356-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/31/31224/abstract-text/7697954/pubmed\" id=\"7697954\" target=\"_blank\">",
"        7697954",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Noyes R Jr, DuPont RL Jr, Pecknold JC, et al, &ldquo;Alprazolam in Panic Disorder and Agoraphobia: Results From a Multicenter Trial. II. Patient Acceptance, Side Effects, and Safety,&rdquo;",
"      <i>",
"       Arch Gen Psychiatry",
"      </i>",
"      , 1988, 45(5):423-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/31/31224/abstract-text/3358644/pubmed\" id=\"3358644\" target=\"_blank\">",
"        3358644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oo CY, Kuhn RJ, Desai N, et al, \"Pharmacokinetics in Lactating Women: Prediction of Alprazolam Transfer Into Milk,\"",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1995, 40(3):231-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/31/31224/abstract-text/8527284/pubmed\" id=\"8527284\" target=\"_blank\">",
"        8527284",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfefferbaum B, Overall JE, Boren HA, et al, &ldquo;Alprazolam in the Treatment of Anticipatory and Acute Situational Anxiety in Children With Cancer,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1987, 26(4):532-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/31/31224/abstract-text/3654506/pubmed\" id=\"3654506\" target=\"_blank\">",
"        3654506",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rickels K, &ldquo;Alprazolam Extended-Release in Panic Disorder,&rdquo;",
"      <i>",
"       Expert Opin Pharmacother",
"      </i>",
"      , 2004, 5(7):1599-611.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/31/31224/abstract-text/15212610/pubmed\" id=\"15212610\" target=\"_blank\">",
"        15212610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scavone JM, Greenblatt DJ, Goddard JE, et al, &ldquo;The Pharmacokinetics and Pharmacodynamics of Sublingual and Oral Alprazolam in the Post-Prandial State,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1992, 42(4):439-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/31/31224/abstract-text/1516609/pubmed\" id=\"1516609\" target=\"_blank\">",
"        1516609",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scavone JM, Greenblatt DJ, and Shader RI, &ldquo;Alprazolam Kinetics Following Sublingual and Oral Administration,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 1987, 7(5):332-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/31/31224/abstract-text/3680603/pubmed\" id=\"3680603\" target=\"_blank\">",
"        3680603",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sheehan DV, Sheehan KH, and Raj BA, &ldquo;The Speed of Onset of Action of Alprazolam-XR Compared to Alprazolam-CT in Panic Disorder,&rdquo;",
"      <i>",
"       Psychopharmacol Bull",
"      </i>",
"      , 2007, 40(2):63-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/31/31224/abstract-text/17514187/pubmed\" id=\"17514187\" target=\"_blank\">",
"        17514187",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simeon JG and Ferguson HB, &ldquo;Alprazolam Effects in Children With Anxiety Disorders,&rdquo;",
"      <i>",
"       Can J Psychiatry",
"      </i>",
"      , 1987, 32(7):570-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/31/31224/abstract-text/3315169/pubmed\" id=\"3315169\" target=\"_blank\">",
"        3315169",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simeon JG, Ferguson HB, Knott V, et al, &ldquo;Clinical, Cognitive, and Neurophysiological Effects of Alprazolam in Children and Adolescents With Overanxious and Avoidant Disorders,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1992, 31(1):29-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/31/31224/abstract-text/1537778/pubmed\" id=\"1537778\" target=\"_blank\">",
"        1537778",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wikner BN, Stiller CO, Bergman U, et al, \"Use of Benzodiazepines and Benzodiazepine Receptor Agonists During Pregnancy: Neonatal Outcome and Congenital Malformations,\"",
"      <i>",
"       Pharmacoepidemiol Drug Saf",
"      </i>",
"      , 2007, 16(11):1203-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/31/31224/abstract-text/17894421/pubmed\" id=\"17894421\" target=\"_blank\">",
"        17894421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8453 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-122.72.80.101-1C61674EA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_31_31224=[""].join("\n");
var outline_f30_31_31224=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132040\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132041\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132085\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132045\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132062\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132046\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2606647\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132047\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132014\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131999\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132087\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132018\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132017\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132081\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132095\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132083\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132021\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132003\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132079\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132008\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132035\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132009\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132025\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132050\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132026\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9405830\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132024\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132011\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132027\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132002\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132020\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8453\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8453|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/29/7637?source=related_link\">",
"      Alprazolam: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/35/7735?source=related_link\">",
"      Alprazolam: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_31_31225="Establishing the cause of Cushing's syndrome";
var content_f30_31_31225=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Establishing the cause of Cushing's syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/31/31225/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/31/31225/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/31/31225/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/31/31225/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/31/31225/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/31/31225/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/31/31225/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the diagnosis of hypercortisolism is established, its cause must be determined (",
"    <a class=\"graphic graphic_table graphicRef50582 \" href=\"UTD.htm?6/1/6172\">",
"     table 1",
"    </a>",
"    ). The tests listed in the figure do not differentiate Cushing's syndrome from non-Cushing's syndrome because the response of normal corticotropes is most often similar to that of corticotrope adenomas. Thus, testing for the cause of Cushing's syndrome should be performed only if the normal corticotrope responses are suppressed by ongoing hypercortisolism (",
"    <a class=\"graphic graphic_algorithm graphicRef79853 \" href=\"UTD.htm?0/24/384\">",
"     algorithm 1",
"    </a>",
"    ). This precaution will avoid erroneous diagnosis of Cushing's disease in a normal individual or a patient with another cause of Cushing's syndrome.",
"   </p>",
"   <p>",
"    Both laboratory and patient errors can cause misleading results. One way to minimize these errors is to make certain that the results of different tests are internally consistent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16435?source=see_link\">",
"     \"Basic principles in the laboratory evaluation of adrenocortical function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to establishing the cause of Cushing's syndrome will be reviewed here. The causes, pathophysiology, and diagnosis of Cushing's syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26489?source=see_link\">",
"     \"Causes and pathophysiology of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=see_link\">",
"     \"Establishing the diagnosis of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Primary adrenal disease versus ACTH-secreting tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the evaluation is to determine whether the hypercortisolism is ACTH-dependent (ie, due to a pituitary or nonpituitary ACTH-secreting tumor), or ACTH-independent (ie, due to an adrenal source) by measuring plasma ACTH (",
"    <a class=\"graphic graphic_algorithm graphicRef79853 \" href=\"UTD.htm?0/24/384\">",
"     algorithm 1",
"    </a>",
"    ). This test is now best performed using a two-site immunoradiometric assay (IRMA) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40246?source=see_link\">",
"     \"Measurement of ACTH, CRH, and other hypothalamic and pituitary peptides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Plasma ACTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma ACTH concentrations are normally between 20 and 80",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (4.5 and 18",
"    <span class=\"nowrap\">",
"     pmol/L)",
"    </span>",
"    at 8 AM. The values fall during the waking hours and are usually less than 20",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (4.5",
"    <span class=\"nowrap\">",
"     pmol/L)",
"    </span>",
"    at 4 PM and less than 10",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (2.2",
"    <span class=\"nowrap\">",
"     pmol/L),",
"    </span>",
"    usually less than 5",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (1.1",
"    <span class=\"nowrap\">",
"     pmol/L),",
"    </span>",
"    within one hour after the usual time of falling sleep.",
"   </p>",
"   <p>",
"    In theory, plasma ACTH should be measured between about 11 PM and midnight or at bedtime, when its concentration is normally nearing or at the nadir [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In practice, however, measurements at any time of the day are satisfactory in patients in whom hypercortisolism has been established, because they lack a normal circadian rhythm.",
"   </p>",
"   <p>",
"    ACTH secretion is episodic in patients with Cushing's syndrome of any cause [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/4\">",
"     4",
"    </a>",
"    ]. Because of this, measurement on at least two separate days is recommended. One can abbreviate the diagnostic evaluation by obtaining blood for ACTH measurement on the same days that a late-night cortisol or 24-hour urine specimen is collected if the patient is strongly suspected of having Cushing's syndrome. If the diagnosis of Cushing's syndrome is confirmed, the specimens can be sent for ACTH assay to determine if the hypercortisolism is ACTH-dependent or -independent.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A low plasma ACTH concentration [&lt;5",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      (1.1",
"      <span class=\"nowrap\">",
"       pmol/L)]",
"      </span>",
"      in a hypercortisolemic patient is evidence of ACTH-independent disease [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/5\">",
"       5",
"      </a>",
"      ]; thin-section CT imaging of the adrenal glands is usually the next diagnostic procedure in these patients. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Imaging for primary adrenal disease'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      One can assume that cortisol secretion is ACTH-dependent (ie, due to pituitary disease or ectopic ACTH or CRH secretion) if the plasma ACTH concentration is above 20",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      (4.4",
"      <span class=\"nowrap\">",
"       pmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Plasma ACTH values between 5 and 20",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      (1.1 to 4.4",
"      <span class=\"nowrap\">",
"       pmol/L)",
"      </span>",
"      are less definitive, but usually indicate that cortisol secretion is ACTH-dependent. For these patients, a CRH stimulation test may be helpful (see",
"      <a class=\"local\" href=\"#H10\">",
"       'CRH stimulation test'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      There is a positive correlation between basal plasma ACTH values and the size of the pituitary adenoma in patients with Cushing's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/6\">",
"       6",
"      </a>",
"      ]. As an example, in one series of 18 ACTH-secreting macroadenomas and 183 microadenomas, mean baseline serum ACTH concentrations were 135.8 &plusmn; 32.5",
"      <span class=\"nowrap\">",
"       ng/L",
"      </span>",
"      (29.9 &plusmn; 7.2",
"      <span class=\"nowrap\">",
"       pmol/L)",
"      </span>",
"      and 45.0 &plusmn; 4.3",
"      <span class=\"nowrap\">",
"       ng/L",
"      </span>",
"      (9.9 &plusmn; 0.95",
"      <span class=\"nowrap\">",
"       pmol/L),",
"      </span>",
"      respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ACTH-INDEPENDENT CUSHING'S SYNDROME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Imaging for primary adrenal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient has ACTH-independent Cushing's syndrome, thin-section CT imaging of the adrenal glands is usually the next procedure, looking for an adrenal mass (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70712 graphicRef53633 \" href=\"UTD.htm?14/41/14997\">",
"     image 1A-B",
"    </a>",
"    ); on the other hand, bilateral hyperplasia may be seen with ACTH-dependent disease as well as ACTH-independent bilateral macronodular adrenal hyperplasia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76679 graphicRef75144 \" href=\"UTD.htm?23/18/23846\">",
"     image 2A-B",
"    </a>",
"    ). Magnetic resonance imaging (MRI) should not be recommended as the initial procedure because it is more costly.",
"   </p>",
"   <p>",
"    Typically, adrenal adenomas are smaller than carcinomas and have a lower unenhanced CT attenuation value [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/8\">",
"     8",
"    </a>",
"    ]. The presence of necrosis, hemorrhage, and calcification favors a diagnosis of carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12826?source=see_link\">",
"     \"Clinical presentation and evaluation of adrenocortical tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=see_link\">",
"     \"The adrenal incidentaloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the unenhanced CT attenuation values are &gt;10 Hounsfield units, MRI may provide additional information about the benign or malignant nature of the adrenal tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/9\">",
"     9",
"    </a>",
"    ]. Blood levels of adrenal androgens also may be elevated in patients with adrenal carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12826?source=see_link\">",
"     \"Clinical presentation and evaluation of adrenocortical tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PET scanning with fluorodeoxyglucose can be useful in identifying adrenal carcinoma in unilateral adrenal tumors with a higher index of suspicion for malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12826?source=see_link\">",
"     \"Clinical presentation and evaluation of adrenocortical tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Additional evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If imaging suggests a unilateral adrenal adenoma, no further testing is needed. However, if bilateral disease or a possible carcinoma is seen, additional testing may be indicated to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage the possible adrenal cancer (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12826?source=see_link\">",
"       \"Clinical presentation and evaluation of adrenocortical tumors\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Distinguish whether bilateral masses are both functional or whether one is a non-functioning incidentaloma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=see_link\">",
"       \"The adrenal incidentaloma\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Identify forms of bilateral macronodular adrenal hyperplasia that may be amenable to medical treatment (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/45/730?source=see_link\">",
"       \"Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Determine whether patients with possible primary pigmented nodular adrenal disease have components of the Carney Complex (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22072?source=see_link\">",
"       \"Cushing's syndrome due to primary pigmented nodular adrenocortical disease\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ACTH-DEPENDENT CUSHING'S SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with ACTH-dependent Cushing's syndrome, the final stage of the diagnostic evaluation is to determine the source of ACTH secretion (",
"    <a class=\"graphic graphic_algorithm graphicRef79853 \" href=\"UTD.htm?0/24/384\">",
"     algorithm 1",
"    </a>",
"    ). The great majority of these patients have a pituitary corticotroph adenoma (Cushing's disease) (",
"    <a class=\"graphic graphic_table graphicRef50582 \" href=\"UTD.htm?6/1/6172\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75003 \" href=\"UTD.htm?37/55/38772\">",
"     image 3",
"    </a>",
"    ) rather than ectopic ACTH secretion, bearing in mind that ectopic CRH secretion may very rarely cause Cushing's syndrome.",
"   </p>",
"   <p>",
"    In patients with the classic form of ectopic ACTH syndrome, the degree of ACTH hypersecretion and excretion of urinary cortisol is typically greater, and hypokalemia is more common than in those with Cushing's disease. However, because of overlap, especially with occult tumors, other tests should be performed to confirm the diagnosis. Ectopic ACTH-secreting tumors typically do not process POMC efficiently. Because of this and their higher ACTH production they have a higher plasma ratio of ACTH precursors (POMC and proACTH) to ACTH compared to Cushing's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/10\">",
"     10",
"    </a>",
"    ]. Although not clinically available at present, such a test may be useful in the future.",
"   </p>",
"   <p>",
"    Patients with ACTH-dependent disease should undergo non-invasive tests (a high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppression test and CRH stimulation test). Suppression of cortisol during dexamethasone administration coupled with increases in plasma ACTH and serum cortisol after CRH administration are consistent with the diagnosis of a pituitary adenoma (Cushing's disease).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     High-dose dexamethasone suppression tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    tests take advantage of the fact that ACTH secretion by the pituitary adenomas that cause Cushing's disease is only relatively resistant to negative feedback regulation by glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/11\">",
"     11",
"    </a>",
"    ]. In contrast, most nonpituitary tumors associated with the ectopic ACTH syndrome are completely resistant to feedback inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/12\">",
"     12",
"    </a>",
"    ], with the exception of some carcinoid tumors, usually bronchial carcinoids [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26489?source=see_link\">",
"     \"Causes and pathophysiology of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many endocrinologists use the overnight high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppression test (8 mg dexamethasone given orally at 11 PM to midnight) with serum cortisol end points, because it is shorter than the standard two-day test and avoids urine collection [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/11,15\">",
"     11,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    administration, a single blood sample is drawn at 8 AM the next day for measurement of serum cortisol and, if one wishes, plasma ACTH and serum dexamethasone. With this protocol, the 8 AM serum cortisol concentration is less than 5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (140",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    in most patients with Cushing's disease (ie, a pituitary tumor), and is usually undetectable in normals.",
"   </p>",
"   <p>",
"    An alternative test strategy involves calculation of the suppression of morning serum cortisol concentration on the day before and after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    administration, and considering a 50 (or 69) percent or more suppression to indicate Cushing's disease&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37528?source=see_link&amp;anchor=H10#H10\">",
"     \"Dexamethasone suppression tests\", section on 'Overnight 8 mg test'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    None of the high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    tests correctly categorizes every patient with ACTH-dependent Cushing's syndrome. Therefore, it is prudent to perform at least one test in addition to the dexamethasone suppression test, even in patients who meet current criteria for suppression, as the specificity of this test is less than 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=see_link\">",
"     \"Establishing the diagnosis of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37528?source=see_link\">",
"     \"Dexamethasone suppression tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other approaches omit the high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    test for patients with ACTH-dependent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. Instead, these patients have the combination of a CRH stimulation test and pituitary MRI imaging,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inferior petrosal venous sinus sampling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     CRH stimulation test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with Cushing's disease respond with ACTH and cortisol increases within 45 minutes after the intravenous administration of corticotropin-releasing hormone (CRH, Acthrel&reg;) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/20-26\">",
"     20-26",
"    </a>",
"    ]. Patients with adrenal tumors with increased urinary free cortisol and most with ectopic ACTH-secreting tumors do not respond because pituitary ACTH secretion is suppressed. Patients with adrenal tumors would be identified by plasma ACTH measurement and usually would not receive CRH. Thus, a response to CRH should differentiate Cushing's disease from all other causes of Cushing's syndrome (",
"    <a class=\"graphic graphic_algorithm graphicRef79853 \" href=\"UTD.htm?0/24/384\">",
"     algorithm 1",
"    </a>",
"    ). However, the criteria for interpretation have varied at different centers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26311?source=see_link\">",
"     \"Corticotropin-releasing hormone stimulation test\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The CRH test may be used in combination with a separate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppression test. If both indicate Cushing's disease, few patients with ectopic ACTH secretion are falsely diagnosed, but a number with Cushing's disease are missed. Any other combination of results does not discriminate between the forms of ACTH-dependent Cushing's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/21,27\">",
"     21,27",
"    </a>",
"    ]. As a result, many patients require inferior petrosal sinus sampling, and some have advocated for initial use of this procedure in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26311?source=see_link\">",
"     \"Corticotropin-releasing hormone stimulation test\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H12\">",
"     'Petrosal venous sinus catheterization'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Vasopressin stimulation test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasopressin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    (dDAVP) also stimulates ACTH release in most patients with Cushing's disease and usually induces a response similar to that of CRH; when given with CRH it can improve sensitivity in Cushing's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/29\">",
"     29",
"    </a>",
"    ]. Optimal criteria for its interpretation have not been defined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36312?source=see_link\">",
"     \"Vasopressin and desmopressin stimulation test\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26311?source=see_link\">",
"     \"Corticotropin-releasing hormone stimulation test\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Petrosal venous sinus catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most direct way to demonstrate pituitary ACTH hypersecretion is to document a central-to-peripheral ACTH gradient in the blood draining the tumor. The petrosal venous sinus drains the pituitary via the cavernous sinus [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To perform this procedure, catheters are inserted via the jugular or femoral veins into both inferior petrosal veins. It is important that each catheter be in the proper location, not in the jugular bulb or vein, because of the large dilution factor produced by blood returning from other areas of the cranium.",
"   </p>",
"   <p>",
"    ACTH is measured in petrosal and peripheral venous plasma before and within 10 minutes after administration of CRH. CRH is given to overcome the pulsatility of ACTH secretion in some patients with Cushing's disease (",
"    <a class=\"graphic graphic_figure graphicRef60086 \" href=\"UTD.htm?2/18/2336\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Both inferior petrosal sinuses can be catheterized successfully in up to 90 percent of patients, but only when attempted by clinicians who perform the procedure often [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/33\">",
"     33",
"    </a>",
"    ]. Cavernous-inferior petrosal sinus venography should be performed at the end of the procedure to document adequate catheter placement and normal venous anatomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A central-to-peripheral plasma ACTH gradient of &ge;2.0 before CRH administration, or &ge;3.0 after CRH, is diagnostic of a pituitary source of ACTH; the gradient is usually much greater, especially after CRH injection [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/34\">",
"     34",
"    </a>",
"    ]. In 14 studies, 759 of a total of 800 patients with proven Cushing's disease were correctly identified (95 percent sensitivity), while 115 of 124 with presumed or proven ectopic ACTH secretion were correctly identified (93 percent specificity) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/5,33-44\">",
"     5,33-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     False negatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;False negative results likely result from poor catheter placement or anomalous or asymmetric venous drainage. A false-negative result was found in 0.8 percent in one series of 501 patients, but in 11 percent of another series of 78 patients with Cushing's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/36,45\">",
"     36,45",
"    </a>",
"    ]. Thus, lack of a central gradient on inferior petrosal sinus sampling is useful only if cavernous-inferior petrosal sinus venography demonstrates normal and symmetrical venous drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study evaluated the utility of prolactin measurement of inferior petrosal sinus samples as a way to evaluate the adequacy of sampling. Petrosal-to-peripheral ratios for ACTH were normalized to petrosal sinus-to-peripheral ratios for prolactin in 33 patients with Cushing's disease and five with ectopic ACTH secretion. Three patients without a central ACTH gradient had ACTH:prolactin ratios within the range of patients with Cushing's disease, and were cured after pituitary surgery. Thus, prolactin measurements may help to validate IPSS results [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/49\">",
"     49",
"    </a>",
"    ]. Another three studies endorse the approach [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. However, while this is a promising approach, the specific criteria for interpretation vary between centers.",
"   </p>",
"   <p>",
"    Transsphenoidal exploration has been proposed for patients without a diagnostic gradient. This strategy is most likely to succeed if no ectopic source has been identified after body imaging, and if peripheral ACTH levels during petrosal sampling increased significantly with CRH stimulation and the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppression test supports a pituitary etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     False positives",
"    </span>",
"    &nbsp;&mdash;&nbsp;False positive results occur rarely in patients with ectopic ACTH syndrome or an adrenal tumor. Presumably pituitary ACTH secretion is incompletely suppressed in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/28,53\">",
"     28,53",
"    </a>",
"    ]. Because of this concern, we recommend documentation of a twofold or greater increase in UFC for six to eight weeks before inferior petrosal sinus sampling to ensure that the normal corticotropes are suppressed.",
"   </p>",
"   <p>",
"    CRH is not commercially available in certain countries or is more expensive than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    . Desmopressin has thus been used in place of CRH to perform petrosal sinus sampling in small series [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/36,46\">",
"     36,46",
"    </a>",
"    ]. In a larger retrospective series of 56 patients with ACTH-dependent Cushing's syndrome, desmopressin alone was found to amplify the central to peripheral ACTH gradient and to provide sensitivity and specificities similar to reported series using CRH [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36312?source=see_link\">",
"     \"Vasopressin and desmopressin stimulation test\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Tumor localization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have shown that a gradient of &ge;1.4 between the ACTH concentrations in the two sinuses predicted the side of the tumor with up to 71 percent accuracy if catheters were appropriately placed [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/34\">",
"     34",
"    </a>",
"    ]. However, others have not found such strong predictive values [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/40,47\">",
"     40,47",
"    </a>",
"    ]. Since there is a 50 percent chance of correctly predicting the location without the aid of any anatomical data, this expensive procedure cannot be justified for localization alone.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of serious complications, such as a cerebrovascular accident, is 0.2 percent when the procedure is performed by an experienced radiologist [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/54\">",
"     54",
"    </a>",
"    ]. In one series of 166 patients, transient cranial nerve palsy occurred in one patient [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/37\">",
"     37",
"    </a>",
"    ]. In another series of 44 patients, one developed hemiparesis and gaze palsy after the study [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulmonary embolism and deep venous thrombosis have been reported, but their frequency in large series is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. In view of the risk of thromboembolic events, some groups give",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    for anticoagulation before the procedure and protamine afterward to avoid the possibility of inferior petrosal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cavernous sinus venous thrombosis, but most do not believe that this is necessary.",
"   </p>",
"   <p>",
"    The frequency of less serious complications, such as inguinal or jugular hematomas is less common.",
"   </p>",
"   <p>",
"    Some investigators recommend that all patients with ACTH-dependent Cushing's syndrome undergo bilateral catheterization of the inferior petrosal venous sinuses [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/46-48,58,59\">",
"     46-48,58,59",
"    </a>",
"    ]. While petrosal sinus sampling has the best overall diagnostic accuracy, it is more expensive, less safe and less available than non-invasive tests.",
"   </p>",
"   <p>",
"    In our opinion, the risk of venous sampling is rarely justified in a patient with a clear-cut pituitary tumor larger than 6 mm on MRI if the patient has responses to CRH and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    that support the diagnosis of Cushing's disease.",
"   </p>",
"   <p>",
"    In patients with a normal pituitary MRI, it is reasonable to use non-invasive tests first. Hypercortisolemic patients with positive responses to both CRH and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    are nearly certain to have Cushing's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/21,27\">",
"     21,27",
"    </a>",
"    ]. Patients with one or more negative responses are still statistically more likely to have Cushing's disease than ectopic ACTH secretion, making petrosal sinus sampling a reasonable alternative to imaging for a non-pituitary tumor. However, there has been no formal study of which algorithm is best. In the absence of such studies, the choice of diagnostic tests will be influenced not only by their availability and cost, but also by other features such as extremely elevated UFC and plasma ACTH concentrations, hypokalemia and rapid onset of hypercortisolism, all of which favor the diagnosis of ectopic ACTH secretion.",
"   </p>",
"   <p>",
"    Other candidates for petrosal sampling are patients with non-invasive studies diagnostic of Cushing's disease who have undergone subtotal or total hypophysectomy without clinical improvement or any effect on ACTH secretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Other venous sampling tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral internal jugular venous sampling has been proposed as a useful alternative test, with the advantages of simplicity, safety, and no requirement for specialized expertise. However, the sensitivity of this test (83 to 87.5 percent) is relatively close to the pre-test probability of Cushing's disease and is inferior to petrosal sinus sampling [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/42-45,60\">",
"     42-45,60",
"    </a>",
"    ]. Its utility may be restricted to those patients who would benefit from venous sampling, such as those with conflicting results on non-invasive tests, but who do not have access to petrosal sinus sampling.",
"   </p>",
"   <p>",
"    The limited ability of petrosal sinus sampling to identify the site of corticotroph adenomas led to evaluation of cavernous sinus sampling for this purpose. In two large series, the sensitivity and specificity of a cavernous sinus-to-peripheral venous plasma ACTH gradient were similar to those of petrosal sinus sampling. Localization of the adenoma, based on a lateralization ratio of &ge;1.4, was correct in 62 to 83 percent in whom tumors were found at surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. However, hemihypophysectomy was curative in only about 50 percent of patients when it was based on the location of tumor predicted by cavernous sinus sampling [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/62\">",
"     62",
"    </a>",
"    ]. Thus, this technically more demanding procedure does not appear to have superior diagnostic accuracy or lateralization ability compared to petrosal sinus sampling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Cushing's syndrome and its cause lie entirely in the domain of the endocrine laboratory. Imaging procedures provide no information about function and are useful only for tumor localization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Pituitary MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unenhanced and gadolinium-enhanced high-resolution MR images of the sella turcica should be obtained before petrosal sinus sampling to exclude a tumor more than 6 mm in size, which might obviate the need for venous sampling. The procedure also is indicated before transsphenoidal exploration to document the anatomy of the sella turcica.",
"   </p>",
"   <p>",
"    MRI is more sensitive than CT in detecting corticotroph adenomas, but still detects only about 50 percent of these tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/63\">",
"     63",
"    </a>",
"    ]. Dynamic MRI (ie, obtaining images very rapidly after gadolinium administration) or spoiled gradient recalled acquisition MRI techniques may provide slightly greater sensitivity than conventional MRI, but yield more false-positive scans [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pituitary imaging is not necessary in patients in whom endocrine testing suggests ectopic ACTH secretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Ectopic ACTH-secreting tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal strategy for detecting these tumors has not been defined. The available modalities (CT, MRI, PET and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    scintigraphy) are complementary. CT or MRI of the lungs or abdomen is unnecessary in patients who have a positive inferior petrosal sinus sampling test [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT and MRI scans can identify and localize anatomically some tumors. In one prospective study the sensitivity of CT was higher (53 percent) than that of MRI (37 percent) although confidence intervals overlapped [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/67\">",
"     67",
"    </a>",
"    ]. It is cost-effective to obtain images of the chest first, since most ACTH-secreting tumors are located there.",
"   </p>",
"   <p>",
"    Small bronchial carcinoids can be confused with pulmonary vasculature on CT or MR images [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/68\">",
"     68",
"    </a>",
"    ]. Small thymic masses are seen on MRI in about one-third of patients with Cushing's disease; these are usually not thymic carcinoids, but represent residual normal thymic tissue, particularly in patients under the age of 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/69\">",
"     69",
"    </a>",
"    ]. Abdominal imaging rarely detects occult ectopic ACTH-secreting tumors, but may reveal hepatic metastases.",
"   </p>",
"   <p>",
"    Some ectopic ACTH-secreting tumors can be detected by scintigraphy with 111-In-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    or an analog of octreotide ([111-In-diethylene triamine pentaacetic acid-D-Phe-1]-octreotide, or pentetreotide) because, like other neuroendocrine tumors, their cells have cell-surface receptors for somatostatin (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70712 graphicRef53633 \" href=\"UTD.htm?14/41/14997\">",
"     image 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/70-72\">",
"     70-72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    111-In-pentetreotide scintigraphy is not specific for ACTH-secreting tumors; pentetreotide is also taken up by non-neuroendocrine tumors such as breast carcinomas, brain tumors, and malignant lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/73\">",
"     73",
"    </a>",
"    ], and by active autoimmune inflammatory and active and chronic granulomatous lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sensitivity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    scintigraphy for detecting occult tumors that secrete ACTH ranges from 30 to 53 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/67,75-77\">",
"     67,75-77",
"    </a>",
"    ]. Failure to detect these tumors may be related to their small size or inadequate expression of somatostatin receptors. In three studies, 6 of 30 patients had false-positive results (radiation fibrosis, inflammation, follicular thyroid adenoma, accessory spleen). In a few patients, however, scintigraphy but not CT or MR identified the tumor and, in five patients, negative scintigraphy correctly refuted false-positive CT or MRI scans [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/75-77\">",
"     75-77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the high false positive rate, the presence of the tumor ideally should be confirmed by CT or MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. The role of repeat scintigraphy after a negative scan is not known.",
"   </p>",
"   <p>",
"    In one study (18)F-fluorodeoxyglucose positron emission tomography did not identify any tumor not shown by CT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MRI, and thus is not recommended for routine use [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     OTHER DIAGNOSTIC TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    stimulation test was recommended in the past. The test is rarely used now because it does not discriminate well between Cushing's disease and ectopic ACTH secretion, the compound is difficult to obtain, access to the necessary assays is limited, and the possible need for inpatient admission is inconvenient [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31225/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16135?source=see_link\">",
"     \"Metyrapone stimulation tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/61/6099?source=see_link\">",
"       \"Patient information: Cushing's syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/19/13619?source=see_link\">",
"       \"Patient information: Cushing's syndrome (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A series of steps in patients with proven endogenous Cushing's syndrome can usually establish the cause of hypercortisolism. We suggest the following approach (",
"    <a class=\"graphic graphic_algorithm graphicRef79853 \" href=\"UTD.htm?0/24/384\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Determine whether the hypercortisolism is ACTH-dependent (ie, due to a pituitary or non-pituitary ACTH-secreting tumor), or ACTH-independent (ie, due to an adrenal source) by measuring plasma ACTH.",
"     </li>",
"     <li>",
"      A low plasma ACTH concentration [&lt;5",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      (1.1",
"      <span class=\"nowrap\">",
"       pmol/L)]",
"      </span>",
"      in a hypercortisolemic patient is evidence of ACTH-independent disease; thin-section CT imaging of the adrenal glands is usually the next diagnostic procedure in these patients.",
"     </li>",
"     <li>",
"      Patients with ACTH-independent disease and bilateral adrenal micronodular or macronodular hyperplasia on imaging require additional testing.",
"     </li>",
"     <li>",
"      Patients with an intermediate plasma ACTH concentration, 5 to 20",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      (1.1 to 4.4",
"      <span class=\"nowrap\">",
"       pmol/L),",
"      </span>",
"      should undergo CRH testing. The presence of an ACTH response indicates Cushing's disease.",
"     </li>",
"     <li>",
"      The remaining majority of patients with ACTH-dependent disease (ACTH &gt;20",
"      <span class=\"nowrap\">",
"       pg/mL)",
"      </span>",
"      should undergo a pituitary MRI. If a clear pituitary lesion &gt;6 mm is identified and high dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      and CRH tests are consistent with Cushing&rsquo;s disease, no further diagnostic tests are required.",
"     </li>",
"     <li>",
"      The remaining majority of patients with ACTH-dependent disease (ACTH &gt;20",
"      <span class=\"nowrap\">",
"       pg/mL)",
"      </span>",
"      should undergo non-invasive tests (a high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      suppression test and CRH stimulation test)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      inferior petrosal sinus sampling.",
"     </li>",
"     <li>",
"      Suppression of cortisol during",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      administration as well as increases in ACTH and cortisol after CRH administration are consistent with the diagnosis of a pituitary adenoma (Cushing's disease).",
"     </li>",
"     <li>",
"      Petrosal sinus sampling with CRH stimulation is recommended for patients with unclear MRI (lesions &lt;6mm) or non-concordant non-invasive tests to distinguish between Cushing's disease and ectopic ACTH secretion.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/1\">",
"      Raff H, Findling JW. A new immunoradiometric assay for corticotropin evaluated in normal subjects and patients with Cushing's syndrome. Clin Chem 1989; 35:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/2\">",
"      Weitzman ED, Fukushima D, Nogeire C, et al. Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects. J Clin Endocrinol Metab 1971; 33:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/3\">",
"      Veldhuis JD, Iranmanesh A, Johnson ML, Lizarralde G. Amplitude, but not frequency, modulation of adrenocorticotropin secretory bursts gives rise to the nyctohemeral rhythm of the corticotropic axis in man. J Clin Endocrinol Metab 1990; 71:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/4\">",
"      Van Cauter E, Refetoff S. Evidence for two subtypes of Cushing's disease based on the analysis of episodic cortisol secretion. N Engl J Med 1985; 312:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/5\">",
"      Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F. Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 1999; 84:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/6\">",
"      Selvais P, Donckier J, Buysschaert M, Maiter D. Cushing's disease: a comparison of pituitary corticotroph microadenomas and macroadenomas. Eur J Endocrinol 1998; 138:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/7\">",
"      Woo YS, Isidori AM, Wat WZ, et al. Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. J Clin Endocrinol Metab 2005; 90:4963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/8\">",
"      Blake MA, Kalra MK, Sweeney AT, et al. Distinguishing benign from malignant adrenal masses: multi-detector row CT protocol with 10-minute delay. Radiology 2006; 238:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/9\">",
"      Ilias I, Sahdev A, Reznek RH, et al. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer 2007; 14:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/10\">",
"      Oliver RL, Davis JR, White A. Characterisation of ACTH related peptides in ectopic Cushing's syndrome. Pituitary 2003; 6:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/11\">",
"      LIDDLE GW. Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 1960; 20:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/12\">",
"      Liddle GW, Nicholson WE, Island DP, et al. Clinical and laboratory studies of ectopic humoral syndromes. Recent Prog Horm Res 1969; 25:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/13\">",
"      Strott CA, Nugent CA, Tyler FH. Cushing's syndrome caused by bronchial adenomas. Am J Med 1968; 44:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/14\">",
"      Malchoff CD, Orth DN, Abboud C, et al. Ectopic ACTH syndrome caused by a bronchial carcinoid tumor responsive to dexamethasone, metyrapone, and corticotropin-releasing factor. Am J Med 1988; 84:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/15\">",
"      Dichek HL, Nieman LK, Oldfield EH, et al. A comparison of the standard high dose dexamethasone suppression test and the overnight 8-mg dexamethasone suppression test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1994; 78:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/16\">",
"      Tyrrell JB, Findling JW, Aron DC, et al. An overnight high-dose dexamethasone suppression test for rapid differential diagnosis of Cushing's syndrome. Ann Intern Med 1986; 104:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/17\">",
"      Aron DC, Raff H, Findling JW. Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1997; 82:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/18\">",
"      Tsigos C, Chrousos GP. Differential diagnosis and management of Cushing's syndrome. Annu Rev Med 1996; 47:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/19\">",
"      Findling, JW. Differential diagnosis of Cushing's syndrome. Endocrinologist 1996; 7:17S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/20\">",
"      Reimondo G, Paccotti P, Minetto M, et al. The corticotrophin-releasing hormone test is the most reliable noninvasive method to differentiate pituitary from ectopic ACTH secretion in Cushing's syndrome. Clin Endocrinol (Oxf) 2003; 58:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/21\">",
"      Nieman LK, Chrousos GP, Oldfield EH, et al. The ovine corticotropin-releasing hormone stimulation test and the dexamethasone suppression test in the differential diagnosis of Cushing's syndrome. Ann Intern Med 1986; 105:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/22\">",
"      Nieman LK, Oldfield EH, Wesley R, et al. A simplified morning ovine corticotropin-releasing hormone stimulation test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1993; 77:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/23\">",
"      Tsagarakis S, Tsigos C, Vasiliou V, et al. The desmopressin and combined CRH-desmopressin tests in the differential diagnosis of ACTH-dependent Cushing's syndrome: constraints imposed by the expression of V2 vasopressin receptors in tumors with ectopic ACTH secretion. J Clin Endocrinol Metab 2002; 87:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/24\">",
"      Orth DN, DeBold CR, DeCherney GS, et al. Pituitary microadenomas causing Cushing's disease respond to corticotropin-releasing factor. J Clin Endocrinol Metab 1982; 55:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/25\">",
"      Newell-Price J, Morris DG, Drake WM, et al. Optimal response criteria for the human CRH test in the differential diagnosis of ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab 2002; 87:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/26\">",
"      Pecori Giraldi F, Invitti C, Cavagnini F, Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-pituitary-adrenal axis. The corticotropin-releasing hormone test in the diagnosis of ACTH-dependent Cushing's syndrome: a reappraisal. Clin Endocrinol (Oxf) 2001; 54:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/27\">",
"      Hermus AR, Pieters GF, Pesman GJ, et al. The corticotropin-releasing-hormone test versus the high-dose dexamethasone test in the differential diagnosis of Cushing's syndrome. Lancet 1986; 2:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/28\">",
"      Findling JW, Raff H. Diagnosis and differential diagnosis of Cushing's syndrome. Endocrinol Metab Clin North Am 2001; 30:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/29\">",
"      Dickstein G, DeBold CR, Gaitan D, et al. Plasma corticotropin and cortisol responses to ovine corticotropin-releasing hormone (CRH), arginine vasopressin (AVP), CRH plus AVP, and CRH plus metyrapone in patients with Cushing's disease. J Clin Endocrinol Metab 1996; 81:2934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/30\">",
"      Doppman JL, Oldfield E, Krudy AG, et al. Petrosal sinus sampling for Cushing syndrome: anatomical and technical considerations. Work in progress. Radiology 1984; 150:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/31\">",
"      Oldfield EH, Girton ME, Doppman JL. Absence of intercavernous venous mixing: evidence supporting lateralization of pituitary microadenomas by venous sampling. J Clin Endocrinol Metab 1985; 61:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/32\">",
"      Oldfield EH, Chrousos GP, Schulte HM, et al. Preoperative lateralization of ACTH-secreting pituitary microadenomas by bilateral and simultaneous inferior petrosal venous sinus sampling. N Engl J Med 1985; 312:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/33\">",
"      Kaltsas GA, Giannulis MG, Newell-Price JD, et al. A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing's disease and the occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1999; 84:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/34\">",
"      Oldfield EH, Doppman JL, Nieman LK, et al. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome. N Engl J Med 1991; 325:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/35\">",
"      Wiggam MI, Heaney AP, McIlrath EM, et al. Bilateral inferior petrosal sinus sampling in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome: a comparison with other diagnostic tests. J Clin Endocrinol Metab 2000; 85:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/36\">",
"      Doppman JL, Chang R, Oldfield EH, et al. The hypoplastic inferior petrosal sinus: a potential source of false-negative results in petrosal sampling for Cushing's disease. J Clin Endocrinol Metab 1999; 84:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/37\">",
"      Lefournier V, Gatta B, Martinie M, et al. One transient neurological complication (sixth nerve palsy) in 166 consecutive inferior petrosal sinus samplings for the etiological diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 1999; 84:3401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/38\">",
"      Bonelli FS, Huston J 3rd, Carpenter PC, et al. Adrenocorticotropic hormone-dependent Cushing's syndrome: sensitivity and specificity of inferior petrosal sinus sampling. AJNR Am J Neuroradiol 2000; 21:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/39\">",
"      Booth GL, Redelmeier DA, Grosman H, et al. Improved diagnostic accuracy of inferior petrosal sinus sampling over imaging for localizing pituitary pathology in patients with Cushing's disease. J Clin Endocrinol Metab 1998; 83:2291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/40\">",
"      L&oacute;pez J, Barcel&oacute; B, Lucas T, et al. Petrosal sinus sampling for diagnosis of Cushing's disease: evidence of false negative results. Clin Endocrinol (Oxf) 1996; 45:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/41\">",
"      Ilias I, Torpy DJ, Pacak K, et al. Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab 2005; 90:4955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/42\">",
"      Ilias I, Chang R, Pacak K, et al. Jugular venous sampling: an alternative to petrosal sinus sampling for the diagnostic evaluation of adrenocorticotropic hormone-dependent Cushing's syndrome. J Clin Endocrinol Metab 2004; 89:3795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/43\">",
"      Lefournier V, Martinie M, Vasdev A, et al. Accuracy of bilateral inferior petrosal or cavernous sinuses sampling in predicting the lateralization of Cushing's disease pituitary microadenoma: influence of catheter position and anatomy of venous drainage. J Clin Endocrinol Metab 2003; 88:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/44\">",
"      Colao A, Faggiano A, Pivonello R, et al. Inferior petrosal sinus sampling in the differential diagnosis of Cushing's syndrome: results of an Italian multicenter study. Eur J Endocrinol 2001; 144:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/45\">",
"      Swearingen B, Katznelson L, Miller K, et al. Diagnostic errors after inferior petrosal sinus sampling. J Clin Endocrinol Metab 2004; 89:3752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/46\">",
"      McCance DR, McIlrath E, McNeill A, et al. Bilateral inferior petrosal sinus sampling as a routine procedure in ACTH-dependent Cushing's syndrome. Clin Endocrinol (Oxf) 1989; 30:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/47\">",
"      Tabarin A, Greselle JF, San-Galli F, et al. Usefulness of the corticotropin-releasing hormone test during bilateral inferior petrosal sinus sampling for the diagnosis of Cushing's disease. J Clin Endocrinol Metab 1991; 73:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/48\">",
"      Mamelak AN, Dowd CF, Tyrrell JB, et al. Venous angiography is needed to interpret inferior petrosal sinus and cavernous sinus sampling data for lateralizing adrenocorticotropin-secreting adenomas. J Clin Endocrinol Metab 1996; 81:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/49\">",
"      Findling JW, Kehoe ME, Raff H. Identification of patients with Cushing's disease with negative pituitary adrenocorticotropin gradients during inferior petrosal sinus sampling: prolactin as an index of pituitary venous effluent. J Clin Endocrinol Metab 2004; 89:6005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/50\">",
"      Mulligan GB, Faiman C, Gupta M, et al. Prolactin measurement during inferior petrosal sinus sampling improves the localization of pituitary adenomas in Cushing's disease. Clin Endocrinol (Oxf) 2012; 77:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/51\">",
"      Sharma ST, Raff H, Nieman LK. Prolactin as a marker of successful catheterization during IPSS in patients with ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab 2011; 96:3687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/52\">",
"      Grant P, Dworakowska D, Carroll P. Maximizing the accuracy of Inferior petrosal sinus sampling: validation of the use of Prolactin as a marker of pituitary venous effluent in the diagnosis of Cushing's disease. Clin Endocrinol (Oxf) 2012; 76:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/53\">",
"      Yamamoto Y, Davis DH, Nippoldt TB, et al. False-positive inferior petrosal sinus sampling in the diagnosis of Cushing's disease. Report of two cases. J Neurosurg 1995; 83:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/54\">",
"      Miller DL, Doppman JL, Peterman SB, et al. Neurologic complications of petrosal sinus sampling. Radiology 1992; 185:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/55\">",
"      Gandhi CD, Meyer SA, Patel AB, et al. Neurologic complications of inferior petrosal sinus sampling. AJNR Am J Neuroradiol 2008; 29:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/56\">",
"      Obuobie K, Davies JS, Ogunko A, Scanlon MF. Venous thrombo-embolism following inferior petrosal sinus sampling in Cushing's disease. J Endocrinol Invest 2000; 23:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/57\">",
"      Blevins LS Jr, Clark RV, Owens DS. Thromboembolic complications after inferior petrosal sinus sampling in patients with cushing's syndrome. Endocr Pract 1998; 4:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/58\">",
"      Findling JW, Aron DC, Tyrrell JB, et al. Selective venous sampling for ACTH in Cushing's syndrome: differentiation between Cushing disease and the ectopic ACTH syndrome. Ann Intern Med 1981; 94:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/59\">",
"      Findling JW, Kehoe ME, Shaker JL, Raff H. Routine inferior petrosal sinus sampling in the differential diagnosis of adrenocorticotropin (ACTH)-dependent Cushing's syndrome: early recognition of the occult ectopic ACTH syndrome. J Clin Endocrinol Metab 1991; 73:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/60\">",
"      Erickson D, Huston J 3rd, Young WF Jr, et al. Internal jugular vein sampling in adrenocorticotropic hormone-dependent Cushing's syndrome: a comparison with inferior petrosal sinus sampling. Clin Endocrinol (Oxf) 2004; 60:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/61\">",
"      Graham KE, Samuels MH, Nesbit GM, et al. Cavernous sinus sampling is highly accurate in distinguishing Cushing's disease from the ectopic adrenocorticotropin syndrome and in predicting intrapituitary tumor location. J Clin Endocrinol Metab 1999; 84:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/62\">",
"      Liu C, Lo JC, Dowd CF, et al. Cavernous and inferior petrosal sinus sampling in the evaluation of ACTH-dependent Cushing's syndrome. Clin Endocrinol (Oxf) 2004; 61:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/63\">",
"      Hall WA, Luciano MG, Doppman JL, et al. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 1994; 120:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/64\">",
"      Tabarin A, Laurent F, Catargi B, et al. Comparative evaluation of conventional and dynamic magnetic resonance imaging of the pituitary gland for the diagnosis of Cushing's disease. Clin Endocrinol (Oxf) 1998; 49:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/65\">",
"      Patronas N, Bulakbasi N, Stratakis CA, et al. Spoiled gradient recalled acquisition in the steady state technique is superior to conventional postcontrast spin echo technique for magnetic resonance imaging detection of adrenocorticotropin-secreting pituitary tumors. J Clin Endocrinol Metab 2003; 88:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/66\">",
"      Heaney A, Loughrey G, McCance D, et al. Is whole-lung CT scanning still necessary in all cases of ACTH-dependent Cushing's syndrome in the era of petrosal sinus sampling? QJM 1999; 92:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/67\">",
"      Pacak K, Ilias I, Chen CC, et al. The role of [(18)F]fluorodeoxyglucose positron emission tomography and [(111)In]-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing's syndrome. J Clin Endocrinol Metab 2004; 89:2214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/68\">",
"      Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 1998; 19:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/69\">",
"      Hanson JA, Sohaib SA, Newell-Price J, et al. Computed tomography appearance of the thymus and anterior mediastinum in active Cushing's syndrome. J Clin Endocrinol Metab 1999; 84:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/70\">",
"      de Herder WW, Krenning EP, Malchoff CD, et al. Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion. Am J Med 1994; 96:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/71\">",
"      Phlipponneau M, Nocaudie M, Epelbaum J, et al. Somatostatin analogs for the localization and preoperative treatment of an adrenocorticotropin-secreting bronchial carcinoid tumor. J Clin Endocrinol Metab 1994; 78:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/72\">",
"      Zemskova MS, Gundabolu B, Sinaii N, et al. Utility of various functional and anatomic imaging modalities for detection of ectopic adrenocorticotropin-secreting tumors. J Clin Endocrinol Metab 2010; 95:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/73\">",
"      Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med 2002; 32:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/74\">",
"      Vanhagen PM, Krenning EP, Reubi JC, et al. Somatostatin analogue scintigraphy in granulomatous diseases. Eur J Nucl Med 1994; 21:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/75\">",
"      Torpy DJ, Chen CC, Mullen N, et al. Lack of utility of (111)In-pentetreotide scintigraphy in localizing ectopic ACTH producing tumors: follow-up of 18 patients. J Clin Endocrinol Metab 1999; 84:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/76\">",
"      Tabarin A, Valli N, Chanson P, et al. Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1999; 84:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/77\">",
"      Reincke M, Allolio B, Arlt W, K&ouml;rber C. Comment on primary localization of an ectopic ACTH-producing bronchial carcinoid tumor by indium111 pentetreotide scintigraphy. J Clin Endocrinol Metab 1999; 84:3399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/78\">",
"      Howlett TA, Drury PL, Perry L, et al. Diagnosis and management of ACTH-dependent Cushing's syndrome: comparison of the features in ectopic and pituitary ACTH production. Clin Endocrinol (Oxf) 1986; 24:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/79\">",
"      de Herder WW, Lamberts SW. Tumor localization--the ectopic ACTH syndrome. J Clin Endocrinol Metab 1999; 84:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31225/abstract/80\">",
"      Avgerinos PC, Yanovski JA, Oldfield EH, et al. The metyrapone and dexamethasone suppression tests for the differential diagnosis of the adrenocorticotropin-dependent Cushing syndrome: a comparison. Ann Intern Med 1994; 121:318.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 156 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-BC92F1AF1C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_31_31225=[""].join("\n");
var outline_f30_31_31225=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Primary adrenal disease versus ACTH-secreting tumor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Plasma ACTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ACTH-INDEPENDENT CUSHING'S SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Imaging for primary adrenal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Additional evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ACTH-DEPENDENT CUSHING'S SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      High-dose dexamethasone suppression tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CRH stimulation test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Vasopressin stimulation test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Petrosal venous sinus catheterization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Interpretation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - False negatives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - False positives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Tumor localization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Other venous sampling tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Pituitary MRI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Ectopic ACTH-secreting tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      OTHER DIAGNOSTIC TESTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/156\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/156|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?0/24/384\" title=\"algorithm 1\">",
"      Diagnosis Cushings syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/156|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/11/1201\" title=\"diagnostic image 1A\">",
"      Ectopic adrenal adenoma CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/39/41599\" title=\"diagnostic image 1B\">",
"      Adrenal cancer CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/46/14049\" title=\"diagnostic image 2A\">",
"      Adrenal hyperplasia CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/8/9345\" title=\"diagnostic image 2B\">",
"      Adrenal hyperplasia MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/55/38772\" title=\"diagnostic image 3\">",
"      Cushings disease MRI I",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/156|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/18/2336\" title=\"figure 1\">",
"      Episodic cortisol in Cushings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/156|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/1/6172\" title=\"table 1\">",
"      Causes of Cushings syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16435?source=related_link\">",
"      Basic principles in the laboratory evaluation of adrenocortical function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26489?source=related_link\">",
"      Causes and pathophysiology of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12826?source=related_link\">",
"      Clinical presentation and evaluation of adrenocortical tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26311?source=related_link\">",
"      Corticotropin-releasing hormone stimulation test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/45/730?source=related_link\">",
"      Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22072?source=related_link\">",
"      Cushing's syndrome due to primary pigmented nodular adrenocortical disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37528?source=related_link\">",
"      Dexamethasone suppression tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=related_link\">",
"      Establishing the diagnosis of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40246?source=related_link\">",
"      Measurement of ACTH, CRH, and other hypothalamic and pituitary peptides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16135?source=related_link\">",
"      Metyrapone stimulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/19/13619?source=related_link\">",
"      Patient information: Cushing's syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/61/6099?source=related_link\">",
"      Patient information: Cushing's syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=related_link\">",
"      The adrenal incidentaloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36312?source=related_link\">",
"      Vasopressin and desmopressin stimulation test",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_31_31226="Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)";
var content_f30_31_31226=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/31/31226/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/31/31226/contributors\">",
"     Claire Shovlin, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/31/31226/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/31/31226/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/31/31226/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/31/31226/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/31/31226/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu syndrome), an autosomal dominant vascular disorder, has a variety of clinical manifestations. Among the most common are epistaxis, gastrointestinal bleeding, and iron deficiency anemia, along with characteristic mucocutaneous telangiectasia. In addition, arteriovenous malformations (AVMs) commonly occur in the pulmonary, hepatic, and cerebral circulations, demanding knowledge of the risks and benefits of screening and treatment of patients with these complications.",
"   </p>",
"   <p>",
"    The pathophysiology, diagnosis, and management of HHT will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Issues related to pulmonary arteriovenous malformations are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32263?source=see_link\">",
"     \"Pulmonary arteriovenous malformations: Diagnostic evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27656?source=see_link\">",
"     \"Pulmonary arteriovenous malformations: Epidemiology, etiology, pathology, and clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DISEASE OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHT was first recognized in the 19th century as a familial disorder with abnormal vascular structures causing bleeding from the nose and gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Later descriptions by Rendu, Osler, Weber, and Hanes brought the disorder to the attention of the general medical community. These resulted in the eponym Osler-Weber-Rendu syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/6-8\">",
"     6-8",
"    </a>",
"    ], although Hanes' suggestion of the name hereditary hemorrhagic telangiectasia is usually preferred [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination of epistaxis, gastrointestinal bleeding, and iron deficiency anemia associated with characteristic telangiectasia on the lips, oral mucosa, and fingertips (",
"    <a class=\"graphic graphic_picture graphicRef77416 \" href=\"UTD.htm?10/34/10786\">",
"     picture 1",
"    </a>",
"    ) has become firmly established as a medical entity. However, this constellation of findings underestimates the other, potentially life-threatening aspects of this disorder. By the 1940s, additional abnormal vessels were being described in HHT, particularly arteriovenous malformations (AVMs) of the pulmonary [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/10\">",
"     10",
"    </a>",
"    ], hepatic [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/11\">",
"     11",
"    </a>",
"    ], and cerebral [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/12\">",
"     12",
"    </a>",
"    ] circulations. It is now recognized that at least 50 percent of HHT patients have pulmonary involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/13-15\">",
"     13-15",
"    </a>",
"    ], more than 30 percent have hepatic involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/16,17\">",
"     16,17",
"    </a>",
"    ], and approximately 10 percent have cerebral involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/13,18\">",
"     13,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Onset of disease manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manifestations of HHT are not generally present at birth, but develop with increasing age. Epistaxis is usually the earliest sign of disease, often occurring in childhood. Pulmonary AVMs generally become apparent after puberty, although they may be present during childhood, while mucocutaneous and gastrointestinal telangiectasias develop progressively with age. Age of development of cerebral vascular malformations appears to depend on type [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/19\">",
"     19",
"    </a>",
"    ]. By the age of 16 years, approximately 70 percent of individuals will have developed some clinical sign of HHT, rising to over 90 percent by the age of 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are specific times in patients&rsquo; lives when their HHT pathologies become more hazardous, the most important of which is pregnancy, which results in a 1 percent risk of maternal death per pregnancy (due to pulmonary AVM [PAVM] hemorrhage, cerebral hemorrhage, and thrombotic complications), with all maternal deaths occurring in women previously considered well. (See",
"    <a class=\"local\" href=\"#H12130483\">",
"     'Pregnancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with HHT present to a wide range of clinicians spanning medical, surgical, general practice disciplines, and emergency departments, many of whom lack appreciation of the full range of consequences of the diagnosis of HHT for patients and their families [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/23\">",
"     23",
"    </a>",
"    ]. Most patients are unaware of their diagnosis of HHT [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/24\">",
"     24",
"    </a>",
"    ]. As a result, HHT has been subject to under-reporting.",
"   </p>",
"   <p>",
"    Epidemiologic studies suggest likely prevalence rates between 1:5000 and 1:8000 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/25-29\">",
"     25-29",
"    </a>",
"    ], with much higher rates described in certain geographically isolated populations (eg, 1:1330 in Afro-Caribbean residents of Curacao and Bonaire [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/29\">",
"     29",
"    </a>",
"    ]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mutations in HHT",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHT is inherited as an autosomal dominant trait with varying penetrance and expression. Mutations in at least five genes can cause HHT, with two major disease genes on chromosome 9 (ENG, protein product: endoglin, OMIM #187300) and chromosome 12 (ACVRL1, protein product: activin receptor-like kinase 1, ALK-1, OMIM #600376). These disease subtypes are designated HHT1 and HHT2, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/1,30-32\">",
"     1,30-32",
"    </a>",
"    ]. Approximately 600 different HHT-causing mutations have been described; neither gene displays a common mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/1\">",
"     1",
"    </a>",
"    ]. The",
"    <a class=\"external\" href=\"file://arup.utah.edu/database/HHT/\">",
"     HHT mutation database",
"    </a>",
"    underwent extensive review in 2012 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small proportion of patients have HHT due to a mutation in the MADH4 gene (protein product: Smad4, OMIM #175050) as part of a juvenile polyposis-HHT overlap syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/34\">",
"     34",
"    </a>",
"    ]. Two further HHT genes have been localized to chromosomes 5 (HHT3) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/21\">",
"     21",
"    </a>",
"    ] and 7 (HHT4) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3224?source=see_link&amp;anchor=H21759704#H21759704\">",
"     \"Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families\", section on 'Juvenile polyposis syndrome and familial juvenile polyposis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endoglin, ALK-1 and Smad4 proteins modulate signalling by the transforming growth factor (TGF)-beta superfamily, ligands for which include TGF-betas, activins, inhibins and bone morphogenetic proteins (BMPs). Endoglin and ALK-1 are transmembrane glycoproteins expressed abundantly on vascular endothelial cells. ALK-1 is a type I receptor for the superfamily; endoglin associates with different superfamily receptor complexes, and Smad4 lies downstream in signal transduction cascades.",
"   </p>",
"   <p>",
"    In most cell types, TGF-beta 1 signalling via the type II receptor TbetaRII is propagated through ALK-5 (TbetaRI), although in endothelial cells, TbetaRII signalling can also be propagated through ALK-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/36\">",
"     36",
"    </a>",
"    ]. Endoglin can modify TGF-beta-1 signaling, but with the discovery of specific ligands for ALK-1, attention has also focused on bone morphogenetic protein (BMP) ligands BMP9 and BMP10 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/37\">",
"     37",
"    </a>",
"    ]. Of interest, the pure pulmonary artery hypertension (PAH) phenotype seen in patients with HHT is indistinguishable from primary PAH in the general population, due to mutations in the related BMPR2, which also associates with ALK-1. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Disease phenotypes'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7304?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenesis of pulmonary hypertension\", section on 'Genetic mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several animal models of HHT have been described. Null mice for ENG and ACVRL1 die between E10.5&ndash;11.5 because of gross vascular and cardiac defects, potentially reflecting aberrant placental vascular development [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/22\">",
"     22",
"    </a>",
"    ]. Heterozygous mice develop variable, but more HHT-specific, features including nosebleeds, telangiectasia, dilated vessels and AVMs [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Conditional LoxP knockout alleles have been generated for all three HHT genes and for ALK-1 result in models in which HHT-like vascular malformations occur in a consistent and predictable manner [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is believed that in most, if not all, cases, HHT results from endoglin or ALK-1 haploinsufficiency (ie, lack of sufficient protein for normal function). Since endothelial cells derived directly from arteriovenous malformations in patients with HHT1 or HHT2 also appear to express half the normal levels of endoglin and ALK-1, these malformations do not seem to be due to an additional local loss of",
"    <span class=\"nowrap\">",
"     endoglin/ALK-1",
"    </span>",
"    expression due to a conventional genetic \"second hit\" [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differing disease patterns in members of the same family in humans, as well as in mouse models, suggest that other genetic and environmental influences modify the HHT phenotype. Why AVMs develop in particular vascular beds and not others is unclear, and is the subject of ongoing research.",
"   </p>",
"   <p>",
"    There is substantial current interest in possible roles of vascular endothelial growth factor (VEGF) in HHT. Increased plasma levels of VEGF and TGF-beta-1 have been seen in HHT patients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Furthermore, treatment with angiogenesis inhibitors appears to have some efficacy in treating HHT. It is currently unclear whether VEGF is involved directly in the pathogenesis of what has been recognized as a TGF-beta superfamily disease, or whether these observations reflect the role of angiogenesis as a \"second hit\" phenomenon in HHT. (See",
"    <a class=\"local\" href=\"#H12129737\">",
"     'Angiogenesis inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Disease phenotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowing whether a patient has an endoglin or ALK-1 mutation does not allow a strong prediction of the likely course of HHT, since all features of HHT can be seen in both HHT1 and HHT2. Nevertheless, pulmonary and cerebral AVMs are more common in HHT1 patients, while hepatic AVMs, hepatic AVM-associated pulmonary hypertension, and pulmonary arterial hypertension are more common in HHT2 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/44-48\">",
"     44-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of interest, pulmonary hypertension is not a single disease entity, and can result from multiple causes in HHT, particularly secondary to hepatic AVMs, or as a pure pulmonary arterial hypertension (PAH) indistinguishable from PAH in the general population where it is due to mutations in the related BMPR2 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7304?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenesis of pulmonary hypertension\", section on 'Genetic mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with HHT experience only epistaxis, mucocutaneous telangiectasia, and a tendency to develop iron deficiency anemia secondary to the blood loss. For HHT patients who do not present spontaneously to a clinician before the age of 60 years, there is no excess mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/27\">",
"     27",
"    </a>",
"    ]. However, there is significant morbidity and mortality in younger patients, predominantly attributed to the consequences of visceral involvement, especially pulmonary and cerebral involvement, leading to embolic stroke and brain abscess (PAVM) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63662 \" href=\"UTD.htm?42/25/43423\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74593 \" href=\"UTD.htm?12/12/12493\">",
"     table 1",
"    </a>",
"    ) and hemorrhagic stroke (CAVM).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Epistaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous recurrent epistaxis from telangiectasia of the nasal mucosa is the most common clinical manifestation of HHT. Some patients experience no or minimal occasional episodes, but for the majority, recurrent and frequent epistaxis is a feature, with many patients experiencing daily bleeds. Management of epistaxis includes nasal humidification regimes, dedicated ENT treatments (including emergency nasal packing) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/49,50\">",
"     49,50",
"    </a>",
"    ] and medical treatments. Iron supplementation and transfusions may be required. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Localized bleeding'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/41/1690?source=see_link\">",
"     \"Approach to the adult with epistaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26536?source=see_link\">",
"     \"Management of epistaxis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Gastrointestinal bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent gastrointestinal bleeding occurs in up to one-third patients with HHT, often presenting as iron deficiency anemia or an acute gastrointestinal bleeding episode, most commonly in patients over the age of 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Gastrointestinal bleeding probably contributes less frequently to iron deficiency than under-recognized epistaxis. In many patients, improvement in nasal hemorrhage is able to significantly reduce iron and transfusion requirements.",
"   </p>",
"   <p>",
"    Telangiectasia occur throughout the gastrointestinal tract, and are more common in the stomach or duodenum than in the colon (",
"    <a class=\"graphic graphic_picture graphicRef50137 graphicRef73541 \" href=\"UTD.htm?17/23/17778\">",
"     picture 2A-B",
"    </a>",
"    ). They are visualized by endoscopy and are similar in size and appearance to mucocutaneous telangiectasia, and may be surrounded by an anemic halo. Less commonly, arteriovenous malformations (AVMs) and aneurysms occur; these lesions may be visualized on angiographic studies of the gastrointestinal tract (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52754 \" href=\"UTD.htm?38/41/39583\">",
"     image 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8410?source=see_link\">",
"     \"Angiodysplasia of the gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Mucocutaneous telangiectasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Telangiectasia of the skin and buccal mucosa occur in about 75 percent of individuals, typically presenting after childhood, and increasing in size and number with age [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/51\">",
"     51",
"    </a>",
"    ]. They mostly occur on the lips, tongue, buccal mucosa, and fingertips, but can occur elsewhere (",
"    <a class=\"graphic graphic_picture graphicRef77416 \" href=\"UTD.htm?10/34/10786\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef52483 \" href=\"UTD.htm?36/32/37376\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/53\">",
"     53",
"    </a>",
"    ]. Bleeding can occur but is rarely clinically important. The main concern is cosmetic; short-term benefits may be obtained via laser or other ablation therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20480786\">",
"    <span class=\"h2\">",
"     Sites of large arteriovenous malformations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically important arteriovenous malformations (AVMs) can occur in a number of organs, such as the lung, brain, and liver. While single AVMs can occur sporadically in the normal population as well as in patients with HHT, the presence of multiple AVMs in an organ such as the lung or brain make a sporadic etiology less likely [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/24,54\">",
"     24,54",
"    </a>",
"    ]. However, single AVMs are still strongly associated with&nbsp;HHT in both organs. Additionally, CT-based research screening programs of asymptomatic individuals have identified pancreatic AVMs at surprisingly high frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Pulmonary AVMs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary AVMs are thin walled abnormal vessels that replace normal capillaries between the pulmonary arterial and venous circulations, often resulting in bulbous sac-like structures (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56072 \" href=\"UTD.htm?3/22/3426\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54651 \" href=\"UTD.htm?21/7/21616\">",
"     image 4",
"    </a>",
"    ). They provide a direct capillary-free communication between the pulmonary and systemic circulations. Pulmonary arterial blood passing through these right-to left shunts cannot be oxygenated, leading to hypoxemia. Hypoxemia results in a polycythemic stimulus, which can lead to clinically significant levels of secondary polycythemia.",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, screening for, and treatment of pulmonary AVMs are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32263?source=see_link\">",
"     \"Pulmonary arteriovenous malformations: Diagnostic evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27656?source=see_link\">",
"     \"Pulmonary arteriovenous malformations: Epidemiology, etiology, pathology, and clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly, the majority of pulmonary AVM patients have no respiratory symptoms and most are unaware that they have HHT or pulmonary AVMs [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/24\">",
"     24",
"    </a>",
"    ]. In one review, fewer than one-third of affected individuals exhibited physical signs indicating a substantial right-to-left shunt (eg, cyanosis, clubbing, and polycythemia) (",
"    <a class=\"graphic graphic_table graphicRef54074 \" href=\"UTD.htm?7/32/7692\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/56\">",
"     56",
"    </a>",
"    ]. These proportions are likely to fall still further as more patients are diagnosed with more sensitive screening programs.",
"   </p>",
"   <p>",
"    Patients with pulmonary AVMs are at risk of complications, most commonly neurological sequelae due to paradoxical embolism, with embolic material evading the filtering function of the pulmonary capillaries and reaching the central nervous system. Catastrophic embolic cerebral events (cerebral abscess and embolic stroke), and transient ischemic attacks occur in patients with clinically silent PAVMs, and carry significant morbidity and mortality, indicating the need for early diagnosis and intervention (eg, antibiotic prophylaxis for interventional procedures, especially dental, embolization of pulmonary AVMs) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/24,57\">",
"     24,57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12358?source=see_link&amp;anchor=H22767252#H22767252\">",
"     \"Pulmonary arteriovenous malformations: Treatment\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, hemorrhage may occur from the fragile PAVM vessels into a bronchus or the pleural cavity, causing hemoptysis or hemothorax, respectively. However, this is rare outside of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/24,58\">",
"     24,58",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12130483\">",
"     'Pregnancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An increased prevalence of migraine has been described in PAVM patients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/59\">",
"     59",
"    </a>",
"    ], a finding that has also been associated with right-to-left shunting due to a patent foramen ovale. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link&amp;anchor=H130649662#H130649662\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Right-to-left cardiac shunt'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Cerebral AVMs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HHT may have cerebral or spinal cord involvement. The vascular malformations include telangiectasias, micro AVMs, nidus AVMs (the &ldquo;classical&rdquo; variety), and arteriovenous fistulae (generally found in children). The prognosis depends upon the type and location of the lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/19\">",
"     19",
"    </a>",
"    ]. Other pathology can occur as in the general population (",
"    <a class=\"graphic graphic_picture graphicRef75190 \" href=\"UTD.htm?15/59/16304\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/19,60\">",
"     19,60",
"    </a>",
"    ]. Cerebral AVMs affect approximately 10 percent of HHT patients, are often multiple, and are usually silent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/13,18,54,61\">",
"     13,18,54,61",
"    </a>",
"    ]. They can lead to headache, seizures, ischemia of the surrounding tissue due to a steal effect, or hemorrhage. The latter may be less frequent than that seen in non-HHT cerebral AVMs, in part due to the lower frequency of associated aneurysms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18584?source=see_link&amp;anchor=H9#H9\">",
"     \"Vascular malformations of the central nervous system\", section on 'Capillary telangiectasias'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cerebral hemorrhage usually has devastating effects. Thus, patients with symptoms suggestive of cerebral AVMs deserve further assessment as in the non-HHT population, including noninvasive imaging and ultimately assessment by experienced neurointerventional centers. The question of screening asymptomatic individuals with HHT for cerebral AVMs remains controversial in HHT as in the general population, and the results of the ARUBA trial [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/62\">",
"     62",
"    </a>",
"    ] are eagerly awaited. Practice differs between countries. (See",
"    <a class=\"local\" href=\"#H7830949\">",
"     'Cerebral AVMs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Cerebral magnetic resonance imaging (MRI) is the most sensitive noninvasive test (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53992 \" href=\"UTD.htm?33/37/34384\">",
"     image 5",
"    </a>",
"    ), although it will fail to detect a significant proportion of AVMs, and is contraindicated in screening settings for patients with pulmonary AVMs embolized with non-MRI compatible coils.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Hepatic involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Silent hepatic involvement occurs in up to 74 percent of patients with HHT [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/16,17,63,64\">",
"     16,17,63,64",
"    </a>",
"    ]. Symptoms related to these lesions are much less frequent and can include high-output heart failure, portal hypertension, and biliary disease, reflecting different patterns of vascular involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. Large AVMs between the hepatic artery and hepatic vein can cause a significant left-to-right shunt with increased cardiac output that, particularly when combined with anemia, places patients at risk of angina and heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/65,68\">",
"     65,68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29816?source=see_link\">",
"     \"Hepatic hemangioma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Portal hypertension and hepatic encephalopathy, particularly after episodes of gastrointestinal bleeding, may result both from shunts between the hepatic artery and portal vein, and from increased sinusoidal blood flow, leading to enhanced deposition of fibrous tissue and pseudocirrhosis of the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatic AVMs may be suspected in patients with HHT who have hepatomegaly, a liver bruit, or abnormal liver function tests. The diagnosis can be established by computed tomography, MRI, Doppler ultrasonography, or angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/69\">",
"     69",
"    </a>",
"    ]. Liver biopsy is not recommended as it is not useful in the diagnosis of HHT and may be complicated by bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The natural history of hepatic AVMs was studied in 154 patients with HHT and hepatic vascular malformations who were followed over a median period of 44 months (range: 12 to 181 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/70\">",
"     70",
"    </a>",
"    ]. Eight (5.2 percent) died from vascular malformation-related complications and 39 (25.3 percent) experienced non-fatal complications. The average incidence rates of death and complications were 1.1 and 3.6 per 100 person-years, respectively, while the rate of complete response to therapy was 63 percent. (See",
"    <a class=\"local\" href=\"#H7830609\">",
"     'Therapy for localized lesions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12131106\">",
"    <span class=\"h2\">",
"     Venous thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HHT are at increased risk of venous thromboemboli, the management of which can be compounded by other aspects of their HHT. In a study of 609 patients with HHT recruited prospectively in two separate series at a single center, low serum iron levels, attributed to inadequate replacement of hemorrhagic iron losses, were associated with elevated plasma levels of coagulation factor VIII and an increased venous thromboembolic (VTE) risk [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In each series, there was an inverse association between factor VIII levels and serum iron that persisted after adjustment for age, inflammation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    von Willebrand factor. Low serum iron levels were also associated with VTE: the age-adjusted OR of 0.91 (95% CI 0.86-0.97) per 1",
"    <span class=\"nowrap\">",
"     &mu;mol/L",
"    </span>",
"    increase in serum iron implied a 2.5-fold increase in VTE risk for a serum iron of 6",
"    <span class=\"nowrap\">",
"     &mu;mol/L",
"    </span>",
"    compared with the mid-normal range (17",
"    <span class=\"nowrap\">",
"     &mu;mol/L).",
"    </span>",
"    The association appeared to depend upon factor VIII levels, as once adjusted for factor VIII levels, the association between VTE and iron was no longer evident.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of HHT may be suspected in patients with the above clinical manifestations, particularly if there is a first-degree relative with HHT (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Clinical features'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Consensus criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;International consensus diagnostic criteria (the Curacao diagnostic criteria) are based upon the following four findings [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Spontaneous and recurrent epistaxis",
"     </li>",
"     <li>",
"      Multiple mucocutaneous telangiectasias",
"     </li>",
"     <li>",
"      Visceral involvement (eg, gastrointestinal, pulmonary, cerebral, or hepatic AVMs)",
"     </li>",
"     <li>",
"      A first-degree relative with HHT",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These criteria define \"definite\", \"suspected\", and \"unlikely\" HHT when three or four, two, or zero to one of these criteria are present, respectively. The diagnosis may be confirmed by formal genetic testing for mutations involving endoglin, ALK-1, or SMAD4, although this is not required to make a diagnosis of HHT. Mutation testing does not detect all mutations that might be present and may cause confusion by identification of non-disease-causing polymorphisms.",
"   </p>",
"   <p>",
"    Several centers for genetic testing are available in different countries, with details available through the HHT Foundation International website [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/74\">",
"     74",
"    </a>",
"    ]. Previously reported mutations are registered on the HHT mutation database, available at",
"    <a class=\"external\" href=\"file://arup.utah.edu/database/HHT/\">",
"     file://arup.utah.edu/database/HHT/",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6888057\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29948893\">",
"    <span class=\"h3\">",
"     Overall strategy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening to diagnose arteriovenous malformations (AVMs) in individuals at risk of HHT, but without symptoms relevant to the AVMs, is not the same as investigation of a symptomatic patient. In general, screening, assuming the individual is in agreement, consists of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basic clinical examination",
"     </li>",
"     <li>",
"      Evaluation for anemia and iron deficiency",
"     </li>",
"     <li>",
"      Pulmonary AVM screening",
"     </li>",
"     <li>",
"      Cerebral AVM screening (only performed in some countries or families; pre-screening discussions are encouraged)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional testing is performed based upon results of the initial assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/73\">",
"     73",
"    </a>",
"    ] or specific family issues. Protocols depend upon the importance attached to the detection of asymptomatic lesions in particular viscera, the diagnostic expertise available locally, and the degree to which establishment of the extent of HHT is important in the particular healthcare system. International Guidelines on management of HHT were published in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The details and rationale for our screening strategy are described in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7831188\">",
"    <span class=\"h3\">",
"     Iron deficiency anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishment and optimization of iron status is crucial in HHT. In addition to symptoms of iron deficiency that would be seen in a patient without HHT, patients with HHT and low iron are at higher risk of venous thromboemboli (VTE) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/71\">",
"     71",
"    </a>",
"    ]. Serum iron rather than ferritin levels appear to be most helpful in this regard. (See",
"    <a class=\"local\" href=\"#H12131106\">",
"     'Venous thromboembolism'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link&amp;anchor=H23#H23\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\", section on 'Estimation of iron stores'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=see_link\">",
"     \"Treatment of anemia due to iron deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558383443\">",
"    <span class=\"h3\">",
"     Pulmonary AVMs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HHT should be screened for pulmonary arteriovenous malformations (PAVMs) because of the high incidence of unsuspected PAVM and evidence that treatment reduces stroke and brain abscess risks [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/13,14,24,75-78\">",
"     13,14,24,75-78",
"    </a>",
"    ] . It is also important that women with HHT undergo screening before becoming pregnant, since PAVMs can rupture in later pregnancy leading to hemoptysis or hemothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/56,77,79\">",
"     56,77,79",
"    </a>",
"    ]; in a series of 484 pregnancies, this occurred in 1 percent (95% CI 0.1, 1.9%) of pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32263?source=see_link\">",
"     \"Pulmonary arteriovenous malformations: Diagnostic evaluation\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H12130483\">",
"     'Pregnancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7830949\">",
"    <span class=\"h3\">",
"     Cerebral AVMs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening of asymptomatic patients for cerebral AVMs is recommended in many countries, but remains controversial in others. On the one hand, cerebral hemorrhages in HHT patients are usually life-changing and may be fatal. On the other hand, most HHT-related cerebral AVMs will never bleed, and investigation and treatments carry risks. Both sets of considerations differ with the precise anatomy and location of the AVM [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other important considerations are that cerebral AVMs are more common in HHT1 families [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/44-48,80\">",
"     44-48,80",
"    </a>",
"    ], and that the lifelong risk of hemorrhage is higher for younger patients because of their longer predicted lifespan. In the UK and other countries, risk-benefit considerations for asymptomatic cerebral AVMs are usually not interpreted in favor of treatment because the risks of intervention are too high for the low risk of hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/81\">",
"     81",
"    </a>",
"    ]. Up to 10 percent of screened individuals would be faced with the identification of cerebral AVMs for which no treatment or management options would be recommended. At several institutions in Europe, these considerations are discussed openly with the patient and, generally, cerebral MRI is not performed. However, for any individual with a family member who has had a cerebral hemorrhage, or in whom there is any concern regarding cerebral symptoms, a cerebral MRI is recommended to rule out a chance inheritance of familial aneurysms (which carry a higher risk of hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/58\">",
"     58",
"    </a>",
"    ]) or presence of an unstable, symptomatic cerebral AVM. Further recommendations await the results of the ARUBA trial [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558392706\">",
"    <span class=\"h3\">",
"     Screening SMAD4 mutation carriers",
"    </span>",
"    &nbsp;&mdash;&nbsp;For individuals with SMAD4 mutations, more extensive surveillance is required, in keeping with juvenile polyposis screening protocols. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3224?source=see_link&amp;anchor=H21759711#H21759711\">",
"     \"Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families\", section on 'Screening and surveillance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Asymptomatic screening for other manifestations of HHT has not yet become routinely established in clinical practice, and may differ according to particular features of the family history.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7830609\">",
"    <span class=\"h2\">",
"     Therapy for localized lesions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7830667\">",
"    <span class=\"h3\">",
"     Arteriovenous malformations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of arteriovenous malformations involving the lung, liver, and central nervous system is complex and should be performed by clinicians with expertise in this area:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For pulmonary AVMs, embolotherapy is recommended [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12358?source=see_link&amp;anchor=H22767252#H22767252\">",
"       \"Pulmonary arteriovenous malformations: Treatment\", section on 'Natural history'",
"      </a>",
"      .) Surgery may be warranted if the anatomy precludes successful embolization.",
"     </li>",
"     <li>",
"      Cerebral AVMs may be treated with embolotherapy, surgical removal, or stereotactic radiotherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18584?source=see_link&amp;anchor=H9#H9\">",
"       \"Vascular malformations of the central nervous system\", section on 'Capillary telangiectasias'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For hepatic AVMs, the treatment of patients with symptomatic liver involvement is generally supportive in order to reduce the complications noted above (eg, heart failure, complications of portal hypertension, biliary disease) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/70,82\">",
"       70,82",
"      </a>",
"      ]. If medical management fails, liver transplantation is the treatment of choice. In patients who develop acute hepatic failure (eg, acute biliary necrosis syndrome) or intractable heart failure or portal hypertension, liver transplantation may be life-saving [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/66,83-85\">",
"       66,83-85",
"      </a>",
"      ]. Embolization is no longer recommended because of higher morbidity and mortality compared with transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/67,86\">",
"       67,86",
"      </a>",
"      ]. Use of the angiogenesis inhibitor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      in this setting may also be considered. (See",
"      <a class=\"local\" href=\"#H12129737\">",
"       'Angiogenesis inhibitors'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Localized bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with symptomatic HHT most commonly experience episodes of epistaxis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gastrointestinal hemorrhage. The management of these complications is generally the same as the treatment of either condition in the absence of HHT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/41/1690?source=see_link\">",
"     \"Approach to the adult with epistaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8410?source=see_link\">",
"     \"Angiodysplasia of the gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of topical, systemic, and surgical treatments are available for epistaxis, with variable efficacy. Cauterization is best avoided due to damage of the nasal mucosa, prompting vascular regrowth. Treatments are generally directed to patients either experiencing massive hemorrhages or experiencing daily epistaxis, and include nasal humidification regimens, laser ablation, arterial ligation, septodermoplasty, and unilateral or bilateral surgical closure of the nostrils [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/87-91\">",
"     87-91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Repeated endoscopic ablation of gastrointestinal lesions may be used to control bleeding in the short term (",
"    <a class=\"graphic graphic_picture graphicRef79901 \" href=\"UTD.htm?17/47/18164\">",
"     picture 5",
"    </a>",
"    ), although the results are not as good as in the non-HHT population [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/92\">",
"     92",
"    </a>",
"    ]. Surgery has limited success due to recurrent disease, but may be useful for emergency control of hemorrhage from discrete lesions, as may embolization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34695?source=see_link&amp;anchor=H6#H6\">",
"     \"Argon plasma coagulation in the management of gastrointestinal hemorrhage\", section on 'Angiodysplasia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antihemorrhagic medical treatments have been sought. Two therapies are supported by evidence from randomized, controlled trials: female hormones and anti-estrogens. (See",
"    <a class=\"local\" href=\"#H12129701\">",
"     'Hormones and antifibrinolytic agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    While there is no controlled trial evidence published at this point, there are encouraging data regarding several other therapies, of which anti-angiogenic agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ) appear to show the most promise. (See",
"    <a class=\"local\" href=\"#H12129737\">",
"     'Angiogenesis inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Iron deficiency anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with iron deficiency anemia secondary to blood loss from the vascular lesions of HHT are managed conservatively by repletion of the lost iron. Initial management is via the use of oral iron preparations. If the bleeding is severe enough, blood transfusions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    parenteral iron therapy may also be required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=see_link\">",
"     \"Treatment of anemia due to iron deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7830739\">",
"    <span class=\"h3\">",
"     Bleeding telangiectasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;For local treatment of bleeding lesions, different types of laser or argon plasma coagulation devices are available, with the exact method used depending on operator preference and availability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12130353\">",
"    <span class=\"h2\">",
"     Systemic agents to manage bleeding",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12129701\">",
"    <span class=\"h3\">",
"     Hormones and antifibrinolytic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of treatments have shown promise in small studies for the management of recurrent bleeding secondary to gastrointestinal and nasopharyngeal arteriovenous malformations in patients with HHT. These have included estrogen preparations and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , for which there is evidence from randomized controlled trials of benefit in HHT, and uncontrolled reports or case series, with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    , high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    , and other agents [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/93-99\">",
"     93-99",
"    </a>",
"    ]. Potential beneficial effects from such agents need to be balanced against the recognition that many are prothrombotic maneuvers, and that patients with HHT are not protected against thromboembolic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12129723\">",
"    <span class=\"h3\">",
"     Estrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a double-blind, randomized controlled trial, the daily oral use of 50 micrograms of ethinylestradiol plus 1 milligram norethisterone resulted in a significant reduction in transfusion requirements in 10 patients with a prior mean transfusion requirement of 19 packed cell units per year [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/101\">",
"     101",
"    </a>",
"    ]. These data have been extrapolated in clinical practice to patients with lesser degrees of hemorrhage not necessarily associated with regular transfusion requirements.",
"   </p>",
"   <p>",
"    A 0.1 percent estriol (a low-potency metabolite of estradiol) ointment applied twice daily to the nasal mucosa produced reversible squamous metaplasia in 12 patients with HHT, suggesting its use to reduce the fragility of the nasal mucosa and lessen the resulting incidence of epistaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Higher dose conjugated estrogens in the \"hormone replacement\" range (over 625",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    ethinylestradiol equivalent), and antifibrinolytic agents, such as local or systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/95,103\">",
"     95,103",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/96\">",
"     96",
"    </a>",
"    ], are also widely used in the management of HHT related bleeding. These therapies have not been supported by data from randomized controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12129730\">",
"    <span class=\"h3\">",
"     Antiestrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;An efficacy trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was initiated in 46 patients with a diagnosis of epistaxis due to HHT. Although few details are available, self-assessment of quality of life, degree of epistaxis, and hemoglobin levels were reported to be improved [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/105\">",
"     105",
"    </a>",
"    ]. No patient required blood transfusion during the treatment period (mean: 23.4 months) and only one patient had minor side effects of the drug.",
"   </p>",
"   <p>",
"    A smaller double-blind, placebo-controlled trial explored the use of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for six months) in 21 patients with epistaxis due to HHT [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/99\">",
"     99",
"    </a>",
"    ]. There was a significant reduction in the frequency of epistaxis in the 10 tamoxifen-treated group, accompanied in many cases by either a rise in hemoglobin or a reduction in transfusion requirements. A potential improvement in mucocutaneous telangiectasia was also reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12129737\">",
"    <span class=\"h3\">",
"     Angiogenesis inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been much excitement surrounding the use of angiogenesis inhibitors in HHT (eg, the VEGF antagonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ), resulting in improvement in bleeding episodes, reductions in cardiac output and liver size, as well as temporarily obviating the need for hepatic transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/106-111\">",
"     106-111",
"    </a>",
"    ]. While placebo controlled trials are yet to be reported, the following studies are of great interest:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       Bevacizumab",
"      </a>",
"      , whether administered intravenously, injected locally, or sprayed topically to the nasal mucosa, appears to have been effective in reducing the severity of epistaxis in non-controlled series [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/111-116\">",
"       111-116",
"      </a>",
"      ]. Care should be taken to avoid injection of this agent into the cartilaginous nasal septum, as this route may be associated with perforation of the nasal septum.",
"     </li>",
"     <li>",
"      In a phase II study,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      given every 14 days for a total of six injections) was given to 25 patients with severe liver involvement and a high cardiac index related to HHT, in whom liver transplantation was not feasible. At six months, the cardiac index normalized in 5 of the 23 evaluable patients and was reduced in another 15, for an overall response rate of 87 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/117\">",
"       117",
"      </a>",
"      ]. The mean duration of epistaxis decreased from 221",
"      <span class=\"nowrap\">",
"       minutes/month",
"      </span>",
"      at the start of treatment to 134",
"      <span class=\"nowrap\">",
"       minutes/month",
"      </span>",
"      at six months, along with a significant improvement in quality of life. Two cases of grade III hypertension were noted, which were successfully treated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the above observations in patients with liver involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/107,117\">",
"     107,117",
"    </a>",
"    ], the proper use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    in HHT patients with liver failure, once standard medical therapies have failed, is not clear for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although liver transplantation is subject to the limitation of donor livers as well as recipient status, particularly age, it is an effective long-term treatment for liver failure in HHT, with 10-year survivals of approximately 80 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Long-term efficacy and side effects of this and other angiogenesis inhibitors when used in patients with HHT and liver failure (and for any indication for that matter) are not fully known at this time [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathophysiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36538?source=see_link\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=see_link\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, while the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    may be reasonable in patients with extensive hepatic AVMs and resistant liver failure in whom liver transplantation is not feasible, results of the above bevacizumab trial are not sufficiently robust for bevacizumab to be employed in patients with complicated liver AVMs or to replace liver transplantation as first line management of liver failure once standard medical therapies have failed. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Hepatic involvement'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Positive reports following the use of the angiogenesis inhibitors",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    have also been presented [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/118-120\">",
"     118-120",
"    </a>",
"    ], and mechanistic support is available [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/120\">",
"     120",
"    </a>",
"    ]. It appears that such treatments, like other antiangiogenic maneuvers, need to be given repeatedly and may have serious local and systemic side effects. Because of the lack of randomized controls and anecdotal nature of these reports, as well as the lack of long-term efficacy and safety data, we believe that use of these agents should be restricted to their evaluation in carefully selected, consenting patients in randomized controlled trials within experienced HHT centers [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12129803\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;In provocative case reports, the use of immunosuppressive agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    , interferon) has been associated with resolution of previously noted telangiectasias of the skin, buccal mucosa, and upper gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/121,122\">",
"     121,122",
"    </a>",
"    ]. Clinical trials of these agents are in progress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12130483\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports have highlighted major complications of pregnancy in women with HHT. However, our series of 484 pregnancies in 199 women indicated that the vast majority are able to have a normal pregnancy. This is an important observation, since women with HHT are sometimes led to believe that pregnancy is too dangerous to undertake. That said, a small proportion of women did experience life-threatening complications, even in those who previously had only minor symptoms of HHT.",
"   </p>",
"   <p>",
"    In this series, the following complications were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/58\">",
"     58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pulmonary AVM hemorrhage &mdash; 1.4 percent (95% CI 0.2-2.5)",
"     </li>",
"     <li>",
"      Stroke &mdash; 1.2 percent (95% CI 0.3-2.2)",
"     </li>",
"     <li>",
"      Maternal deaths &mdash; 1.0 percent (95% CI 0.1-1.9)",
"     </li>",
"     <li>",
"      Myocardial infarction &mdash; 0.2 percent (1 case)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    General recommendations for the management of women with HHT include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All pregnancies in women with HHT should be considered \"high risk.\"",
"     </li>",
"     <li>",
"      Since spinal AVMs affect approximately 1 to 2 percent of HHT patients, many anesthetists will not perform epidural analgesia in HHT mothers unless MRI scans have excluded this possibility.",
"     </li>",
"     <li>",
"      Pulmonary AVMs will enlarge during pregnancy, and fatal hemorrhage from maternal pulmonary AVMs has been described [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/58,79\">",
"       58,79",
"      </a>",
"      ]. As a result, women with HHT should be screened for pulmonary AVMs and treated maximally before pregnancy, although treatment may be safely undertaken in late pregnancy if required [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/123\">",
"       123",
"      </a>",
"      ]. Hemoptysis of any degree or sudden severe dyspnea should be considered a medical emergency, prompting urgent hospitalization and institution of appropriate treatment.",
"     </li>",
"     <li>",
"      Cerebral MRI should be performed in women with HHT and a family history of cerebral hemorrhage or in those with cerebral symptoms. A prolonged second stage of labor should be avoided in women in whom cerebral AVMs have not been excluded.",
"     </li>",
"     <li>",
"      In keeping with the general advice for patients with pulmonary AVMs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      HHT [",
"      <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/14,24\">",
"       14,24",
"      </a>",
"      ], antibiotic prophylaxis should be provided during delivery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Anecdotal data suggest that epistaxis may get worse and skin telangiectasia become more prominent during pregnancy; there are no firm data regarding effects on hepatic or cerebral AVMs. The patient should also be made aware that any offspring will have a 50 percent risk of inheriting HHT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32872?source=see_link&amp;anchor=H11#H11\">",
"     \"Brain arteriovenous malformations\", section on 'Risk during pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12130505\">",
"    <span class=\"h2\">",
"     Airline travel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the fact that patients with HHT commonly have low oxygen saturations and anemia, two parameters generally used to indicate lack of medical fitness to fly, reassuring flight tolerance data have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/124\">",
"     124",
"    </a>",
"    ]. Using a retrospective questionnaire-based study, the authors examined in-flight complications and predictors in 145 HHT patients (96 with PAVMs) who reported 3950 flights, totalling 18,943 flight hours. Dyspnea and thrombotic complications were less common than expected and could not be predicted from sea level oxygen saturations or hemoglobin concentrations.",
"   </p>",
"   <p>",
"    Nosebleeds that can bar individuals from boarding a flight occurred in 13.6 percent (11.5 to 15.8 percent) of long-haul flights. The findings should influence preflight advice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7830493\">",
"    <span class=\"h1\">",
"     SCREENING OF FAMILY MEMBERS AND CHILDREN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar principles apply to screening of family members as for probands. A crucial issue concerning family screening is that no child of a patient with HHT can be informed that",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    does not have HHT unless the diagnosis has been excluded by formal genetic testing, since symptoms may not occur in affected individuals until later in life [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/125\">",
"     125",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Onset of disease manifestations'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6888057\">",
"     'Screening'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For children, there are further differences in practice, in part reflecting the uncertainty as to whether silent AVMs pose sufficient danger in childhood to balance the risks of childhood radiation, and in part reflecting the ethics of screening an asymptomatic child who is too young to give consent and will likely not understand the implications of testing. Institutions therefore differ in their screening regimens. Practice ranges from screening for all manifestations of HHT to deferring screening in most asymptomatic children until post-puberty, unless dictated otherwise by family history [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In families with a known genetic defect, genetic screening of family members by analysis of peripheral blood can be performed, followed by the above protocol in family members with the HHT genotype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12130735\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Educational materials for patients with HHT, and the location of specialized centers for diagnosing and managing HHT and pulmonary arteriovenous malformations are available from the",
"    <a class=\"external\" href=\"file://hht.org/\">",
"     HHT Foundation International",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/74\">",
"     74",
"    </a>",
"    ] and from the",
"    <a class=\"external\" href=\"file://www.telangiectasia.co.uk/\">",
"     Telangiectasis Self Help Group",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/31/31226/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/42/26274?source=see_link\">",
"       \"Patient information: Arteriovenous malformations in the brain (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;International consensus diagnostic criteria for HHT are based upon the following four criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Spontaneous and recurrent nosebleeds",
"     </li>",
"     <li>",
"      Multiple mucocutaneous telangiectasias",
"     </li>",
"     <li>",
"      Visceral involvement (eg, gastrointestinal, pulmonary, cerebral, or hepatic AVMs)",
"     </li>",
"     <li>",
"      A first degree relative with HHT",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These criteria define \"definite\", \"suspected\", and \"unlikely\" HHT when three or four, two, or zero to one of these criteria are present, respectively. The diagnosis may also be confirmed by formal genetic testing for mutations involving endoglin, ALK-1, or SMAD4 (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Pathophysiology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'Consensus criteria'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to make specific treatment recommendations for a disease that may be asymptomatic or have a wide spectrum of clinical manifestations including minimal to life-threatening degrees of epistaxis or gastrointestinal bleeding, as well as varying severities of arteriovenous malformations of the liver, lung, and central nervous system, leading to complications such as high output heart failure, portal hypertension, liver failure, hemoptysis, polycythemia, cerebral abscess, and stroke. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The absence of randomized controlled trials for most of the available treatments does not facilitate formal recommendations other than embolization of pulmonary AVMs to reduce the incidence of stroke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12358?source=see_link&amp;anchor=H22767252#H22767252\">",
"     \"Pulmonary arteriovenous malformations: Treatment\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of HHT complications is generally the same as the treatment of the same condition (eg, epistaxis, gastrointestinal bleeding) in the absence of HHT (",
"    <a class=\"graphic graphic_table graphicRef74593 \" href=\"UTD.htm?12/12/12493\">",
"     table 1",
"    </a>",
"    ). Accordingly, patients with HHT must be followed carefully by specialists dealing with the organ system(s) involved in the particular patient, using a graded approach tailored to the severity of the clinical problem. (See",
"    <a class=\"local\" href=\"#H7830609\">",
"     'Therapy for localized lesions'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/1\">",
"      Govani FS, Shovlin CL. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet 2009; 17:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/2\">",
"      Dupuis-Girod S, Bailly S, Plauchu H. Hereditary hemorrhagic telangiectasia: from molecular biology to patient care. J Thromb Haemost 2010; 8:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/3\">",
"      Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 2010; 24:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/4\">",
"      Sutton HG. Epistaxis as an indication of impaired nutrition, and of degeneration of the vascular system. Medical Mirror 1864; 1:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/5\">",
"      Legg W. A case of haemophilia complicated with multiple naevi. Lancet 1876; ii:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/6\">",
"      Rendu H. Epistaxis repetees chez un sujet porteur de petits angiomes cutanes et muquez. Gazette des Hopitaux Civils et Militaires (Paris) 1896; 135:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/7\">",
"      Osler W. On a family form of recurring epistaxis, associated with multiple telangiectases of the skin and mucous membranes. Bulletin of the Johns Hopkins Hospital 1901; 12:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/8\">",
"      Weber F. Multiple hereditary developmental angiomata (telangiectases) of the skin and mucous membranes associated with recurring hemorrhages. Lancet 1907; ii:160&ndash;2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/9\">",
"      Hanes FM. Multiple hereditary telangiectases causing hemorrhage (hereditary hemorrhagic telangiectasia). Bulletin of the Johns Hopkins Hospital 1909; 20:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/10\">",
"      Rundles RW. Hemorrhagic telangiectasia with pulmonary artery aneurysm: case report. Am J Med Sci 1945; 210:76&ndash;81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/11\">",
"      SMITH JL, LINEBACK MI. Hereditary hemorrhagic telangiectasia; nine cases in one Negro family, with special reference to hepatic lesions. Am J Med 1954; 17:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/12\">",
"      Rom&aacute;n G, Fisher M, Perl DP, Poser CM. Neurological manifestations of hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber disease): report of 2 cases and review of the literature. Ann Neurol 1978; 4:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/13\">",
"      Haitjema T, Disch F, Overtoom TT, et al. Screening family members of patients with hereditary hemorrhagic telangiectasia. Am J Med 1995; 99:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/14\">",
"      Cottin V, Plauchu H, Bayle JY, et al. Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. Am J Respir Crit Care Med 2004; 169:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/15\">",
"      van Gent MW, Post MC, Snijder RJ, et al. Real prevalence of pulmonary right-to-left shunt according to genotype in patients with hereditary hemorrhagic telangiectasia: a transthoracic contrast echocardiography study. Chest 2010; 138:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/16\">",
"      Piantanida M, Buscarini E, Dellavecchia C, et al. Hereditary haemorrhagic telangiectasia with extensive liver involvement is not caused by either HHT1 or HHT2. J Med Genet 1996; 33:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/17\">",
"      McDonald JE, Miller FJ, Hallam SE, et al. Clinical manifestations in a large hereditary hemorrhagic telangiectasia (HHT) type 2 kindred. Am J Med Genet 2000; 93:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/18\">",
"      Fulbright RK, Chaloupka JC, Putman CM, et al. MR of hereditary hemorrhagic telangiectasia: prevalence and spectrum of cerebrovascular malformations. AJNR Am J Neuroradiol 1998; 19:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/19\">",
"      Krings T, Ozanne A, Chng SM, et al. Neurovascular phenotypes in hereditary haemorrhagic telangiectasia patients according to age. Review of 50 consecutive patients aged 1 day-60 years. Neuroradiology 2005; 47:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/20\">",
"      Wallace GM, Shovlin CL. A hereditary haemorrhagic telangiectasia family with pulmonary involvement is unlinked to the known HHT genes, endoglin and ALK-1. Thorax 2000; 55:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/21\">",
"      Cole SG, Begbie ME, Wallace GM, Shovlin CL. A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet 2005; 42:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/22\">",
"      Bourdeau A, Dumont DJ, Letarte M. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 1999; 104:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/23\">",
"      Gallitelli M, Pasculli G, Fiore T, et al. Emergencies in hereditary haemorrhagic telangiectasia. QJM 2006; 99:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/24\">",
"      Shovlin CL, Jackson JE, Bamford KB, et al. Primary determinants of ischaemic stroke/brain abscess risks are independent of severity of pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia. Thorax 2008; 63:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/25\">",
"      Bideau A, Plauchu H, Brunet G, Robert J. Epidemiological investigation of Rendu-Osler disease in France: its geographical distribution and prevalence. Popul 1989; 44:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/26\">",
"      Dakeishi M, Shioya T, Wada Y, et al. Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Hum Mutat 2002; 19:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/27\">",
"      Kjeldsen AD, Vase P, Green A. Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. J Intern Med 1999; 245:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/28\">",
"      Guttmacher AE, Marchuk DA, White RI Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med 1995; 333:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/29\">",
"      Westermann CJ, Rosina AF, De Vries V, de Coteau PA. The prevalence and manifestations of hereditary hemorrhagic telangiectasia in the Afro-Caribbean population of the Netherlands Antilles: a family screening. Am J Med Genet A 2003; 116A:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/30\">",
"      Berg JN, Gallione CJ, Stenzel TT, et al. The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2. Am J Hum Genet 1997; 61:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/31\">",
"      McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994; 8:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/32\">",
"      Johnson DW, Berg JN, Baldwin MA, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996; 13:189.",
"     </a>",
"    </li>",
"    <li>",
"     file://arup.utah.edu/database/HHT/ (Accessed on August 29, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/34\">",
"      Abdalla SA, Letarte M. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet 2006; 43:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/35\">",
"      Bayrak-Toydemir P, McDonald J, Akarsu N, et al. A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am J Med Genet A 2006; 140:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/36\">",
"      Bertolino P, Deckers M, Lebrin F, ten Dijke P. Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders. Chest 2005; 128:585S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/37\">",
"      Bailly S. HHT is not a TGF-beta disease. Blood 2008; 111:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/38\">",
"      Gu Y, Jin P, Zhang L, et al. Functional analysis of mutations in the kinase domain of the TGF-beta receptor ALK1 reveals different mechanisms for induction of hereditary hemorrhagic telangiectasia. Blood 2006; 107:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/39\">",
"      Urness LD, Sorensen LK, Li DY. Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet 2000; 26:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/40\">",
"      Park SO, Lee YJ, Seki T, et al. ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood 2008; 111:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/41\">",
"      Bourdeau A, Cymerman U, Paquet ME, et al. Endoglin expression is reduced in normal vessels but still detectable in arteriovenous malformations of patients with hereditary hemorrhagic telangiectasia type 1. Am J Pathol 2000; 156:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/42\">",
"      Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/43\">",
"      Sadick H, Riedel F, Naim R, et al. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 2005; 90:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/44\">",
"      Kjeldsen AD, M&oslash;ller TR, Brusgaard K, et al. Clinical symptoms according to genotype amongst patients with hereditary haemorrhagic telangiectasia. J Intern Med 2005; 258:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/45\">",
"      Letteboer TG, Mager JJ, Snijder RJ, et al. Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia. J Med Genet 2006; 43:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/46\">",
"      Sabb&agrave; C, Pasculli G, Lenato GM, et al. Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers. J Thromb Haemost 2007; 5:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/47\">",
"      Lesca G, Olivieri C, Burnichon N, et al. Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network. Genet Med 2007; 9:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/48\">",
"      Bossler AD, Richards J, George C, et al. Novel mutations in ENG and ACVRL1 identified in a series of 200 individuals undergoing clinical genetic testing for hereditary hemorrhagic telangiectasia (HHT): correlation of genotype with phenotype. Hum Mutat 2006; 27:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/49\">",
"      AAssar OS, Friedman CM, White RI Jr. The natural history of epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 1991; 101:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/50\">",
"      Vaiman M, Martinovich U, Eviatar E, et al. Fibrin glue in initial treatment of epistaxis in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease). Blood Coagul Fibrinolysis 2004; 15:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/51\">",
"      Plauchu H, de Chadar&eacute;vian JP, Bideau A, Robert JM. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989; 32:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/52\">",
"      Kjeldsen AD, Kjeldsen J. Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Am J Gastroenterol 2000; 95:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/53\">",
"      Pasculli G, Quaranta D, Lenato GM, et al. Capillaroscopy of the dorsal skin of the hands in hereditary hemorrhagic telangiectasia. QJM 2005; 98:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/54\">",
"      Bharatha A, Faughnan ME, Kim H, et al. Brain arteriovenous malformation multiplicity predicts the diagnosis of hereditary hemorrhagic telangiectasia: quantitative assessment. Stroke 2012; 43:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/55\">",
"      Lacout A, Pelage JP, Lesur G, et al. Pancreatic involvement in hereditary hemorrhagic telangiectasia: assessment with multidetector helical CT. Radiology 2010; 254:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/56\">",
"      Shovlin CL, Letarte M. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 1999; 54:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/57\">",
"      Shovlin C, Bamford K, Wray D. Post-NICE 2008: Antibiotic prophylaxis prior to dental procedures for patients with pulmonary arteriovenous malformations (PAVMs) and hereditary haemorrhagic telangiectasia. Br Dent J 2008; 205:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/58\">",
"      Shovlin CL, Sodhi V, McCarthy A, et al. Estimates of maternal risks of pregnancy for women with hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): suggested approach for obstetric services. BJOG 2008; 115:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/59\">",
"      Post MC, Letteboer TG, Mager JJ, et al. A pulmonary right-to-left shunt in patients with hereditary hemorrhagic telangiectasia is associated with an increased prevalence of migraine. Chest 2005; 128:2485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/60\">",
"      Stephan MJ, Nesbit GM, Behrens ML, et al. Endovascular treatment of spinal arteriovenous fistula in a young child with hereditary hemorrhagic telangiectasia. Case report. J Neurosurg 2005; 103:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/61\">",
"      Maher CO, Piepgras DG, Brown RD Jr, et al. Cerebrovascular manifestations in 321 cases of hereditary hemorrhagic telangiectasia. Stroke 2001; 32:877.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.arubastudy.org/ (Accessed on August 30, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/63\">",
"      Buscarini E, Danesino C, Plauchu H, et al. High prevalence of hepatic focal nodular hyperplasia in subjects with hereditary hemorrhagic telangiectasia. Ultrasound Med Biol 2004; 30:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/64\">",
"      Buonamico P, Suppressa P, Lenato GM, et al. Liver involvement in a large cohort of patients with hereditary hemorrhagic telangiectasia: echo-color-Doppler vs multislice computed tomography study. J Hepatol 2008; 48:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/65\">",
"      Garcia-Tsao G, Korzenik JR, Young L, et al. Liver disease in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2000; 343:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/66\">",
"      DeLeve LD, Valla DC, Garcia-Tsao G, American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology 2009; 49:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/67\">",
"      Buscarini E, Plauchu H, Garcia Tsao G, et al. Liver involvement in hereditary hemorrhagic telangiectasia: consensus recommendations. Liver Int 2006; 26:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/68\">",
"      Caselitz M, Wagner S, Chavan A, et al. Clinical outcome of transfemoral embolisation in patients with arteriovenous malformations of the liver in hereditary haemorrhagic telangiectasia (Weber-Rendu-Osler disease). Gut 1998; 42:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/69\">",
"      Buscarini E, Buscarini L, Civardi G, et al. Hepatic vascular malformations in hereditary hemorrhagic telangiectasia: imaging findings. AJR Am J Roentgenol 1994; 163:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/70\">",
"      Buscarini E, Leandro G, Conte D, et al. Natural history and outcome of hepatic vascular malformations in a large cohort of patients with hereditary hemorrhagic teleangiectasia. Dig Dis Sci 2011; 56:2166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/71\">",
"      Livesey JA, Manning RA, Meek JH, et al. Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiectasia. Thorax 2012; 67:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/72\">",
"      Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/73\">",
"      Faughnan ME, Palda VA, Garcia-Tsao G, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 2011; 48:73.",
"     </a>",
"    </li>",
"    <li>",
"     Available at 1-800-448-6389 or on the Foundation's website at file://hht.org/ (Accessed on September 18, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/75\">",
"      Fuchizaki U, Miyamori H, Kitagawa S, et al. Hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease). Lancet 2003; 362:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/76\">",
"      Vase P, Holm M, Arendrup H. Pulmonary arteriovenous fistulas in hereditary hemorrhagic telangiectasia. Acta Med Scand 1985; 218:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/77\">",
"      Ference BA, Shannon TM, White RI Jr, et al. Life-threatening pulmonary hemorrhage with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia. Chest 1994; 106:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/78\">",
"      McAllister KA, Lennon F, Bowles-Biesecker B, et al. Genetic heterogeneity in hereditary haemorrhagic telangiectasia: possible correlation with clinical phenotype. J Med Genet 1994; 31:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/79\">",
"      Shovlin CL, Winstock AR, Peters AM, et al. Medical complications of pregnancy in hereditary haemorrhagic telangiectasia. QJM 1995; 88:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/80\">",
"      Bayrak-Toydemir P, McDonald J, Markewitz B, et al. Genotype-phenotype correlation in hereditary hemorrhagic telangiectasia: mutations and manifestations. Am J Med Genet A 2006; 140:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/81\">",
"      Lasjaunias P. Cerebro medullary arteriovenous locations in children and adults with HHT. Hematology Meeting Reports 2007; 1:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/82\">",
"      Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/83\">",
"      Lerut J, Orlando G, Adam R, et al. Liver transplantation for hereditary hemorrhagic telangiectasia: Report of the European liver transplant registry. Ann Surg 2006; 244:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/84\">",
"      Boillot O, Bianco F, Viale JP, et al. Liver transplantation resolves the hyperdynamic circulation in hereditary hemorrhagic telangiectasia with hepatic involvement. Gastroenterology 1999; 116:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/85\">",
"      Dupuis-Girod S, Chesnais AL, Ginon I, et al. Long-term outcome of patients with hereditary hemorrhagic telangiectasia and severe hepatic involvement after orthotopic liver transplantation: a single-center study. Liver Transpl 2010; 16:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/86\">",
"      Miller FJ Jr, Whiting JH, Korzenik JR, White RI. Caution with use of hepatic embolization in the treatment of hereditary hemorrhagic telangiectasia. Radiology 1999; 213:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/87\">",
"      Lund VJ, Howard DJ. A treatment algorithm for the management of epistaxis in hereditary hemorrhagic telangiectasia. Am J Rhinol 1999; 13:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/88\">",
"      Hitchings AE, Lennox PA, Lund VJ, Howard DJ. The effect of treatment for epistaxis secondary to hereditary hemorrhagic telangiectasia. Am J Rhinol 2005; 19:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/89\">",
"      K&uuml;hnel TS, Wagner BH, Schurr CP, Strutz J. Clinical strategy in hereditary hemorrhagic telangiectasia. Am J Rhinol 2005; 19:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/90\">",
"      Bergler W, Sadick H, Gotte K, et al. Topical estrogens combined with argon plasma coagulation in the management of epistaxis in hereditary hemorrhagic telangiectasia. Ann Otol Rhinol Laryngol 2002; 111:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/91\">",
"      Folz BJ, Tennie J, Lippert BM, Werner JA. Natural history and control of epistaxis in a group of German patients with Rendu-Osler-Weber disease. Rhinology 2005; 43:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/92\">",
"      Sargeant IR, Loizou LA, Rampton D, et al. Laser ablation of upper gastrointestinal vascular ectasias: long term results. Gut 1993; 34:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/93\">",
"      Marshall JK, Hunt RH. Hormonal therapy for bleeding gastrointestinal mucosal vascular abnormalities: a promising alternative. Eur J Gastroenterol Hepatol 1997; 9:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/94\">",
"      Lewis BS, Salomon P, Rivera-MacMurray S, et al. Does hormonal therapy have any benefit for bleeding angiodysplasia? J Clin Gastroenterol 1992; 15:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/95\">",
"      Sabb&agrave; C, Gallitelli M, Palasciano G. Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/96\">",
"      Saba HI, Morelli GA, Logrono LA. Brief report: treatment of bleeding in hereditary hemorrhagic telangiectasia with aminocaproic acid. N Engl J Med 1994; 330:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/97\">",
"      Jameson JJ, Cave DR. Hormonal and antihormonal therapy for epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 2004; 114:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/98\">",
"      Sabb&agrave; C, Pasculli G, Cirulli A, et al. Rendu-Osler-Weber disease: experience with 56 patients. Ann Ital Med Int 2002; 17:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/99\">",
"      Yaniv E, Preis M, Hadar T, et al. Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial. Laryngoscope 2009; 119:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/100\">",
"      Shovlin CL, Sulaiman NL, Govani FS, et al. Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. Thromb Haemost 2007; 98:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/101\">",
"      van Cutsem E, Rutgeerts P, Vantrappen G. Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone. Lancet 1990; 335:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/102\">",
"      Sadick H, Bergler WF, Oulmi-Kagermann J, et al. Estriol induced squamous metaplasia on the nasal mucosa in patients with hereditary hemorrhagic telangiectasia. Arch Med Res 2005; 36:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/103\">",
"      Klepfish A, Berrebi A, Schattner A. Intranasal tranexamic acid treatment for severe epistaxis in hereditary hemorrhagic telangiectasia. Arch Intern Med 2001; 161:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/104\">",
"      Vase P. Estrogen treatment of hereditary hemorrhagic telangiectasia. A double-blind controlled clinical trial. Acta Med Scand 1981; 209:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/105\">",
"      Yaniv E, Preis M, Shevro J, et al. Anti-estrogen therapy for hereditary hemorrhagic telangiectasia - a long-term clinical trial. Rhinology 2011; 49:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/106\">",
"      Flieger D, Hainke S, Fischbach W. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 2006; 85:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/107\">",
"      Mitchell A, Adams LA, MacQuillan G, et al. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl 2008; 14:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/108\">",
"      Simonds J, Miller F, Mandel J, Davidson TM. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 2009; 119:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/109\">",
"      Bose P, Holter JL, Selby GB. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009; 360:2143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/110\">",
"      Oosting S, Nagengast W, de Vries E. More on bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009; 361:931; author reply 931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/111\">",
"      Karnezis TT, Davidson TM. Efficacy of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/112\">",
"      Davidson TM, Olitsky SE, Wei JL. Hereditary hemorrhagic telangiectasia/avastin. Laryngoscope 2010; 120:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/113\">",
"      Chen S 4th, Karnezis T, Davidson TM. Safety of intranasal Bevacizumab (avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/114\">",
"      Brinkerhoff BT, Poetker DM, Choong NW. Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2011; 364:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/115\">",
"      Suppressa P, Patrizia S, Liso A, et al. Low dose intravenous bevacizumab for the treatment of anaemia in hereditary haemorrhagic telangiectasia. Br J Haematol 2011; 152:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/116\">",
"      Guldmann R, Dupret A, Nivoix Y, et al. Bevacizumab nasal spray: Noninvasive treatment of epistaxis in patients with Rendu-Osler disease. Laryngoscope 2012; 122:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/117\">",
"      Dupuis-Girod S, Ginon I, Saurin JC, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 2012; 307:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/118\">",
"      Bauditz J, Lochs H. Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding. World J Gastroenterol 2007; 13:5979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/119\">",
"      Bowcock SJ, Patrick HE. Lenalidomide to control gastrointestinal bleeding in hereditary haemorrhagic telangiectasia: potential implications for angiodysplasias? Br J Haematol 2009; 146:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/120\">",
"      Lebrin F, Srun S, Raymond K, et al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 2010; 16:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/121\">",
"      Skaro AI, Marotta PJ, McAlister VC. Regression of cutaneous and gastrointestinal telangiectasia with sirolimus and aspirin in a patient with hereditary hemorrhagic telangiectasia. Ann Intern Med 2006; 144:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/122\">",
"      Wheatley-Price P, Shovlin C, Chao D. Interferon for metastatic renal cell cancer causing regression of hereditary hemorrhagic telangiectasia. J Clin Gastroenterol 2005; 39:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/123\">",
"      Gershon AS, Faughnan ME, Chon KS, et al. Transcatheter embolotherapy of maternal pulmonary arteriovenous malformations during pregnancy. Chest 2001; 119:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/124\">",
"      Mason CG, Shovlin CL. Flight-related complications are infrequent in patients with hereditary haemorrhagic telangiectasia/pulmonary arteriovenous malformations, despite low oxygen saturations and anaemia. Thorax 2012; 67:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/31/31226/abstract/125\">",
"      Cohen JH, Faughnan ME, Letarte M, et al. Cost comparison of genetic and clinical screening in families with hereditary hemorrhagic telangiectasia. Am J Med Genet A 2005; 137:153.",
"     </a>",
"    </li>",
"    <li>",
"     www.telangiectasia.co.uk (Accessed on September 18, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1345 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-543A21084C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_31_31226=[""].join("\n");
var outline_f30_31_31226=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DISEASE OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Onset of disease manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mutations in HHT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Disease phenotypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Epistaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Mucocutaneous telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20480786\">",
"      Sites of large arteriovenous malformations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Pulmonary AVMs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Cerebral AVMs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Hepatic involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12131106\">",
"      Venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Consensus criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6888057\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29948893\">",
"      - Overall strategy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7831188\">",
"      - Iron deficiency anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H558383443\">",
"      - Pulmonary AVMs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7830949\">",
"      - Cerebral AVMs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H558392706\">",
"      - Screening SMAD4 mutation carriers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7830609\">",
"      Therapy for localized lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7830667\">",
"      - Arteriovenous malformations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Localized bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Iron deficiency anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7830739\">",
"      - Bleeding telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12130353\">",
"      Systemic agents to manage bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12129701\">",
"      - Hormones and antifibrinolytic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12129723\">",
"      - Estrogens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12129730\">",
"      - Antiestrogens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12129737\">",
"      - Angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12129803\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12130483\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12130505\">",
"      Airline travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7830493\">",
"      SCREENING OF FAMILY MEMBERS AND CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12130735\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1345\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1345|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/25/43423\" title=\"diagnostic image 1\">",
"      Cerebral abscess with PAVM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/41/39583\" title=\"diagnostic image 2\">",
"      Angiodysplasia colon angio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/22/3426\" title=\"diagnostic image 3\">",
"      Arteriovenous malformation CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/7/21616\" title=\"diagnostic image 4\">",
"      PAVM angiogram I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/37/34384\" title=\"diagnostic image 5\">",
"      Dark flow void from AVM on MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1345|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/34/10786\" title=\"picture 1\">",
"      Mucosal telangiectasias in HHT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/41/3742\" title=\"picture 2A\">",
"      Angiodysplasia endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/37/21072\" title=\"picture 2B\">",
"      Colonic angiodysplasia Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/32/37376\" title=\"picture 3\">",
"      Osler Weber Rendu",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/59/16304\" title=\"picture 4\">",
"      AVM pretreatment angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/47/18164\" title=\"picture 5\">",
"      AVMs APC Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1345|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/12/12493\" title=\"table 1\">",
"      Clinical features of HHT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/32/7692\" title=\"table 2\">",
"      Complications of pulmonary AVMs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8410?source=related_link\">",
"      Angiodysplasia of the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/41/1690?source=related_link\">",
"      Approach to the adult with epistaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34695?source=related_link\">",
"      Argon plasma coagulation in the management of gastrointestinal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32872?source=related_link\">",
"      Brain arteriovenous malformations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=related_link\">",
"      Causes and diagnosis of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29816?source=related_link\">",
"      Hepatic hemangioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26536?source=related_link\">",
"      Management of epistaxis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7304?source=related_link\">",
"      Pathogenesis of pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/42/26274?source=related_link\">",
"      Patient information: Arteriovenous malformations in the brain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3224?source=related_link\">",
"      Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32263?source=related_link\">",
"      Pulmonary arteriovenous malformations: Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27656?source=related_link\">",
"      Pulmonary arteriovenous malformations: Epidemiology, etiology, pathology, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12358?source=related_link\">",
"      Pulmonary arteriovenous malformations: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36538?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=related_link\">",
"      Treatment of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18584?source=related_link\">",
"      Vascular malformations of the central nervous system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_31_31227="High risk sports spine injury";
var content_f30_31_31227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sports with high risk for head and spine injury",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Auto racing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Motorcycling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cycling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Football",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lacrosse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ice hockey",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rugby",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Boxing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wrestling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Martial arts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diving",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gymnastics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trampolining",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soccer (goalie)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hang gliding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parachuting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sky diving",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skating/rollerblading",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skiing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Track (pole vaulting)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Equestrian sports",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Cantu, RC. Head and spine injuries in youth sports. Clin Sports Med 1995; 14:517. Copyright &copy; 1995 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_31_31227=[""].join("\n");
var outline_f30_31_31227=null;
var title_f30_31_31228="HCW prophylaxis recs II";
var content_f30_31_31228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Postexposure prophylaxis for vaccine-preventable diseases in health care workers - II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Definition of",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Prophylaxis",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Work restrictions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Susceptible",
"       </td>",
"       <td class=\"subtitle2\">",
"        Exposed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Varicella zoster",
"       </td>",
"       <td>",
"        None of the following: history of varicella, serologic evidence of immunity, two doses of varicella vaccine",
"       </td>",
"       <td>",
"        Cohabiting confined air space or face-to-face contact in open area with a patient who has active lesions or in the 48 hours before onset of primary infection",
"       </td>",
"       <td>",
"        Varicella zoster immune globulin (125 U/10 kg intramuscularly) for immunocompromised or pregnant health care workers or varicella vaccine if no contraindications",
"       </td>",
"       <td>",
"        Furlough from health care facility until all lesions are dry and crusted or from day 8 after first exposure to day 21 after last exposure (extend to day 28 if VZIG given)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis A",
"       </td>",
"       <td>",
"        None of the following: history of hepatitis A, serologic evidence of immunity, two doses of hepatitis A vaccine",
"       </td>",
"       <td>",
"        Ingestion of contaminated food, contact with feces from a patient infected with hepatitis A",
"       </td>",
"       <td>",
"        Immune globulin 0.02 mL/kg&nbsp;intramuscularly in gluteal or deltoid within 14 days of exposure; consider concurrent hepatitis A vaccination",
"       </td>",
"       <td>",
"        Relieve from direct patient contact and food handling until&nbsp;seven days after onset of jaundice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pertussis",
"       </td>",
"       <td>",
"        All health care workers",
"       </td>",
"       <td>",
"        Direct contact with respiratory secretions or droplets from infected person",
"       </td>",
"       <td>",
"        <p>",
"         Azithromycin&nbsp;500 mg&nbsp;orally&nbsp;on day one followed by 250 mg&nbsp;orally&nbsp;daily&nbsp;on days two to five (trimethoprim-sulfamethoxazole is an alternative)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Active disease or symptomatic postexposure",
"         </strong>",
"         - furlough from health care facility from beginning of catarrhal stage to&nbsp;third week after onset of paroxysms or&nbsp;five days after effective therapy",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Asymptomatic postexposure",
"         </strong>",
"         - no restriction providing antibiotic therapy is taken",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neisseria meningitidis",
"       </td>",
"       <td>",
"        All health care workers",
"       </td>",
"       <td>",
"        Direct contact with respiratory secretions from infected person",
"       </td>",
"       <td>",
"        Ciprofloxacin 500 mg&nbsp;orally x 1 or ceftriaxone 250 mg&nbsp;intramuscularly x 1 or rifampin 600 mg&nbsp;orally&nbsp;twice daily&nbsp;for&nbsp;two&nbsp;days",
"       </td>",
"       <td>",
"        No restriction",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_31_31228=[""].join("\n");
var outline_f30_31_31228=null;
var title_f30_31_31229="Dx vomiting children by system";
var content_f30_31_31229=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of pediatric vomiting: A system approach",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Gastrointestinal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anatomic (eg, congenital stenosis, atresias, webs)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Motility disorder",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Foreign body",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Obstruction (eg, malrotation/volvulus, Hirschsprung disease, pyloric stenosis, intussusception, incarcerated hernia)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Eosinophilic esophagitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cholecystitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Appendicitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Necrotizing enterocolitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Peritonitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cyclic vomiting",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Peptic ulcer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trauma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pancreatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hepatobiliary disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastroenteritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Meningitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Urinary tract infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Parasites (eg, Giardia, Ascaris, Cryptosporidium)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pharyngitis (eg, Streptococcus)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Helicobacter pylori",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Otitis media",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Viral",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sepsis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Neurologic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Intracranial mass",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cerebral edema (eg, diabetic ketoacidosis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hydrocephalus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Postconcussion syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pseudotumor cerebri",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Migraine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Seizures",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Endocrine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diabetic ketoacidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Adrenal insufficiency (eg, congenital adrenal hyperplasia)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Renal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Obstructive uropathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Renal insufficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Glomerulonephritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Renal tubular acidosis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Respiratory",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Postussive (eg, asthma, foreign body)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sinusitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Metabolic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inborn errors of metabolism (eg, galactosemia, amino acid disorders, organic acidemia, fatty acid oxidation disorders)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Immunologic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anaphylaxis (eg, milk/soy protein allergy)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dietary protein intolerance (eg, milk protein enteritis - infants)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chronic granulomatous disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Graft versus host disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Other",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pregnancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Psychogenic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Toxic ingestion",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_31_31229=[""].join("\n");
var outline_f30_31_31229=null;
var title_f30_31_31230="Triquetral fracture lateral xray";
var content_f30_31_31230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Triquetral fracture on lateral plain x-ray",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this lateral radiograph of the wrist, a fracture of the dorsal surface of the triquetrum is apparent (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_31_31230=[""].join("\n");
var outline_f30_31_31230=null;
var title_f30_31_31231="Herpetic whitlow";
var content_f30_31_31231=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Herpetic whitlow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In addition to erythema, swelling, and pain, herpetic whitlow is characterized by the presence of vesicular or pustular lesions. Patients may also experience fever, lymphadenitis, and epitrochlear or axillary lymphadenopathy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nikkels AF, Peirard GE. Treatment of mucocutaneous presentations of herpes simplex virus infections. Am J Clin Dermatol 2002; 3:479. Copyright &copy; 2002 Adis International.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_31_31231=[""].join("\n");
var outline_f30_31_31231=null;
